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PLAIN SUMMARY 
 
Evidence suggests that 85% of biomedical research spending, i.e. 200 billion US dollars 
every year, goes to waste. In 2014, The Lancet published a series of five reviews showing 
how dividends from the investment in research might be increased at five stages - from the 
relevance and priorities of the questions being asked, to how the research is designed, 
conducted, and reported. Value and waste have since then become buzzwords in the 
academic as well as public debate surrounding health research. Although academic 
institutions are the major driving force of patient-oriented clinical research receiving large 
proportions of public funding they have been slow responders to the Series’ 
recommendations. Some of the identified underlying reasons include a lack of a common 
understanding of “value” as a concept and sparse practical guidance for academia on how to 
improve it.  This work represents the first effort to formulate an academic response to The 
Lancet series on increasing value in clinical research by investigating the two distinct 
concepts in the equation: “Quality” and “cost”.  
 
In a first step, we systematically reviewed existing quality concepts, both in the medical 
literature and across international clinical research stakeholder groups. Precise definitions of 
quality were sparse, and stakeholder perspectives of crucial components of quality varied. 
Based on these findings, we then engaged international stakeholder representatives in the 
creation of a comprehensive, consensus-based framework for the quality of clinical research 
that is applicable to all study types and spans the entire lifecycle of a clinical study, i.e. from 
conceptualization of the research question to dissemination of study results. Primarily, it is 
designed to be operationalized in the academic setting and fully supports the REWARD 
Statement. This framework builds the foundation for a common understanding of the concept 
of “quality” and its practical assessment. At Swiss national level, the framework has triggered 
all stakeholders to convene in a first symposium on how to increase value of academic 
clinical research and serves as an agenda for future research on research.  
 
In a second step, we systematically reviewed the current evidence on the costs and 
associated resource use of Randomized Controlled Trials (RCTs), which we found to be 
sparse. Based on this, we laid the foundation for future study cost assessments in academia 
by (i) developing a comprehensive list of items for the retrospective and prospective 
assessment of costs, and (ii) generating first empirical evidence on main cost drivers in a 
case report on two academic RCTs. Although these two RCTs were conducted in very 
different settings and resulted in vastly different costs, the main drivers, i.e. personnel costs 
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during conduct phase, were the same. In addition, we investigated the added value of two 
innovative aspects that affect both study quality and cost, i.e. risk-based trial monitoring and 
remote data collection. We show that both concepts may increase the cost-effectiveness of 
trial conduct and thereby increase value, but only if the methodology is further investigated 
and then, rigorously implemented.  
 
Although we did not take the initially envisioned cost-consequence approach, we have 
certainly created awareness on value and waste in the academic context and engaged the 
major stakeholders in fundamental discussions on how to improve the current situation. In 
the future, the costs occurred need to inform quality assessments of clinical studies in order 
to create a tool that creates “value”, rather than sole quality conformity. Furthermore, the 
willingness-to-pay of academic decision makers in resource-constrained settings will weigh 
into the value equation and needs further investigation in the future. The impact of this work - 
and whether it eventually increases value in the system - now critically depends on its 
rigorous implementation, evaluation, and refinement.  
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CHAPTER 1 
 
INTRODUCTION 
 
 
“Perhaps all of us engaged in the enterprise we call “science” need to pause and reflect on 
the present state of what we do.”  
(Kleinert & Horton, The Lancet, 2014) 
 
1.1 The need for improving value and reducing waste in clinical 
research 
The biomedical research complex has been estimated to consume almost a quarter of a 
trillion US dollars every year. Unfortunately, evidence suggests that a high proportion of this 
sum is avoidably wasted [1-7]. The output of new pharmaceutical drugs has been decreasing 
for the past decade and the prices have risen steadily, leading to access problems for many 
patients [8]. Most university-initiated technology transfer units created to protect and sell 
academically generated intellectual property cost more than they earn [9]. Although much of 
the world follows the Moore law on the doubling of output (e.g. computing power) per unit 
cost every 2 years, drug development and clinical trials are moving in the opposite direction 
[10]. 
 
In 2014, The Lancet published a series of five reviews showing how dividends from the 
investment in research might be increased at five stages - from the relevance and priorities 
of the questions being asked, to how the research is designed, conducted, and reported [1, 
2, 4-7]. Seventeen recommendations were addressed to five main stakeholders – funders, 
regulators, journals, academic institutions, and researchers. In the same year, Moors et al. 
[8] suggested a combination of reforms including technological and organizational changes, 
changes in the regulatory, patent, and reimbursement system, and social and/or political 
changes to make drug development more sustainable.  
 
5
Introduction 
In 2016, a follow-up review provided some initial observations of the possible effects of the 
Lancet Series [11].  It suggested that some movement had been provoked across 
stakeholders, but that still much more needed to be done to effectively increase value and 
reduce waste across the biomedical research system. One of the leaders of the movement, 
John Ioannidis, said that “(...) not only are most research findings false, but, furthermore, 
most of the true findings are not useful" [12]. Interestingly, academic institutions had been 
among the slowest responders to the Series’ recommendations.  As the major driving force 
of patient-oriented clinical research receiving large proportions of public funding [13, 14] and 
producing the majority of scientific publications in this area [15], academic institutions would 
be ideally placed to lead the movement.  Historically, however, academia had been criticized 
for low quality research [16]. Criticism included allegations of financial conflicts of interest 
[17], scientific misconduct by a few investigators[18], low dissemination rates of clinical trial 
results [19], and a significantly higher risk for discontinuation compared to industry-funded 
trials [20].  Reasons for the slow progress may be that academia is a complex ecosystem 
including many stakeholders with different agendas and a lack of common policies [11]. 
 
In summary, the evidence that value of research needs to be improved is compelling – 
particularly for academia. Still, the definition of “value” remains vague. This is particularly 
challenging because “value” in itself is the result of an equation of “worth”, i.e. “quality” 
versus “monetary investment” or “cost”, and “willingness-to-pay”. In order to be able to 
successfully operationalize the Lancet Series’ recommendations and thereby increase 
“value”, however, one needs to be very specific about these two underlying concepts.  
 
In this PhD work, we first aimed to develop a cost-consequence approach to improving the 
quality of research. However, we early-on identified gaps in the evidence-base relating to the 
concepts underlying this approach, i.e. (1) a common understanding of the concept of 
“quality” of clinical research, its definition, and its practical assessment, and (2) an empirical 
evidence base for the “cost” of clinical research, its components, and main drivers. In the 
following paragraphs, I describe the rationale and the approach we took to fill both of these 
gaps. Finally, I highlight the rationale for two projects that we conducted to assess the cost-
effectiveness of two aspects of high quality research, risk-based monitoring and remote data 
collection.  
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1.2 The need for a common definition of the quality of research 
“There is clearly a strong feeling among many scientists, and not only Nobel Prize Winners, 
that something has gone wrong with our system for assessing the quality of scientific 
research.” 
 (Kleinert & Horton, The Lancet, 2014) 
Approaches to assess or measure the quality of single clinical studies or whole research 
programs have been limited, mono-dimensional, and often criticized for not being sufficient to 
tackle waste. Quality assurance measures, such as full compliance with the International 
Conference on Harmonization of Good Clinical Practice (ICH GCP) requirements or 100% 
Source Data Verification were even deemed major sources of waste leading to high costs in 
the system without proven benefit [21-23].  The existing international quality guidelines, GCP, 
were criticized for their non-scientific development process and a lack of consensus across 
stakeholder groups [24, 25]. In addition, they were deemed an unsuitable standard for 
investigator-initiated clinical research [26, 27]. 
 
In economics theory, disputes on a definition for “product quality” have a long-standing 
tradition: “Quality is a complex and multifaceted concept. It is also the source of great 
confusion: managers –particularly those in in different functions- frequently fail to 
communicate precisely what they mean by the term” [28]. Quality theories range from “user-
based” to “product-based” to “manufacturing-based”. Equivalents in clinical research could 
be “patient-centered” to “methods-based” to “operational” quality of a study. The “value-
based” approach defines quality in terms of costs and prices. According to this view, a quality 
product is one that provides performance at an acceptable price or conformance at an 
acceptable cost, which has become more prevalent as “quality is increasingly apt to be 
discussed and perceived in relationship to price” [28].  
 
In clinical research, perspectives, priorities, and incentives concerning research quality 
naturally vary across the different involved stakeholders.  Manuscript I entitled “Towards the 
development of a comprehensive framework: Qualitative systematic survey of definitions of 
clinical research quality” describes our systematic search for the existing quality concepts, 
definitions and criteria across clinical research stakeholders, both in the published literature 
and on stakeholder group websites. This work aimed to reflect the heterogeneous quality 
landscape, identify divergent and common stakeholder perceptions, and lay the foundation 
for the future development of a comprehensive definition of quality.  
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In his publication on “how to make more published research true” in 2014, John Ioannidis 
suggested that “joint efforts by multiple stakeholders (in biomedical research) may yield 
solutions that are more likely to be more widely adopted and thus successful” [29].  We fully 
embraced such a user-centered approach by engaging over 100 international experts from 
seven stakeholder groups in a four-round collaborative consensus finding process to define 
the critical items for the quality of clinical research.  Manuscript II entitled “Towards 
increasing value and reducing waste in academic clinical research: Consensus on a 
comprehensive framework of clinical research quality” describes the consensus-based 
development of our framework and highlights first applications in the Swiss context.  
 
 
1.3 The need for evidence on the cost of research 
Cost estimates for research and development (R&D) for new drugs in 2009 ranged from USD 
92 million to USD 884 million per compound [30, 31]. The primary driver of the rising costs is 
clinical costs, especially clinical trials, which increased 10-fold from 1991 to 2003 [32, 33]. 
With a number of initiatives and regulations that were implemented to improve research 
quality and to increase participant protection [34], the complexity and the administrative 
burden of RCTs increased, again raising their overall costs [35-37]. Ultimately, the number of 
RCTs has decreased over the last decade [38] and a substantial proportion of initiated RCTs 
are prematurely discontinued due to organizational and recruitment problems [39] risking that 
more uncertainties about medical treatments will go unaddressed. 
While efforts to make clinical trials more cost-efficient are urgently needed, several 
institutions have criticized the published total cost estimates to be “intransparent” or 
“potential exaggerations” to justify high drug prices [40-42]. A pre-requisite for an 
optimization process, however, are reliable empirical cost data and evidence on cost-drivers.  
Therefore, we aimed to generate an evidence base by a) systematically compiling the 
existing evidence on cost and resource use in RCTs, and b) retrospectively collecting 
detailed resource use and associated costs of two RCTs conducted within our close network. 
Manuscript III entitled “Systematic review on costs and resource use of randomised clinical 
trials shows a lack of empirical data” provides the results of our systematic search for 
empirical evidence on clinical trial costs. Manuscript IV entitled “Cost and resource use 
evaluation of randomised clinical trials: a case study exemplifying standardised assessment 
using a comprehensive cost item list” describes the first case report of detailed cost and 
resource use estimates of two RCTs.  
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1.4 The need for cost-effective solutions 
1.4.1 Approach 1: Trial monitoring 
The cost of assuring operational “quality” in clinical trials – such as monitoring the 
compliance with complex regulatory guidelines – has been described to be one of the major 
drivers of exploding R&D expenditure – and waste in the system [43, 44]. Financial estimates 
of a single monitoring site visit range from USD 800 in 1991 to USD 1500 in 2009 [45, 46],  
with conservative cost estimates for one single query of USD 150 [47]. Traditional monitoring 
approaches relied on intensive on-site visits and 100% Source Data Verification (SDV) 
irrespective of the risk levels in the study, leading to high cost and only limited contribution to 
clinical trial data quality [21-23]. Recent developments at international bodies and regulatory 
agencies such as ICH and the European Medicines Agency have supported the need for 
risk-proportionate approaches to clinical trial monitoring and published respective guidance 
[48-52]. In the academic setting, restricted resources often oblige investigators to apply a 
risk-based approach to trial monitoring. The Risk ADApted MONitoring (ADAMON) Project 
proposed a first instrument for the risk analysis of on-site monitoring in the academic setting 
[53], which we follow at the Clinical Trial Unit Basel since 2012.  
 
In order to shed light on “what works and what doesn’t”, we conducted the first 
comprehensive retrospective study assessing the cost and potential benefits of our current 
monitoring approach. In manuscript V entitled “Generating evidence on a risk-based 
monitoring approach in the academic setting - Lessons learned” we provide evidence on the 
characteristics of findings documented during on-site visits, the factors that might influence 
the number and types of monitoring findings, the costs associated with our approach, and the 
experience of our monitors with the risk-based approach.  
 
1.4.2 Approach 2: High quality data  
High quality research relies on the collection of high quality data. Traditionally, this is done in 
the inpatient setting or through ambulatory visits to a study site. The widespread availability 
of new technologies has the potential of shifting some research activities, including 
enrollment, managing trial activity, reporting results, and safety oversight, away from study 
sites.  Such “remote” research may encourage the participation of a more diverse group of 
patients in research with improved recruitment rates and at lower costs than those of 
conventional trials [1-3], and puts individuals, rather than investigative sites, at the center of 
the research process. However, issues around retention and data quality remain [10, 54-59].  
Therefore, a combination with direct interactions with the research team may allow remote 
approaches to be optimally leveraged [8, 9]. While increasing interest and support from 
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regulators, sponsors, and patients has created much “buzz” around these trials, the 
methodology is still in early stages of development and requires further investigation. 
Manuscript VI entitled “Validity of mobile electronic data capture in clinical studies: A pilot 
study in a pediatric population” describes our pilot study (the TOMACHI study) investigating 
the feasibility of remotely collecting valid (i.e. complete and correct) clinical data and samples 
in a pediatric population utilizing mobile technologies. In addition, we assessed the general 
acceptance, reasons for non-consent, and the resulting costs of this study. As a model, we 
chose children and their caregivers as a population that is a) in urgent need for innovative 
clinical study designs to advance the current knowledge on dosing and action of routinely 
used medicines [60-62] and b) familiar with electronic technologies.   
 
 
1.5 Main Objectives of this PhD 
1) Develop a common understanding of the quality of clinical research across 
stakeholders 
2) Create an evidence base for the costs occurred in clinical research, and their main 
drivers 
3) Evaluate the cost-effectiveness of two aspects of high quality research, risk-based 
monitoring and remote data collection 
 
 
1.6 Contributions by the PhD student  
I had the great opportunity to be the first PhD student at the Clinical Trial Unit (CTU) and was 
therefore part of the conceptualization of this work from the very onset. In this fostering 
environment, I was encouraged to come up with own ideas and received the freedom to 
develop new study plans in very close collaboration with my supervisors. I therefore had a 
substantial role in all aspects of the studies mentioned in this dissertation, i.e. from design, 
planning and conduct trough analysis and dissemination of study results.  
 
After conceptualization and identification of the most suitable study designs with my 
supervisors, I drafted the first version of the study protocols. This included, depending on the 
study, the design of systematic literature reviews and reviews of websites, endpoint 
definitions, quantitative or qualitative analyses plans for main and secondary objectives, data 
management plans, monitoring plans, and the requirements plan for a mobile application 
(TOMACHI). I coordinated the different teams involved in each study including statisticians, 
data managers, monitors, study nurses, and app developers during the drafting process, and 
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submitted ethics proposals (and amendments) for the TOMACHI study, and ethics waivers 
for the quality framework study and the monitoring study.  
 
In the conduct phase, I was responsible for data collection, the project management and 
coordination of the teams contributing to these projects, ranging from 3-12 members. In the 
two systematic reviews (of which one was published in PLOS One, and one is currently 
under review at The Journal of Clinical Epidemiology) I coordinated and extracted data with 
the great help of many team members. Then, after iterative discussion with my supervisors, I 
set up a first matrix for the quality framework which I circulated across over 100 international 
experts in a Delphi process. I planned and coordinated the Delphi process, collected the data 
and engaged with all Delphi participants over two years. In the cost projects, I contributed to 
the development of a comprehensive cost item list and the cost interviews with principal 
investigators. In the TOMACHI study, I was the designated study coordinator overlooking all 
activities that were conducted on site (i.e. recruitment, data collection) by a study nurse team 
and a recruiting physician, and managed all interactions with the ethics committee. I was 
responsible for data management of all qualitative and quantitative data, except the 
TOMACHI study which required data transfer from a mobile application to the data base 
SecuTrial. Throughout these studies, I established a network across stakeholders (e.g. The 
Federal Office of Public Health, EUPATI, or the Swiss Clinical Trial Organization) who 
actively engaged in and supported my work. Additionally, I helped drafting other study 
protocols (e.g. SPIRIT, MARTA) in our collaborative group, collected data for other projects, 
and gave critical and constructive feedback on manuscript drafts. 
 
In the analysis phase, I analyzed both qualitative and descriptive quantitative data, except for 
the TOMACHI study which was performed by a CTU statistician. I critically interpreted the 
data together with my supervisors and co-authors and developed first drafts for all 
manuscripts, coordinated the critical revision by co-authors, submitted and revised 
manuscripts as first and co-first author, and presented and discussed our work at 
international and national conferences. 
 
Finally, although my PhD position was fully funded by the CTU, I wrote a funding proposal to 
the PhD Program for Health Sciences (PPHS) for a top-up stipend which was granted. In 
addition to my PhD work, I also had the fantastic opportunity to take over different roles at 
the CTU, e.g. as maternity cover. For example, I coordinated parts of the Diploma of 
Advance Studies course and supervised 12 students during their Diploma theses, and 
managed the roll-out of a pilot study investigating the feasibility of electronic general consent 
on clinical wards. I am deeply grateful for these diverse opportunities in a very supportive 
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environment that supported my learning, challenged my skills, and taught me to be an 
independent researcher working in and with an interdisciplinary environment.  
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Abstract  
Objective: To systematically survey existing definitions, concepts, and criteria of clinical 
research quality, both developed by stakeholder groups as well as in the medical literature. 
This study serves as a first step in the development of a comprehensive framework for the 
quality of clinical research. 
 
Study Design and Setting: We systematically and in duplicate searched definitions, 
concepts and criteria of clinical research quality on websites of stakeholders in clinical 
research until no further insights emerged and in MEDLINE up to February 2015. 
Stakeholders included governmental bodies, regulatory agencies, the pharmaceutical 
industry, academic and commercial contract research organizations, initiatives, research 
ethics committees, patient organizations and funding agencies from 13 countries. Data 
synthesis involved descriptive and qualitative analyses following the Framework Method on 
definitions, concepts, and criteria of clinical research quality.  Descriptive codes were applied 
and grouped into clusters to identify common and stakeholder-specific quality themes. 
 
Results: Stakeholder concepts on how to assure quality throughout study conduct or articles 
on quality assessment tools were common, generally with no a priori definition of the term 
quality itself. We identified a total of 20 explicit definitions of clinical research quality including 
varying quality dimensions and focusing on different stages in the clinical research process. 
Encountered quality dimensions include ethical conduct, patient safety/rights/priorities, 
internal validity, precision of results, generalizability or external validity, scientific and societal 
relevance, transparency and accessibility of information, research infrastructure and 
sustainability. None of the definitions appeared to be comprehensive either in terms of quality 
dimensions, research stages, or stakeholder perspectives. 
 
Conclusion: Clinical research quality is often discussed but rarely defined. A framework 
defining clinical research quality across stakeholders’ individual perspectives is desirable to 
facilitate discussion, assessment, and improvement of quality at all stages of clinical 
research.  
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Introduction 
Clinical research is necessary to advance our knowledge and practice of diagnosing and 
preventing diseases and treating patients.  However, its complexity and the regulatory 
requirements have significantly increased over the last few years, requiring an ever-rising 
level of scientific, methodological, regulatory and organizational know-how [1]. Global clinical 
research involves billions of dollars and millions of people, yet it is often poorly planned, 
inefficient, or “not useful”, leading to considerable waste of private and public funding [1-8]. 
Low quality research may not only result in misleading findings [9], but may also compromise 
safety and rights of patients. 
 
The regulatory international “ethical and scientific quality standard for designing, conducting, 
recording and reporting trials” – the Good Clinical Practice (GCP) guideline developed by the 
International Conference on Harmonisation (ICH) aims to ensure that safety and rights of 
participants are protected and that trial data are credible [10, 11]. The GCP guideline is a 
widely disseminated and applied standard for the broad concept of clinical research quality.  
However, its limitations include development as an agreement between industry and 
regulatory experts and its focus on data accuracy and extensive formal requirements has 
been criticized as an unsuitable standard for investigator-initiated clinical research [12, 13]. 
The GCP guidelines lack a broad stakeholder consensus and a sound evidence-base [14, 
15].  
 
In academic clinical research, “quality” often relates to design and implementation from the 
standpoint of scientific rigor. Over the last two decades a large number of quality assessment 
instruments and checklists have focused on specific aspects of quality in the context of 
specific types of research (e.g. the Cochrane Risk of Bias (RoB) tool for randomized trials 
[16], the tool for Quality Assessment of Diagnostic Studies (QUADAS-2) [17], or the Risk Of 
Bias In Non-randomized Studies tool (ROBINS-I) [18]). Other instruments have addressed 
the reporting of results from specific study types (e.g. CONsolidated Standards for Reporting 
Trials (CONSORT) [19], STrengthening the Reporting of OBservational studies in 
Epidemiology (STROBE) [20], or Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) [21]) and accordingly the reporting of protocols (e.g. Standard 
Protocol Items: Recommendations for Interventional Trials (SPIRIT) [22]). The Grading, 
Recommendation, Assessment, Development, and Evaluation (GRADE) initiative addresses 
risk of bias and, in addition, imprecision, inconsistency, and indirectness as domains to 
assess the overall quality of a “body of evidence” for the development of evidence-based 
clinical guidelines [23]. These instruments and checklists are useful means to address 
specific aspects of quality but do not consider the research process itself.  
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In other research fields,  including higher education [24], legal sciences [25], or political 
sciences [26] , the assessment of overall research quality has been described as complex, 
ambiguous, and a “major issue”. Increasingly, efforts have been directed towards the 
development of comprehensive quality frameworks [27]. Such broader approaches to quality 
assessment should consider the extent to which research meets the needs and expectations 
of stakeholders, and therefore depends on their perspective. However, the stakeholders in 
clinical research are numerous and their particular interests and priorities differ. 
Measurements of quality of clinical research may therefore be limited, or distorted, if prior 
consensus on a definition of quality has not been reached, and if the complexity of clinical 
research itself and the variety of stakeholders involved has not been taken into account. 
Avedis Donabedian, a pioneer in the assessment of the quality of care, declared in 1980: 
“What is missing (…) is a unifying theory of the definition and measurement of quality of 
care” ( …) Before we attempt to assess the quality of care, either in general terms or in any 
particular site or situation, it is necessary to come to an agreement on what the elements that 
constitute it are” [28, 29]. 
 
This study aims to provide an overview of the existing definitions, concepts, and criteria of 
clinical research quality and to examine their variability by systematically synthesizing 
qualitative sources from the involved stakeholder groups and the medical literature. Clinical 
research in this context is defined as research conducted with patients to answer therapeutic, 
preventive, diagnostic, or prognostic questions or investigations of the mechanisms of human 
disease. We explicitly exclude research focusing on health care system processes, 
structures or policies (such as health services research or health technology assessments) 
and research with healthy volunteers. The findings of this study will inform the next step, i.e. 
the composition and structure of a comprehensive framework for clinical research quality as 
a common goal to increase value and reduce waste.  
 
 
Methods  
We conducted two systematic searches for definitions, concepts, and criteria of clinical 
research quality (see Box 1 for definitions of terms). We searched (i) websites and any linked 
documents of stakeholders in clinical research, and (ii) the published medical literature.  
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Search of stakeholder websites 
Stakeholder website selection 
We searched stakeholder organizations (national ministry of health, regulatory body, 
pharmaceutical industry association, academic research organization, ethics committee, 
patients’ organization, funding agency, and initiative for clinical research) in 13 countries 
(Australia, Austria, Canada, France, Germany, Italy, Japan, Norway, Spain, Sweden, 
Switzerland, USA, UK) to provide perspectives from developed nations in different 
geographic regions. To identify at least one representative national stakeholder organization 
per stakeholder category in each of the 12 countries, we used personal contacts to one 
recognized expert in clinical research or public health per country. For the two contacts that 
did not respond (Australia, Norway), we identified the national organizations for all categories 
through a web search. We additionally searched for websites of inter- or supranational 
bodies involved in clinical research (e.g. ICH, WHO, Horizon2020, international associations) 
and the global 2013 Top10 pharmaceutical companies (IMSExecutive) and Contract 
Research Organizations (pharma-iq.com). We eventually identified publicly available 
websites of 155 organizations using the Google Search Engine (see S1 Table for the full list 
of screened organizations).  
 
Eligibility criteria and search process 
We systematically and in duplicate screened each website for a statement on a definition or 
concept of quality by the respective organization (e.g. “our trials are of high quality because 
they matter to patients”, or “quality means relevant, valid, and ethical trials”) using the 
keywords “quality” or “good” and “clinical research” or “clinical studies” or “clinical trials” or 
“research” in the website’s search function. If we did not find a statement on quality, we 
extended the search to related website content, e.g. “our policy”, “what we do”, “standards & 
quality assurance” etc., as well as organizational statements, guidelines, and reports. Within 
these documents we repeated the search for the above search terms using the respective 
search function. If no statements were found through the search function, the text was 
manually searched for paragraphs that described either a) the standards according to which 
the organization performed clinical research (i.e. ICH-GCP, Declaration of Helsinki, etc.), b) 
criteria according to which the organization assesses the quality of clinical research (e.g. 
evaluation criteria of funding programs), c) the processes used to assure the quality of 
clinical research within an organization (e.g. “quality assurance procedures”), or d) criteria 
which a “good study” should fulfil within the organization. We did not consider any statements 
that focused on animal research, quality of life, or quality of health care without providing any 
definition related to clinical research. For websites presented in languages other than English 
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or German, text passages were translated by members of the investigative team (BvN, CPM, 
MMB, MR). 
 
Search of the literature (MEDLINE) 
With the help of an experienced research librarian (NB) we designed a comprehensive 
search strategy using MeSH terms and text words (see S1 Text for full search strategy) and 
conducted a systematic literature search in MEDLINE using the Ovid interface from database 
inception to February 27, 2015. We did not impose any language restrictions.   
 
Eligibility criteria and selection process 
We included any article describing a definition, a concept, criteria, or a checklist, guideline, or 
measurement instrument of quality spanning more than one quality dimension of clinical 
research in general or within a specific clinical discipline. We excluded any articles not 
suggesting a definition, concept, or criteria of clinical research quality (e.g. exclusively 
discussing the implementation or validation of individual quality criteria or guidelines without 
providing any definition related to clinical research), systematic reviews applying an 
assessment tool of a specific aspect of quality (e.g. systematic reviews on the reporting 
quality of trials in a specific field applying CONSORT [19], or articles suggesting a 
measurement instrument/assessment tool of one specific aspect of quality (e.g. the Jadad 
Scale [30]). In addition, we excluded articles that focused on animal research, quality of life, 
or quality of health care without providing any definition related to clinical research. 
 
Working in pairs, methodologically trained reviewers applied the pre-defined eligibility criteria 
independently after undergoing a calibration process. The reviewers first screened titles and 
abstracts. If titles and abstracts suggested an article meeting the above mentioned inclusion 
criteria or if eligibility remained unclear, we obtained corresponding full texts. Disagreements 
were resolved by discussion and consensus. 
 
Data extraction 
We designed standardized extraction sheets suitable for qualitative data extraction (S2 
Table) accompanied by an instruction manual. Before starting data extraction, the data 
extraction forms were piloted and teams of reviewers conducted calibration exercises to 
ensure consistency. We extracted text sections on the definition, concept, or criteria of 
quality from both literature and internet sources independently and in duplicate. Data 
synthesis of included articles involved categorization by overall topic, author, year of 
publication, article citation index (as retrieved in ISI Web of Science by 11 January 2016), 
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and journal name. Internet sources were categorized by stakeholder group, country, and 
name of organization.  
 
Data analysis  
We performed descriptive and qualitative explanatory analyses following the Framework 
Method [31] on definitions, concepts, and criteria of clinical research quality stratified by 
stakeholders and on evaluation criteria of funding agencies for clinical studies. The 
Framework Method belongs to a family of qualitative approaches termed thematic or content 
analysis, which identify commonalities and differences in qualitative data, and eventually 
seek to draw descriptive and/or explanatory conclusions clustered around themes. Its 
defining feature is the matrix output, i.e. rows (cases), columns (codes) providing a structure 
into which the researcher can systematically reduce the data in order to analyze it [32]. We 
therefore applied codes to excerpts of raw data and added or modified as new responses 
emerged. Codes were then grouped into clusters around similar and interrelated ideas to 
identify common and stakeholder-specific quality themes in an iterative process until 
consensus between the three investigators (BvN, MB, CPM) was reached. Themes were 
named after the most frequently recurring terms within the same clusters (e.g. 
generalizability, relevance, high quality data etc.) and were not created or imposed by the 
investigators. 
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Box 1. Glossary of working definitions, in alphabetical order 
 
Clinical Research 
Interventional and observational research addressing health care issues and involving human 
participants. 
 
Concept of quality 
An implicit statement on what clinical research quality means and comprises, e.g. which 
criteria are needed to ensure good quality research (often operational , e.g. “at our institution, 
the factors required to ensure quality are…“), or a discussion of one or multiple quality 
dimensions in the context of clinical research (e.g. internal validity, external validity, 
transparency, etc.) 
 
Definition of quality 
An explicit statement on what clinical research quality means and comprises, e.g. “quality of 
clinical research may be defined as the internal validity of study results and their applicability 
to patient treatment”,  “quality of clinical research is commonly defined as…”, or  “we define 
quality as…”. May include one or multiple quality dimensions. 
 
Quality criteria 
Aspects that are described as integral part(s) of quality, e.g. adherence to guidelines, use of 
standard operating procedures, etc. 
 
Quality dimension 
Overarching categories of quality criteria, e.g. internal validity, external validity, relevance, 
transparency, etc. 
 
Quality framework 
Theoretical foundation for a definition or concept of quality spanning multiple dimensions and 
study phases in a matrix structure; and serving the development of quality indicators for 
operationalization. 
 
Quality indicator 
An instrument to assess or measure an individual quality criterion, a group of quality criteria, 
or a quality dimension, i.e. the operationalization of quality criteria or dimensions (e.g. how to 
assess the adherence to guidelines).  
 
Quality theme 
A recurrent topic in the qualitative analysis of text material about quality definitions, concepts, 
or criteria extracted from stakeholder websites or articles published in the literature. 
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Results  
Definitions or concepts of clinical research quality in different stakeholder groups 
We screened publicly available websites and linked documents of 155 stakeholders. 
Concepts of how to assure quality of clinical research or quality criteria were commonly 
reported among most stakeholder groups (66.4% (103/155); i.e. in 86.1% (31/36) of 
pharmaceutical companies or contract research organizations (CROs), 72% (18/25) of 
academic research organizations or initiatives, 63.6% (14/22) of international and 
governmental organizations, 61.9% (13/21) of regulatory agencies, 57.9% (11/19) of ethics 
committees, and 63.2% (12/19) of funding agencies, respectively), but this was relatively 
uncommon for patient organizations (31%; 4/13). However, only 12 of 155 (7.7%) institutions 
provided an explicit definition of the term ‘clinical research quality’ (pharmaceutical 
companies or CROs: 3/36; academic research organizations and initiatives: 3/25; 
international and governmental organizations: 3/22; regulatory agencies: 2/21; patient 
organizations: 1/13; ethics committees and funding agencies: 0/38) (S3 Table). 
 
Qualitative analysis of the 12 definitions and the 103 quality concepts or criteria resulted in 
both common and stakeholder-specific quality themes often focusing on different stages of 
clinical research (planning/feasibility, conduct, dissemination; Table 1). Common quality 
themes amongst stakeholder groups included the adherence to all applicable national and 
international laws and regulations (e.g. ICH GCP), a scientific and methodologically rigorous 
approach allowing for an efficient and effective answer to the research question, credible and 
high quality data, the inclusion of trained study personnel, and the presence of Standard 
Operating Procedures (SOPs) and monitoring. 
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Table 1. Qualitative analysis of common and stakeholder-specific quality themes in 
the context of clinical research. 
  
Stakeholder Quality theme Content / Explanation 
 All stakeholders 
Adherence to regulations 
& laws 
 Trial performed, data generated, documented, recorded, 
reported in compliance with Declaration of Helsinki,  ICH-
GCP & all national and international applicable regulatory 
requirements 
 Protection and respect for subject’s welfare, dignity and 
rights in accordance with Declaration of Helsinki 
Scientific and 
methodological aspects of 
research 
 Methodologically «sound» study and scientifically valid, 
effective & efficient answer to a scientific question 
 Generation of credible and high quality data  
Further common themes 
 Qualified/trained personnel 
 Presence of Standard Operating Procedures  & adequate 
monitoring procedures 
Governmental bodies 
 
Relevant, transparent, & 
ethical research 
 Ability of a product, process, or service to satisfy stated or 
implied needs 
 Public access to information and findings 
 Impact on research community  
 Integrity, preventing poor performance and misconduct 
Regulatory agencies 
Adherence to guidelines 
 Quality of evidence sufficient to support good decision 
making 
Academic research / 
Clinical Trial Units / 
Initiatives / Networks 
Absence of bias, 
relevance &transparency 
 Understanding of existing evidence, assumptions explicit 
and justified 
 Particular focus on bias prevention, internal & external 
validity, methodological strength 
 Advance knowledge, bear on policy issues, address needs 
of patients early 
 The study should be compelling, useful, and relevant to 
stakeholders and decision makers 
 The study should be objective, independent, and balanced 
 Accurate reporting and transparency 
Pharmaceutical 
industry/ Contract 
Research 
Organizations 
High quality data 
 Fitness for purpose / use  data 
 Relevant to patients, HC professionals & society 
 Publication of all scientifically and clinically relevant 
information 
Ethics committees / 
Institutional Review 
Boards 
Risk/benefit  ratio & 
subject protection 
 Value enhancement of health or knowledge & benefit to 
community 
 Favorable risk/benefit ratio 
 Honesty, integrity, fair subject selection, free informed 
consent 
 Acknowledgement of roles of others in research 
 Responsible communication to the public 
Patient organizations 
Patient involvement & 
applicability 
 Feasible and practical trials, early patient involvement 
 Patient-centeredness as to study procedures, 
inclusion/exclusion criteria and outcomes, impact on patient 
care 
 Fair subject selection  & Meaningful Informed Consent 
 Access to quality information, during and after trial 
 Access to treatment after trial 
 Prevent risks and errors that truly matter to patient safety 
and the validity of the trial data 
Funding agencies 
Feasibility, 
generalizability, & 
objectivity 
 Overall feasibility, no duplication of research 
 Important outcome to end user / potential clinical application 
 Evidence on comparative effectiveness & cost 
 Transparency / Reporting / Access to data 
 Inter-/ multidisciplinarity 
 No conflict of interest (financial/intellectual) 
 Internationally competitive and reproducible capacity to 
attract resources 
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Stakeholder-specific emphasis on quality themes ranged from “high quality data” 
(pharmaceutical industry and CROs); “adherence to guidelines” (regulatory agencies); 
“patient involvement and applicability of research” (patient organizations); “absence of bias, 
relevance, and transparency” (academic research and/or initiatives); to “feasibility, 
generalizability, and objectivity of research” (funding agencies). The terminology used by the 
stakeholders to describe these themes (e.g. relevance, transparency, feasibility), was no less 
open to definition than the overarching concept of “quality” and as well depends on the 
perspective of the observer. In general, priorities within stakeholder groups were similar 
across different countries. However, for national funding agencies we found considerable 
variation in quality criteria that were particularly emphasized as relevant for funding decisions 
across countries (S4 Table). 
 
Definitions or concepts of clinical research quality in the medical literature  
Our systematic MEDLINE search yielded 8’289 titles and abstracts, of which we reviewed 90 
articles in full text (Fig 1). We excluded 43 full text articles from detailed analysis, because 
they did not discuss a definition, concept, or criteria of quality (n=18), they were systematic 
overviews/summaries of existing quality assessment checklists, instruments, or scores, with 
or without critical discussions of their validity and/or reliability (n=5), or they discussed 
specific measurement instruments of a single dimension of quality (n=20). 
 
We included the remaining 47 articles for more detailed analysis (S2 Text). These provided 
concepts on how to assure or improve overall clinical research quality in specific contexts 
(e.g. at an academic institution, in a specific country, in a specific industry setting, or in a 
specific medical field; n=18), or how to improve quality assessment (e.g. of RCTs, in 
radiology or hepatology research; n=6). Measurement instruments or checklists that spanned 
more than one quality dimension were reported in 23 articles. A large proportion of these 
tools provided indicators on how to assess bias (n=21). Almost half of them covered 
indicators on precision (n=16), external validity (n=16), or reporting quality (n=14). Some 
tools additionally covered innovation aspects (n=8) or ethical considerations (n=4). None of 
the reviewed articles provided a definition or concept of clinical research quality spanning the 
encountered range of quality dimensions reflected by stakeholder perspectives such as 
ethical conduct, patient safety, patient values and preferences, absence of bias, precision, 
external validity, relevance, generalizability, transparency, infrastructure, and sustainability. 
Furthermore, we could not identify a definition or concept simultaneously covering several 
dimensions and differentiating between consecutive stages of research (e.g. study planning, 
conduct and dissemination), independent of a specific medical field or study setting.  
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Overall, we identified eight (8.9%) of 90 articles that provided an explicit definition of the term 
‘clinical research quality’ (Table 2). The definitions therein span quality from methodological 
dimensions such as internal validity, external validity, or precision, and operational criteria 
including adherence to guidelines and applicable regulations (ethical conduct), to the effect 
of research at the societal level (relevance). None of the definitions appeared to be 
comprehensive either in terms of quality dimensions, research stages, or stakeholder 
perspectives. Five of the eight articles were cited less than 10 times in ISI Web of Science™ 
by 11.01.2016 (Table 2). 
 
 
Fig 1. Article flow diagram 
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Table 2. Characteristics of articles providing an explicit definition of clinical research quality; by author (n=8). 
Author(s), Year Title Journal Setting Quality definition Cit.
a 
 
Moher, Jadad et. al. 
(1996) [33] 
Assessing the quality of 
randomized controlled trials. 
Current issues and future 
directions. 
International 
Journal of 
Technology  
Assessessment in 
Health Care 
RCTs 
(…) Quality is a construct (concept) that can be defined in many ways, including the literary 
aspects for the report of a trial or its external validity, i.e. the degree to which it is possible to 
generalize trial results. Our focus on one important aspect of methodologic quality (hereafter 
simply "Quality"), internal validity, which we define as the "confidence that the trial design, 
conduct, analysis, and presentation has minimized or avoided biases in its Intervention 
comparisons." However, we recognize that this definition excludes other methodologic aspects of 
quality, for example, those concerned with the precision and reliability of measurements or 
estimation of compliance. (…) 
244 
Verhagen, de Vet et 
al. (2001) [34] 
The art of quality assessment 
of RCTs included in 
systematic reviews 
Journal of Clinical 
Epidemiology 
Systematic 
review of 
RCTs 
(…) Quality of RCTs has recently been defined as: “the likelihood of the trial design to generate 
unbiased results”. This definition covers only the dimension of internal validity. During the 
development of the “Delphi list” for quality assessment, the participants, all experts in the field of 
RCTs, failed to reach consensus on a specific definition, but did agree that the concept of quality 
should comprise more than internal validity alone. From this context we propose the following 
definition of quality: the likelihood of the trial design to generate unbiased results, that are 
sufficiently precise and allow application in clinical practice. (…) 
125 
Njie and Thomas 
(2001) [35] 
Quality issues in clinical 
research and the implications 
on health policy (QICRHP) 
Journal of 
Professional 
Nursing 
General 
(… )In this article, quality in clinical research is the process of developing and implementing 
guidelines to ensure the inclusion of all pertinent aspects of the research process, ensure 
accountability of research team members, adherence to protocol guidelines, and maintenance of 
study integrity and merit. (…)  
1 
Franck, Pendleton 
et al. (2004) [36] 
Quality assurance for clinical 
research: challenges in 
implementing research 
governance in UK hospitals 
International 
Journal of Health 
Care Quality 
Assurance 
Incorporating 
Leadership in 
Health Services 
UK 
hospitals 
(…) The essential elements of high quality research conduct derived from this body of literature 
are: research ethics (dignity, rights, safety, well-being of research participants); scientific quality, 
adherence to regulations (health and safety, medicines and devices); and information integrity 
(data protection, dissemination, financial and intellectual property). (…) 
2 
Switula (2006) [37] 
The concept of quality in 
clinical research 
Science & 
Engineering Ethics General 
(…) Quality in clinical research may be defined as compliance with requirements together with 
credibility and reliability of the data obtained. In the spirit of ISO, we may define quality in the 
clinical research process pictured above as the positive characteristics of the end product, that is 
the reliability and credibility of information collected during the clinical research process. Quality of 
research also means compliance of the whole trial process with pre-defined requirements. The 
customers of the clinical research define these requirements. (…) 
3 
Krestin (2008) [38] 
Evaluating the Quality of 
Radiology Research: What 
Are the Rules of the Game? 
Radiology Radiology 
(…)“I believe that research quality can be defined as the contribution of research to national and 
global social, economic, and scientific progress—that is, the effect of research at the societal level 
contribution of research to society.” (…) 
1 
Bhatt (2011) [39] 
Quality of clinical trials: A 
moving target 
Perspectives in 
Clinical Research FDA (…) Quality of clinical trials depends on data integrity and subject protection. (…) 8 
 Balshem, Helfand 
et al. (2011) [40] 
GRADE guidelines: 3. Rating 
the quality of evidence. 
Journal of Clinical 
Epidemiology 
Quality of 
Evidence 
(…)‘‘Quality’’ as used in GRADE means more than risk of bias and so may also be compromised 
by imprecision, inconsistency, indirectness of study results, and publication bias. In addition, 
several factors can increase our confidence in an estimate of effect. GRADE provides a 
systematic approach for considering and reporting each of these factors. (…) 
690 
a Citations in Web of Science, last updated 11.01.2016 Abbreviations: FDA, US Food and Drug Administration; RCT, Randomized Controlled Trial; UK, United Kingdom 
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Discussion  
Summary of findings 
Our systematic review of stakeholder websites and the medical literature showed that quality 
of clinical research is frequently discussed, but rarely defined. Although stakeholder groups 
seem to agree on a basic concept of quality, their emphasis in the conceptualization of 
clinical research quality varies widely. The medical literature contains many articles 
discussing approaches to measurement or assessments of quality without prior definition of 
the term itself, and without reflecting the diversity of stakeholder needs, interests and 
expectations. A major proportion of these identified quality assessments aim to evaluate the 
“methodological rigor of randomized controlled trials”. The definition of “methodological rigor” 
in itself, however, varies substantially between the reported tools. Most authors suggested 
assessing methodological quality based on the presence or absence of measures to prevent 
bias. Others included dimensions such as external validity, reporting, or relevance of the 
study in question. We did not, however, identify a definition or concept including multiple 
dimensions or differentiating between consecutive stages of research across medical fields, 
or study settings. Although a comprehensive “definition” of quality may be difficult, a 
“concept” or “framework” of research quality, rather than a “definition”, could span all 
research stages and include more than an assessment focused on one aspect of quality. A 
more comprehensive approach to quality assessment, i.e. ranging from conceptualization to 
dissemination of a study as proposed by the authors of the Lancet series on “increasing 
value, reducing waste” [1, 4-7], rather than evaluation of the final published product, would 
assist in identification of errors that matter at earlier stages, and therefore support reduction 
of research “waste” more efficiently. 
 
Strengths and limitations  
To our knowledge this is the first systematic survey addressing definitions and concepts of 
clinical research quality. Our systematic approach was suited to detect knowledge gaps, and 
to examine overlap and differences in perspectives of clinical research quality across 
stakeholder groups. Further strengths of this study include our consideration of websites and 
any linked documents from a large number of stakeholders in 13 different countries in 
addition to a Medline search. Methodologically trained investigators screened articles and 
websites in duplicate following a pre-specified instruction manual and undergoing a 
calibration process.  
 
We acknowledge the following limitations: Although we consider our approach 
comprehensive, we searched only Medline as electronic database and relied on search 
terms in the title, abstract or other records.  Articles in journals not indexed in Medline or 
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providing some definition of research quality in the main text only might have been 
overlooked. However, Medline covers the most impactful journals and articles in current 
medical research and articles specifically focusing on quality of clinical research most likely 
mention this prominently. We may have missed definitions on websites despite screening 
these in duplicate. We would, however, expect stakeholder groups in clinical research to be 
transparent and proactive in defining such an important cornerstone of their activities, 
similarly to efforts in the field of clinical care quality. When coding our findings from the 
website search as well as from the Medline search we felt that we reached saturation, i.e. the 
last excerpts from websites or journal articles on aspects of clinical research quality did not 
bring new insights. The coding and qualitative analysis naturally involved subjective 
judgments of investigators, which we controlled by performing analyses in triplicate (BvN, 
CPM, MB) and comparing codes, findings, and interpretations until we reached consensus. 
Further, we acknowledge that our survey solely portrays perceptions on the quality of 
research in high income nations that may not necessarily overlap with those of low- or 
middle-income countries. With a growing percentage of clinical research being conducted in 
these geographies, a further study investigating quality perceptions of local stakeholders 
taking into consideration societal aspects and beliefs would be of importance. Finally, we did 
not conduct a detailed survey of experts or stakeholder groups - except for national funding 
agencies - nor did we conduct interviews with representatives of these groups to explore 
reasons for the paucity of explicit definitions. 
 
Comparison with other studies and implications 
We are not aware of any other systematic survey on definitions, concepts, or criteria of 
overall clinical research quality. A similar approach has been taken by other authors to 
develop a framework for excellence, however with a distinct focus on translational cancer 
research [41]. In the field of health care quality, the focus of assessments has more and 
more shifted from process-based measurements towards the evaluation of patient outcomes 
and patient satisfaction [42-44]. Clinical research conducted in this context of “patient-
centered” care would explicitly warrant the engagement and involvement of patients in 
setting priorities. However, patients (or their representatives) are only rarely considered when 
discussing the quality of research that might impact their care [45-47]. In our analysis, we 
also found patients to be surprisingly underrepresented. First, patient organizations were 
among the last in providing definitions or concepts of clinical research quality. Second, only 
six (14%) of a total of 43 quality measurement tools or assessments covered an item on 
patient safety and/or rights (Fig 1). Most efforts in quality assessments so far were taken to 
ensure compliance with guidelines, methodologically rigorous designs and valid study 
results. While this may ultimately serve the treatment of disease, we were expecting the 
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clinical research enterprise to put unmet medical need and applicability to the patient 
population first. Compared with medical care, the clinical research machinery still seems to 
function with relatively low engagement of the end user (patients) of the product. 
 
Furthermore, while we expected variations in the perception of quality across stakeholder 
groups, we were surprised how different and vaguely defined some of the concepts were. 
For example, an explicit definition of “high quality data” may be as dependent on the 
perspective of the observer as the definition of “high quality research”. It may be linked to 
concepts such as relevance of the data and absence of errors in the data or the way the data 
is collected. Similarly, the quality criteria used by funding agencies such as “impact”, 
“relevance”, or “feasibility” varied in their clarity and elaboration. Public funding agencies 
have a major role in terms of defining what and how research topics are investigated.  Those 
who use these criteria to evaluate proposals are still left with subjective interpretation, while 
applicants may aim to provide the readers with these buzzwords with not much reflection on 
their meaning.  
 
There remains considerable ambiguity in the use of current quality criteria across and within 
stakeholder groups. Unless carefully explained, these concepts can be easily misinterpreted 
by the stakeholders. Finding consensus on a common definition or concept of clinical 
research quality across national borders, stakeholder groups, and study types may therefore 
seem arduous; assessments of methodological quality do not, however, suffice. Existing 
quality guidelines such as ICH GCP have not been developed based on consensus across 
the full range of stakeholder groups, but only between regulatory experts and industry [15]. 
Existing quality assessment tools predominantly cover single aspects of quality, or particular 
research stages. Furthermore, there is a lack of approaches tailored to stakeholder 
requirements in assessing the quality of clinical research, e.g. from a patient’s perspective on 
how to choose a “good trial”, or from a funding agency’s perspective on how to assess the 
quality of studies before, during, and after the funding period. The authors of a follow-up 
study to the 2014 Lancet series reported that academic institutions in particular had paid only 
little attention to their recommendations on how to increase value in research. Practical 
guidance on how to implement these recommendations is so far lacking and urgently needed 
to increase value of academic research at all stages. 
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Conclusions 
This systematic survey serves as a first step of evidence summary to inform the development 
of a comprehensive framework of clinical research quality. It showed that definitions of 
clinical research quality are rarely provided and the existing definitions fall short of a 
theoretical or empirical framework across different study designs and stages and considering 
the variety of stakeholders involved. Based on our findings, a practically applicable 
framework needs to include the encountered quality dimensions such as ethical conduct, 
patient safety/rights/priorities, internal validity, precision of results, generalizability or external 
validity, scientific and societal relevance, transparency and accessibility of information, 
research infrastructure and sustainability) and consider different study stages such as 
planning, conduct, and dissemination. We plan to circulate framework drafts amongst 
stakeholder representatives of all eight groups until consensus on structure and content is 
reached, and to operationalize the framework through the development of instruments 
guiding stakeholder groups (e.g. academic institutions or funding agencies) in the 
comprehensive quality assessment of the full clinical research continuum. 
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Supporting information  
 
S1 Text. Literature search strategy 
1     Quality Control/  
2     total quality management/  
3     Quality Improvement/  
4     Quality Indicators, Health Care/  
5     exp *Reproducibility of Results/  
6     good clinical practic*.mp.  
7     or/1-6  
8     biomedical research/ or clinical nursing research/  
9     (biomedical and research).ti,ab.  
10     (clinical adj2 research).ti,ab.  
11     Randomized Controlled Trial* as Topic.mp. or Randomized Controlled Trials as Topic/  
12     clinical trial* as topic.mp. or Clinical Trials as Topic/  
13     Research/st [Standards]  
14     or/8-13  
15     7 and 14  
16     ((quality or valid* or data integrity) adj4 (clinical stud* or clinical data or clinical trial* or 
randomized trial* or randomised trial* or control* trial*)).ti,ab.  
17     ((quality or valid* or data integrity) adj4 (clinical or medical or human* or patient*) adj2 
research*).ti,ab.  
18     16 or 17  
19     15 or 18  
20     or/1-6  
21     14 and 20  
22     18 or 21  
23     (approach or assessment* or assessing or assurance or checklist* or check list*).tw.  
24     (code of conduct or concepts or concept or clinimetric* or definition* or evaluation*).tw.  
25     (framework* or guideline* or guidance or instrument or instruments or indicators or 
indicator).tw.  
26     (predictor* or measurement* or measures or measure or process or rating*).tw.  
27     (scale? or score? or standard? or norm? or system? or tool? or dimension? or 
item?).tw.  
28     (factor? or criteria or principle? or grading or grade or attributes or metrics or 
monitor).tw.  
29     (recommendation? or priority or priorities or construct? or determinant? or project?).tw.  
30     (report? or point? or categories or category or summaries or summary or ranking?).tw.  
31     (statistic? or term? or feature? or characteristic? or profile? or pattern? or rule? or 
idea).tw.  
32     (theory or paradigm? or consensus or statement or promotion or promoting or test?).tw.  
33     (improvement* or improving or increasing).tw.  
34     or/23-33  
35     22 and 34  
 
 
 
36
Manuscript I 
S2 Table. Data extraction forms 
A) Excel based extraction form for website search 
Organisation name Location Type of statement source Type of quality statement Text/Statement Comments Reference Link 
 International Government Document Definition     
 USA Journal Article Discussion     
 EU Legal Rule or Regulation Operationalisation     
 Australia Magazine Article Other     
 Canada Personal Communication      
 France Press Release      
 Germany Report      
 Italy Statute      
 Japan Web Page      
 Norway Guideline      
 UK Other      
 Switzerland       
 Spain       
 Sweden       
 Austria       
 Other       
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B) Web-based full text extraction form for literature search 
Name Type Label Options 
relevance list The article is relevant (according to inclusion/exclusion criteria, for details see 
"info") 
yes 
no, exclude 
relevance text Why is article not relevant? Please comment.  
article_type list The article's main focus is on Definition of quality 
Assurance/assessment of quality 
data list Article results are based on Expert consensus 
Author opinion 
Empirical data 
Other 
keytext text Copy key statement on quality definition from article  
keyword text Quality Item/s (separated by ;)  
dimension list To which quality dimension would you add the item/s? Absence of bias 
Precision 
External validity 
Innovation/Relevance 
Reporting/Transparency 
Education/Training 
GCP/Patient safety 
Other/New domain 
scale list Was an existing quality scale/checklist/score used? yes 
no 
namescale text Please provide the name of the scale/checklist/score used  
dimchecklist list Which quality dimension/s does the checklist/scale assess? Absence of bias 
Precision 
External validity 
Innovation/Relevance 
Reporting/Transparency 
Education/Training 
GCP/Patient safety 
Other/New domain 
indicators list Are additional indicators/metrics/measurement instruments or assessment 
methods of quality in clinical research mentioned? 
yes 
no 
nameindicator text Please state what these indicators/metrics/instruments or assessments are:  
addind list For which quality dimension are these indicators/metrics/assessments Absence of bias 
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representative? Precision 
External validity 
Innovation/Relevance 
Reporting/Transparency 
Education/Training 
GCP/Patient Safety 
Other/new domain 
comments text Comments  
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S3 Table. Quality definitions found through systematic internet search; by institution. Total number of 
institutions screened = 155. 
Organization Geographic 
scope 
Quality statement 
Governmental bodies / Jurisdiction 
World Health 
Organisation (WHO) 
International  (…) “Quality” is a measure of the ability of a product, process, or service to satisfy stated or implied needs. A 
high quality product readily meets those needs. In the context of a clinical trial, quality may apply to data (e.g., 
data are accurate and reliable) or processes (e.g., compliance with the study protocol and GCP; ensuring 
informed consent; adequate data handling and record-keeping, etc.). (See WHO GCP Principles 6: Protocol 
Compliance; 7: Informed Consent; 11: Records) (…) For all studies involving human subjects, even in the early 
stages (whether discovery or development), Good Clinical Practices are the correct quality and ethical 
standards. Tight national regulations ensure patient safety and methodological quality of clinical trials. (…) 
Bundesamt für 
Gesundheit (BAG) 
Switzerland (…) Art. 4 Scientific quality 
The sponsor and the investigator of a clinical trial shall ensure scientific quality. In particular: 
a.they shall define a research question based on the current state of scientific knowledge; 
b.they shall use an appropriate scientific methodology; and 
c.they shall ensure the availability of the resources required for the clinical trial and provide the necessary 
infrastructure  (…) 
Department of Health 
(DoH) 
UK  (…)The key elements of a quality research culture are: 
• respect for participants’ dignity, rights, safety and wellbeing; 
• valuing the diversity within society; 
• personal and scientific integrity; 
• leadership; 
• honesty; 
• accountability; 
• openness; 
• clear and supportive management. (…) 
Regulatory Agencies/HTA Bodies 
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Food and Drug 
Administration (FDA) 
USA  (…) “Quality” is characterized by the ability to effectively and efficiently answer the intended question about the 
benefits and risks of a medical product (therapeutic or diagnostic) or procedure while ensuring protection of 
human subjects. (…) 
Elements of a quality clinical study:  
- Scientifically valid and ethically sound experimental design 
- Adequate protection of subjects rights, safety, and welfare 
- Qualified personnel 
- “Adequate” monitoring 
- Current, complete, and accurate data (…) 
European Medicines 
Agency (EMA) 
EU (… ) Quality in this context is commonly defined as fitness for purpose. Clinical research is about generating 
information to support decision making while protecting the safety and rights of participating subjects. The quality 
of information generated should therefore be sufficient to support good decision making. (…) 
Pharmaceutical Manufacturers & Contract Research Organizations 
AstraZeneca UK  (…) Quality in clinical research may be defined as… 
• Reliability and credibility of information providing an answer to a scientific question 
• Compliance of the trial process with defined requirements 
(Nach ISO 9000: A quality is a set of characteristics that a product or service must have to satisfy needs and 
expectations of the customer.  
• Product of clinical research process: information.  
• Customers of clinical research : Society, Research subjects, sponsors, regulatory authorities, 
hospitals/institutions, IECs  (…) 
Pfizer USA  (…) Components for Quality: Clinical research quality is designed and embedded in the clinical trial processes 
and study protocol well in advance of enrollment of the first patient. Components of the quality process related to 
clinical trial sites include:  
• Creating, implementing, and upholding standard operating procedures (SOPs) for trial   execution  
• A quality scientific and medical design of the protocol   
• Clinical investigator and site pre-assessment and selection  
• Regulatory agency and ethics committee approval  
• Developing and providing appropriate informed consent (language, transparency of benefits and risks) and 
obtaining ethics committee approval of the informed consent process  
• Investigator meetings and training  
• Adequate recording and reporting of data  
• Periodic monitoring  
• Audits  
Target Health Inc.  USA (…) A “quality clinical trial” is one where 1) there is “absence of errors that matter” and 2) “are the data fit for 
use/purpose.” Errors “that matter” are those that have a 1) meaningful impact on patient safety and/or 2) 
Interpretation of trial results. (…) 
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Clinical Research Initiatives / Academic Clinical Research Organizations 
COCHRANE 
Collaboration 
International (…) Quality : A vague notion of the methodological strength of a study, usually indicating the extent of bias 
prevention.(…) 
DEPLHI International (…) Quality is a set of parameters in the design and conduct of a study that reflects the validity 
of the outcome, related to the external and internal validity and the statistical model used. (…) 
Swiss Group for 
Clinical Cancer 
Research (SAKK) 
Switzerland (…) Quality is defined by several aspects in our organization. In general quality means the evaluation if we meet 
specific requirements in the development and conduct of our trials. These requirements are defined on different 
levels: 
a) The law (HRA): local applicable law to conduct clinical research 
b) In international guidelines (ICH GCP, GMP Annex 13, EU guidelines ect). 
c) International scientific trial specific standards 
d) Our internal requirements (e.g. internal requirements to conduct trials with high risks (phase I trials), which go 
further than what is specified e.g. in the law) (…) 
Supranational and national patient organizations 
National Breast Cancer 
Coalition and Nancy 
Roach, Colorectal 
Cancer Coalition (USA) 
USA  (…)what “quality” means, i.e., what truly matters, to patients themselves:  
• (…)“quality” and risk-based quality management requires patient-centred clinical trials that are scientifically 
valid and designed to robustly, efficiently answer questions of true import to patients, rather than questions that 
are simply of scientific interest but ultimately would have little impact on enhancing patient care.  
• It requires trials that are designed to prevent risks and errors that truly matter to patient safety and the validity 
of the trial data.  
• In addition, quality means patient-centred trials that appropriately incorporate patient preferences into study 
design and comprise “rational” design that minimises patient burden and maximises patient benefit.  
And from the patients’ perspectives, “quality” also is defined by certain “don’ts”:  
• quality trials are those that do not introduce invasive and/or repeated procedures, unnecessarily numerous 
study visits, and unnecessary costs for patients that are not required for answering the trial’s questions.  
• They do not introduce unnecessarily restrictive inclusion and exclusion criteria that hamper accrual and may 
generate data that do not accurately reflect safety and efficacy for the larger patient population.  
• And participation in such trials does not require unneeded delays in treatment initiation secondary to screening 
and trial arm assignment.  
Coming full circle, quality trials provide uniformity in recruiting patients; are feasible and “practical” for both 
patients and their providers; include patient-centred, patient-friendly informed consents that truly inform patients; 
continually keep trial participants informed—whether the results are positive or negative; and move our body of 
knowledge forward and/or change practice.  
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S4 Table.  Quality themes appearing in proposal evaluation criteria 
of funding agencies  
A) Overview of quality criteria used by national funding agencies  
Overarching quality 
themes 
AU AUS CAN CH DE UK USA NOR 
Horizon 
2020 
Quality of researcher, 
applicant, and/or team x x x x x x x x 
 
Impact and/or 
significance of research 
project 
x 
 
x x 
 
x x x x 
Quality of scientific 
approach and/or 
methods 
x 
 
x x 
 
x x x 
 
Research infrastructure 
& financial capacity at 
applying site 
  
x 
 
x x x x x 
Consideration of 
diversity & equal 
opportunities of 
applicants 
 
x 
  
x 
  
x 
 
Ethical considerations of 
research project 
x 
    
x 
 
x 
 
Originality/innovation of 
research project   
x x 
  
x 
  
Feasibility of research 
project 
x 
  
x 
     
Requested resources or 
funding adequate for 
proposed project 
    
x x 
   
Quality of international / 
national cooperation 
arrangements 
    
x 
  
x 
 
Dissemination & 
communication of 
results 
              x   
Funding agencies by country/region. Australia: Australian Government; National Health and 
Medical Research Council; Austria: Wissenschaftsfonds FWF (Fonds zur Förderung der 
wissenschaftlichen Forschung); Canada: Canadian Institutes of Health Research; Germany: 
Deutsche Forschungsgemeinschaft ; United Kingdom: Medical Research Council ; United States 
of America: National Institutes of Health ; Norway: The Research Council of Norway; Switzerland: 
Swiss National Science Foundation; Europe: Horizon2020 
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B) Examples of criteria used by funding agencies to evaluate research proposals, by quality theme  
Overarching quality themes 
Examples (quotes) 
Quality of researcher, applicant, 
and/or team 
“Qualifications of the applicant(s), including training, experience and independence (relative to career stage). 
- Experience of the applicant(s) in the proposed area of research and with the proposed methodology. 
- Expertise of the applicant(s), as demonstrated by scientific productivity over the past five years (publications, 
books, grants held, etc.). Productivity should be considered in the context of the norms for the research area, 
applicant experience and total research funding of the applicant. 
- Ability to successfully and appropriately disseminate research findings, as demonstrated by knowledge 
translation activities (publications, conference presentations, briefings, media engagements, etc.). 
- Appropriateness of the team of applicants (if more than one applicant) to carry out the proposed research, in 
terms of complementarity of expertise and synergistic potential.” (Canadian Institutes of Health Research) 
 
“Applicants must have the professional competencies and qualifications required to complete 
the proposed action or work programme: it may be assessed on the basis of specific qualifications, 
professional experience and references in the field concerned” (Horizon2020) 
Impact and/or significance of 
research project 
“Assess the potential economic and social impact of the proposed research including: 
- Identification of realistic improvements to human or population health 
- Contribution to relieving disease/disability burden and/or improving quality of life 
- Identification of potential impacts of research and plans to deliver these” (Medical Research Council, UK) 
 
“Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project 
are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will 
successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative 
interventions that drive this field? “ (National Institutes of Health, USA) 
Quality of scientific approach and/or 
methods 
“This criterion gives an indication of the essential, fundamental aspects of the research project. The scientific merit of 
a project will be assessed in relation to the following points: 
- Originality in the form of scientific innovation and/or the development of new knowledge. 
- Whether the research questions, hypotheses and objectives have been clearly and adequately specified. 
- The strength of the theoretical approach, operationalisation and use of scientific methods. 
- Documented knowledge about the research front.  
- The degree to which the scientific basis of the project is realistic.  
- The scientific scope in terms of a multi- and interdisciplinary approach, when relevant.” (The Research 
Council of Norway) 
Research infrastructure & financial 
capacity at applying site 
“Availability and accessibility of personnel, facilities and infrastructure required to conduct the research. 
- Suitability of the environment to conduct the proposed research. 
- Suitability of the environment (milieu, project and mentors) for the training of personnel (if applicable).” 
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(Canadian Institutes of Health Research) 
 
“Will the scientific environment in which the work will be done contribute to the probability of success? Are the 
institutional support, equipment and other physical resources available to the investigators adequate for the project 
proposed? Will the project benefit from unique features of the scientific environment, subject populations, or 
collaborative arrangements?” (National Institutes of Health, USA)  
Consideration of diversity & equal 
opportunities of applicants 
“Proposal reviews should not disadvantage applicants due to extra-scientific reasons, such as age, gender or 
disability. Consider the applicant’s scientific career development rather than his/her age. You may compensate for 
certain extra-scientific disadvantages; unavoidable delays in the applicant’s scientific career (for example childcare 
responsibilities causing longer periods of qualification, gaps in publications, or less time spent abroad) should be 
taken into consideration.” (Deutsche Forschungsgemeinschaft, Germany) 
Ethical considerations of research 
project 
“Does the project give rise to any ethical issues? 
(Wissenschaftsfonds FWF, Austria) 
Originality/innovation of research 
project 
“Originality of the research question” (Swiss National Science Foundation) 
Feasibility of research project “(…) and feasibility of the proposal in terms of strengths and weaknesses” 
(Wissenschaftsfonds FWF, Austria) 
Requested resources or funding 
adequate for proposed project 
“Justification of the proposed staff needs by the work programme 
(…) Necessity and utilisation of the proposed instruments” (Deutsche Forschungsgemeinschaft, Germany) 
Quality of international / national 
cooperation arrangements 
For special programs: “Quality and add-on value of cooperation arrangements” (Deutsche 
Forschungsgemeinschaft, Germany) 
 
Additional criteria: “Quality of national and international cooperation” (The Research Council of Norway)  
Dissemination & communication of 
results 
“This criterion gives an indication of the quality of the dissemination and communication plans for the project. 
Dissemination and communication of results will be assessed in relation to the following points: 
• Plans for scholarly publication, dissemination and other communication activities. 
• Plans for popular science dissemination and communication activities vis-à-vis the general public as well as users 
of the project results, including planned use of channels and measures. 
• Plans for ensuring that important users (in industry, community life and public administration) are incorporated 
into/take part in dissemination activities for the project. 
When assessing dissemination and communication plans, importance should be attached to the level of detail 
provided and how realistic the plans are.” (The Research Council of Norway) 
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Research in context 
Evidence before this study 
In 2014, The Lancet published a Series (“Increasing value: reducing waste”) providing a 
voluminous body of evidence for sources of waste in biomedical research, along with 17 
recommendations on how to increase value, covering various stakeholders including 
funders, regulators, journals, academic institutions, and researchers. In 2016, a follow-up 
article emphasized little recognition of these recommendations by academic institutions. In a 
recent systematic survey of the literature and clinical research stakeholders, we showed that 
a commonly agreed definition or concept of “high quality research” remains to be developed.  
 
Added value of this study 
We suggest the first comprehensive framework that allows for assessment of the quality of 
academic clinical research. It is based on the consensus of a range of stakeholder groups 
across geographic regions, with a focus on its application in the academic setting. For the 
first time, varying stakeholder perspectives on quality are distilled in six quality dimensions 
that apply to all study designs involving patients. The framework provides guidance on how 
to assess quality at any point in a clinical study, i.e. from conceptualization of the research 
question to dissemination of study results. Through its development, major stakeholder 
groups have agreed on a common, holistic approach to quality and how to ultimately 
improve it in the future.  
 
Implications of the available evidence 
This framework may facilitate efforts to reduce waste and increase value, primarily as a 
common structure for the assessment of quality of clinical research at academic institutions. 
In a first step, its development has triggered all national stakeholders in Switzerland to 
convene and discuss the way forward to improve value in clinical research. It is in this 
setting that the framework currently undergoes refinement until it is validated for practice. 
Other interested stakeholder groups may validate the framework for their settings and share 
their approaches, thereby contributing to a growing momentum of increasing value and 
reducing waste. 
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Abstract  
Background: A 2014 Lancet series suggested that a high proportion of investment in 
biomedical research is wasted, and this waste is avoidable. Academic institutions have, thus 
far, shown little attention to recommendations for increasing value and reducing waste.  This 
study aimed to develop a conceptual framework guiding the comprehensive assessment of 
clinical research quality at academic institutions that could facilitate adoption of waste-
reducing strategies. 
 
Methods:  Based on a systematic survey of quality definitions, concepts, and criteria in the 
medical literature and on stakeholder websites from 12 countries, we systematically 
developed a comprehensive framework for clinical research quality. We conducted four 
rounds of an adapted online Delphi process among eight stakeholder groups from 16 
countries that ultimately achieved consensus on structure and content. 
 
Findings: All 52 final Delphi respondents agreed on an overall framework structure.  The 
framework spans five study stages (concept, planning and feasibility, conduct, analysis and 
interpretation, reporting and dissemination) and includes the following dimensions: (1) 
protection of participants’ safety and rights, (2) relevance and patient centeredness and 
involvement, (3) minimization of bias / internal validity, (4) precision, (5) transparency/public 
access to data, and (6) generalizability of study results. These dimensions are interacting 
with two promotors, education and infrastructure, that include a set of factors that may 
enhance all listed quality dimensions. Each quality dimension contains main questions and 
explanatory items that guide quality assessment at each individual research stage from 
conceptualization of the research question through dissemination of study results. Between 
96.2% (50/52) and 100% of Delphi participants agreed on content and wording of these 76 
main questions, depending on the research stage. 
 
Interpretation: We propose the first consensus-based framework guiding the assessment of 
quality of clinical research for academic research. Operationalization of this guidance will 
support the reduction of waste, from posing the right research question to the transparent 
publication of results. 
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Introduction 
Clinical research should generate reliable evidence to best inform decision-making in clinical 
practice and health policy, considering benefits, harms and cost.[1] Evidence on sources and 
extent of waste in research has, however, highlighted imbalanced research question 
selection, poor study design and execution, as well as non-publication and selective 
reporting.[2-6] Clinical research stakeholders have expressed concerns that the current 
model for conducting studies is unaffordable, unsustainable and, for the generation of new 
knowledge, seriously flawed.[1, 7-13] Low quality clinical research may not only result in 
invalid data or distorted outcomes [14], but is also unethical and compromises patients’ 
safety and rights. 
 
In 2014, The Lancet published a Series (“Increasing value, reducing waste”) [8-13] providing 
a voluminous body of evidence for sources of waste in biomedical research that also apply to 
clinical research. Along with a detailed analysis of potential sources of waste, the authors 
made 17 recommendations on how to increase value, covering various stakeholders 
including funders, regulators, journals, academic institutions, and researchers. A follow-up 
article in 2016 offered an overview of the initial stimulus of the series across stakeholder 
communities.[2] Although the authors noted innovation and momentum for corrective actions 
by some stakeholder groups, they specifically emphasized little recognition of the series by 
academic institutions. 
 
As a major driving force of patient-oriented clinical research, academia would be ideally 
placed to lead the movement to reduce waste.  Academia not only receives large proportions 
of public funding [15, 16] but is also producing the majority of scientific publications.[17] 
Despite significant investments in infrastructure, training, and methodological support [18, 
19], the issues raised by the Lancet authors persist. These include financial conflicts of 
interest [20] and scientific misconduct [21], limited dissemination of clinical trial results [22], 
and a higher risk for discontinuation in public versus industry-funded trials.[23] [24]  Potential 
reasons for slow progress and uptake of the Lancet recommendations include a lack of 
common academic policies across a complex ecosystem of stakeholders and their 
agendas.[2] Medical specialties and expert groups, ethics committees, regulatory bodies, 
funding agencies, industrial partners, and patients all have a say in academic research. Their 
perceptions on what constitutes “good clinical research”, however, are  vague and, to the 
extent they are articulated at all, vary.[25] Lack of a prior common understanding of the 
pillars that frame good clinical research, and practical guidance on how to improve the 
current situation, seriously inhibits efforts within the academic system to increase value.   
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The aim of this study was therefore to formulate an academic response to the Lancet series 
by (i) achieving consensus across a wide range of stakeholder groups on a comprehensive 
framework for the quality of clinical research, and (ii) developing guidance on how to 
operationalize the framework. We focus on clinical research conducted with patients and 
take the perspective of high-income countries.  
 
As a model, we highlight examples of the first successful applications of the framework in the 
Swiss academic setting. Switzerland has a long-standing tradition of initiatives that aim to 
improve the quality of academic clinical research. [26] Most prominently, Clinical Trial Units 
(CTUs) at all University hospitals partner with national funders, regulatory bodies, and policy 
makers, but also international initiatives such as the European Patient’s Academy on 
Treatment Innovation (EUPATI) or the European Clinical Research Infrastructures Network 
(ECRIN)[27] to continuously improve academic research.[28] It is in this context that we used 
the framework to establish consensus on the way forward to increase value of clinical 
research.  
 
 
Methods 
We developed a framework guided by the following principles 
i) integrating available empirical evidence on quality through a systematic survey 
[25] informing a first matrix of quality dimensions,  
ii) including the views of a broad range of stakeholder representatives[29-32] 
through four iterative rounds of a modified online Delphi process following current 
guidelines[33-35], 
iii) Addressing operationalization of the framework through detailed feedback of 
stakeholders from the Swiss academic setting. 
 
The scope of the framework covers different types and phases of clinical research. In the 
context of this work, we define clinical research as research conducted with patients to 
answer therapeutic, preventive, diagnostic, or prognostic questions, investigations of the 
mechanisms of human disease, or the development of new technologies. 
 
Appendix A presents a detailed description of the framework development and the 
consensus process.  In short, we consolidated the definitions, criteria, and themes as well as 
the derived tools and checklist identified through our systematic survey [25] into a 
comprehensive framework matrix applying the framework method according to Gale.[36]  We 
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first coded quality definitions, criteria, or themes into quality items (i.e. single aspects of 
quality) and grouped them thematically and according to stages of research.  We conducted 
iterative consultation addressing the comprehensiveness and presentation of the framework 
until we reached internal consensus.  
 
Delphi process 
Our team, with help from affiliated collaborators, and by word of mouth among the related 
networks (e.g. European Patient Academy on Therapeutic Innovation (EUPATI) for patient 
representatives) identified potential stakeholder representatives from 16 countries and seven 
groups (patient organizations and representatives, academic researchers/initiatives, medical 
faculties and clinical trial units, governmental bodies, regulatory agencies,  ethics 
committees, the pharmaceutical industry, and  funding agencies). We recruited participants 
on the basis of awareness of quality issues related to clinical research and ability to provide 
feedback within a specified time window. After invitation of representatives through the 
survey software SurveyMonkey© (www.surveymonkey.net), we conducted two Delphi-rounds 
aimed at (i) identifying any additional quality item that we had not yet considered, and (ii) 
establishing broad consensus across stakeholders on the overall framework structure. 
Consensus was pre-defined as an agreement of 80% or higher. After each round, we shared 
with respondents a summary of the adaptations made based on their suggestions in the 
previous round and asked for their agreement or further improvements and suggestions on 
structure and content. 
 
Seeking consensus on how to operationalize the framework structure in the Swiss academic 
setting, for Delphi rounds three and four, we invited additional stakeholder representatives 
from Switzerland, particularly academics. This included consensus on framework structure, 
content, and wording of main quality questions and corresponding examples. In round four, 
we additionally provided respondents with all anonymized comments, a response by the 
authors to each comment, and the overall agreement score on framework structure and main 
quality questions.  
 
Data Analysis 
Qualitative analysis was done for open-ended questions. We descriptively analyzed 
comments and suggestions for removal, addition, or adaptation of quality dimensions, and 
individual quality items and identified key themes based on repetition of concept words. 
Through discussions amongst the authors, the framework structure and content was adapted 
iteratively and fed back to the survey participants for discussion. Agreement scores were 
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calculated in percentages by dividing the number of participants agreeing by the total of 
participants who provided an answer to the respective question.  
 
Role of the funding source  
This research did not receive grants from funding agencies in the public, commercial, or not-
for-profit sectors. It was fully funded by an in-house grant of the Department of Clinical 
Research, which is co-chaired by Prof. Christiane Pauli-Magnus (CPM). CPM was involved 
in study design, collection, analysis and interpretation of the data, in writing the report, and in 
the decision to submit the paper for publication. The corresponding author had full access to 
all the data in the study and had final responsibility for the decision to submit for publication. 
 
 
Results  
Description of framework structure  
We invited 109 stakeholder representatives from 16 countries to participate in our Delphi 
process (Appendix A, Tables 1 and 2 present response rates). Total response rates ranged 
from 53.0% (58/109) in round one to 96.3% (52/54) in round four, and from 12.5% (3/24) for 
governmental representatives to 83.3% (10/12) of pharmaceutical industry representatives in 
the first round. In all four rounds, academic representatives were overrepresented to allow 
wide participation. After an agreement of 53.1% (26/49) of respondents in round one, 97.1% 
(33/34) in round two and 87.0% (47/54) in round three, 100% (52/52) of survey respondents 
agreed on a final framework structure (i.e. all building blocks, wording, and order) in round 
four.  The final agreement on content, i.e. the 76 main questions and their wording ranged 
from 96.2% (50/52, sustainability and education) and 98.1% (51/52, planning and feasibility) 
to 100% in all other stages. Appendix B presents all versions of the framework with track 
changes and the author’s reply to comments.  Three main building blocks provide the final 
framework is structured into (Figure 1):  
 
a) Six quality dimensions, with a dimension being defined as an overarching concept of 
quality containing multiple individual quality questions (Box 1): (1) Protection of 
patient safety and rights; (2) Relevance of study question and patient centeredness 
and involvement;  (3) Minimization of bias, i.e. internal validity; (4) Precision; (5) 
Transparency and access to data; and (6) Generalizability, i.e. external validity of 
study, 
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b) five successive study stages (concept, planning and feasibility, conduct, analysis and 
interpretation, and reporting and dissemination) to which the dimensions apply, and  
c) two quality promoters (infrastructure, sustainability and education), with a promotor 
being defined as set of factors that may enhance all listed quality dimensions at a 
research institution. 
Figure 1. Structure of the framework for quality of clinical research. Box 1 provides 
a brief description of each dimension and promoter. 
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Box 1. Description of quality dimensions and promoters 
Quality dimensions 
- The first quality dimension, protection of patients’ safety and rights, represents the 
cornerstone of clinical research. It assures that participants’ safety, rights, and well-
being are respected and protected at all times.   
- The second quality dimension, research relevance and patient centeredness and 
involvement reflects the extent to which the research question is scientifically and 
societally beneficial (i.e. leads to improved decision-making in health care) and 
involves patient values and preferences at all stages.  
- The third quality dimension, minimization of bias – or internal validity, reflects the 
extent to which systematic error (bias) is minimized, i.e. through selecting an 
appropriate study design and pre-specifying analyses.  
- The fourth quality dimension, precision - or statistical validity, reflects the extent to 
which random error is minimized (i.e. sufficiently narrow confidence intervals are 
achieved to confirm or reject clinical hypothesis), and to what level precision is 
reported and described in order for readers to be able to judge it.  
- The fifth quality dimension, transparency and access to data, reflects the extent to 
which study planning, conduct, data collection and presentation of results are 
transparent to and accessible for the scientific community and the public. It includes 
the registration of the study in a publicly accessible database, publication of the full 
study protocol,  publication of the study results - independent of their effect size or 
direction-, and explicitly, encouraging access to the full patient-level data set (data 
sharing).  
- The sixth quality dimension, generalizability – or external validity-, reflects the extent 
to which study results are applicable and generalizable to the wider patient 
population in real life circumstances.  
 
Quality promoters 
- The first quality promoter consists of an established research infrastructure with well-
trained personnel and functional facilities on-site. 
- The second quality promoter supports sustainability of a developed infrastructure 
through effective involvement and hands-on training of young and senior 
investigators as well as competent mentoring and early career development, and 
continuous education of study personnel in order to secure a productive clinical 
research environment in the long term. 
For a detailed description of the dimensions and promoters and empirical evidence 
supporting their importance, please see Appendix C. 
57
Manuscript II 
 
 
Operationalization of the framework 
In contrast to the existing quality assessment tools or checklists [25], we aimed to develop a 
framework in which all quality dimensions are applicable to each step in the conduct of 
clinical studies. During Delphi round one and two, participants commented on the 
characterization of study stages and ultimately achieved consensus.  The first study stage, 
conceptualization, starts with a clinical knowledge gap and ends with a clearly defined 
research question and appropriate study design. During the second study stage, planning 
and feasibility, the investigators develop a protocol based on their research question and 
assess the feasibility of their undertaking. This stage ends with approval of the protocol by 
regulatory bodies (if such approval is necessary). The third stage, study conduct, starts with 
the first patient recruited and ends with last patient last visit. During this stage, the 
investigators conduct the study according to the approved protocol. In stage four, analysis 
and interpretation, the investigators process and interpret the study data generated during 
conduct of the study. The last study stage, reporting and dissemination, covers all activities 
after analysis of the data, i.e. publication, dissemination, and archiving of study results.  
 
Applying the framework in the academic clinical research context (e.g. the longitudinal quality 
assessment of a particular study, or a study’s potential for funding), requires guidance on its 
operationalization. To this end, we developed “main quality questions” on which for each 
stage the Delphi participants commented, and on which – following revision - they finally 
agreed (see Appendix B for all versions of the framework and Appendix C, Table 1 for 
agreement scores). These main quality questions illustrate what quality aspect should be 
addressed and answered in a specific study stage. As an example, during concept phase, 
the dimension “Relevance / patient centeredness and involvement” can be further specified 
by asking the main question “Is significant add-on value to already existing evidence given, 
taking into consideration burden of disease and anticipated benefit of treatment?” (Table 1). 
Although the questions are tailored to the academic setting in a high-income country, all 
stakeholder groups agreed on these questions in Delphi round four. The main questions are 
explicitly designed to be broadly applicable to different study designs. More specific guidance 
on how to operationalize the framework for a particular study type or setting is provided by 
descriptive examples complementing the main questions in Appendix D.  
 
The development of the framework has already triggered several Delphi participants and 
members of the Swiss Clinical Trial Organization (SCTO) to organize a first Swiss 
symposium on “Adding value in clinical research: what’s been achieved and how do we 
manage new challenges? in June 2017 (https://www.scto.ch/de/event-
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calendar/symposium/symposium-2017.html). Along with two authors of the Lancet series, the 
current situation in Switzerland was discussed and the quality framework content presented.  
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Table 1. Content of the framework for the quality of clinical research including 
main questions, by research stage. Appendix D presents the full framework including 
quality promoters and examples. 
Study Stage I: Concept 
Milestone: Research question including study type defined and viable 
Dimension Main question 
Protection of patient safety and 
rights 
Can the research question be answered in the given setting? 
Does study consider equity appropriately? 
Is the research design adequate for the stage of an investigated 
technology to ensure patient safety? 
Do the (assumed) short and long term benefits of the study 
outweigh potential risks associated with the study (consistent 
with clinical equipoise)?  
Relevance /  
Patient centeredness and 
involvement 
Is significant add-on value to already existing evidence given, 
taking into consideration burden of disease and anticipated 
benefit of treatment? 
Are patient representatives/ advocates and their needs and 
values adequately involved in the development of the research 
question? 
Are outcome measures patient-relevant? 
Minimization of bias  
(internal validity) 
Is the selected study type/design appropriate to minimize bias?  
Are potential sources of bias anticipated, evaluating the 
magnitude and the likely direction? 
Are outcome measures well-defined, pre-specified, valid, reliable 
and measured at appropriate times? 
Precision 
 
Has estimate of the required sample size been made (for 
feasibility purposes, see “Protection of patient safety & rights”)? 
Transparency / Access to data Is the research question clearly specified (e.g. in a synopsis)? 
Generalizability  
(external validity) 
Are planned study participants representative of patients who 
would use the drug/intervention/diagnostic test in a real-life 
setting?  
 
Study Stage II: Planning and Feasibility 
Milestone: Protocol developed and approved by regulatory bodies 
Dimension Main question 
Protection of patient safety and 
rights  
Do the potential short and long term benefits of the study 
outweigh study burden (due to study visits, intervention, 
procedures etc.)?  
Are patients’ safety and rights protected through the study’s 
adherence to applicable national and international regulations 
and laws?  
Has feasibility been checked thoughtfully based on existing 
evidence? 
Is collection, documentation, and reporting of Adverse Events / 
Serious Adverse Events / Suspected Unexpected Serious 
Adverse Reaction  according to the applicable regulations 
planned and specified in the protocol? 
Are mechanisms established which allow early study termination 
when required and prevent early study termination for 
inadequate reasons? 
Relevance /  
Patient centeredness and 
 Is knowledge transfer/use (e.g. plans for inclusion of results in 
clinical guidelines) planned? 
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involvement 
Minimization of bias (internal 
validity) 
Is statistical analysis pre-specified (using outcomes as defined in 
concept stage)? 
Is study monitoring (adapted to risk of study, if applicable) 
planned and documented in a monitoring plan?? 
Is data management planned and documented in a data 
management plan? 
Is minimization of bias planned for according to the research 
question and study design? 
Precision  
 
Are expected treatment effects and event rates in intervention 
and control groups realistic and estimated based on empirical 
evidence? 
Are recruitment procedures and recruitment monitoring planned 
to ensure sufficient sample size? 
Transparency / Access to data 
Is the protocol in accordance with established standards (e.g. 
SPIRIT 37 or other applicable guidelines depending on study 
design)? 
Is there a dissemination plan to share study information including 
the protocol, summary results, and participant level data? 
Generalizability  
(external validity) 
Are study procedures/observations in line with routine practice in 
the given setting? 
 
Study Stage III: Conduct 
Milestone: Last patient last visit 
Dimension Main question 
Protection of patient safety and 
rights 
 
Is respect for and consideration of patient rights, well-being and 
dignity guaranteed throughout conduct of study? 
Is patient safety guaranteed throughout conduct of study? 
Is study conducted according to protocol? 
Is compliance of participants and study staff with protocol 
monitored? 
Are patients’ safety and rights protected through the study’s 
adherence to applicable national and international regulations 
and laws? 
Relevance /  
Patient centeredness and 
involvement 
Are there any measures in place to assure study participants’ 
involvement, cooperation, and feedback throughout conduct of 
study (e.g. incentives, phone calls, etc.)? 
Minimization of bias (internal 
validity) 
Are data systematically collected as pre-specified in protocol? 
Is monitoring conducted according to the pre-specified 
monitoring plan? 
Precision  
 
Is enrollment of study participants monitored?  
Is variability of study procedures and measurement error 
minimized, e.g. by utilizing centralized monitoring strategies? 
Transparency / Access to data Is study conduct transparent to all involved parties?  
Generalizability (external 
validity) 
Are numbers of participants through different stages of a study 
documented (patient flow) including reasons for leaving the 
study before its end (if voluntarily provided by patient)? 
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Study Stage IV: Analysis and Interpretation 
Milestone: Study data analyzed and interpreted 
Dimension Main question 
Protection of patient safety  & 
rights 
Does data sharing adhere to appropriate data protection 
policies? 
Relevance /  
Patient centeredness 
Are data analyzed so that the use of results by different 
stakeholders is maximized?  
Minimization of bias  
(internal validity) 
Is the data analyzed as pre-specified in the protocol/statistical 
analysis plan? 
Are key confounding variables adjusted for in the analysis (e.g. 
multivariable analysis), if applicable? 
Does the analysis follow an adequate strategy to deal with 
participants in whom treatment or follow-up was not in 
accordance with study protocol? 
Are results interpreted with least possible “spin”? (e.g. without 
intentionally implying greater or lesser effects than actually 
shown by the data)? 
Precision  Is the uncertainty of results considered in the analysis? 
Transparency / Access to data 
Is the analysis code clearly documented and the analysis 
process reproducible? 
Are deviations from the statistical analysis plan or protocol 
adequately documented and reported? 
Generalizability  
(external validity) 
Does the interpretation put the results adequately into context of 
clinical practice/public health? 
 
Study Stage V: Reporting and Dissemination 
Milestone: Study archived and published 
Dimension Main question 
Protection of patient safety and 
rights 
Is study completion/termination communicated to appropriate 
parties and documented in registries? 
Are study participants informed about outcome/main findings of 
the study in plain language (including treatment allocation of 
participant, if applicable)? 
Do study participants get access to products/interventions after 
study, if applicable? 
Relevance /  
Patient centeredness and 
involvement 
Do authors critically reflect on research findings (results as well 
as challenges or mistakes during study conduct) and the 
implications for future research? 
Is the study easily available to decision/policy/guideline makers? 
Are study patients/patient representatives involved in the 
reporting of the study? 
Minimization of bias  
(internal validity) 
Are all outcomes and important study characteristics reported as 
pre-specified in the protocol (outcome reporting bias prevented)? 
Precision  
 
Are absolute and relative treatment effects reported 
accompanied by confidence intervals? 
Is the analysis set of participants clearly specified?  
Transparency / Access to data 
Is dissemination of data and study results maximized? 
Are reporting guidelines followed to facilitate critical appraisal 
and reproducibility? 
Are selective reporting, “spin”, plagiarism and self-plagiarism 
avoided and conflicts of interest declared? 
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Is knowledge transfer & exchange fostered? 
Are study records and data sets kept and archived for the legally 
required period of time?  
Generalizability  
(external validity) 
Is potential impact on clinical practice / public health outlined in 
publicly accessible research reports (e.g. journal publication)? 
Are characteristics of included participants clearly reported 
Are results of pre-specified subgroup analyses, if applicable, 
reported in order to assess the importance of key participant 
characteristics (e.g. disease severity, age or gender)? 
 
 
Discussion  
This study represents the first effort to involve a range of stakeholder groups across 
geographic regions to formulate an academic response to the Lancet series on increasing 
value and reducing waste in clinical research. We suggest a comprehensive, consensus-
based quality framework that is applicable to all study types and spans the entire lifecycle of 
a clinical study, i.e. from conceptualization of the research question to dissemination of study 
results.  We designed the framework to increase value through operationalization by 
academic institutions that, thus far, have shown only little recognition of the Lancet series. 
 
The limited resources in the academic setting urge to emphasize that relevant research 
should build on what is already known, i.e. be preceded by systematic reviews.[38, 39] We 
particularly put emphasis on the conceptualization and planning and feasibility stage at which 
the protocol including research question and study design is developed, and its overall 
feasibility is assessed. Research questions should lead to clinically relevant information gain 
without influence by special interest groups (e.g. industry sponsors). [40] [9, 41] Further, 
feasibility assessments of the planned study are crucial in order to avoid waste in financial 
and human resources – and to justify exposing participants to burdens or risks. A lack of 
feasibility assessment often results in low recruitment rates leading to the many clinical trials 
that are terminated prematurely [7, 23, 42-47] that cannot generate valid scientific knowledge 
and are thus unethical.[48, 49] We highlight that pragmatic study designs or collection of 
real-world data, for example, may capture real-life circumstances in such resource-restrained 
settings and allow for greater applicability and consideration of external validity. [50-53] 
 
At all stages of the framework, we provide guidance on how to involve patients from 
conceptualization of the research question through conduct and eventually, publication and 
dissemination of lay language summaries. Academic clinical research should be patient-
oriented and avoid dominant commercial interest. Investigators should not only align their 
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research with patient priorities and the utilities patients assign to different problems and 
outcomes, but also ensure acceptability of their interventions.[1, 12, 54] Initiatives such as 
the Patient-Centered Outcomes Research Institute (PCORI) [55], the James Lind Alliance 
(www.lindalliance.org), and the INVOLVE Initiative in the UK (www.invo.org.uk) provide 
guidance and suggest patient engagement at all stages of a clinical study. 
 
The framework and its operationalization thus potentially provide a supporting structure for 
the Reducing Waste, Reward Diligence (REWARD) Campaign 
(http://researchwaste.net/reward-statement/) to increase value and reduce waste. At Swiss 
national level, the framework has triggered all stakeholders to convene in a first symposium 
on how to increase value of academic clinical research. 
 
Strengths and weaknesses  
The strength of this study is that it is unique in achieving a consensus among very diverse 
stakeholder groups on a prominent, but complex and ill-defined concept. Our response and 
agreement rates during the two consensus finding rounds were very high.  Moreover, we had 
prepared for this work with an extensive systematic search of the existing definitions, 
approaches, and measurements of clinical research quality across cultures and stakeholder 
groups that revealed a lack of a common concept. We therefore developed this framework 
based on empirical evidence and, before circulating it for consensus, considered the 
interests of a wide variety of stakeholders. The resulting guidance is the first of its kind to 
support academic institutions, researchers, and other stakeholders in the holistic assessment 
of study quality with the overall aim of increasing value and reducing waste in clinical 
research.  
 
Our study has several limitations. In the Delphi process, participation varied across 
stakeholder groups and therefore, some stakeholder opinions may be under- or 
overrepresented.  For example, patients are underrepresented because it was rather difficult 
for them to comment on later, more complex versions of the framework. We made every 
effort to contact and motivate patient representatives and to explain the framework content in 
plain language. In contrast, academics were intentionally overrepresented. We limited 
stakeholders to those who were willing to reply in English, German, French, or Italian.  
 
We are aware that the framework with its 76 main questions covers a substantial number of 
topics and might be considered too comprehensive for application in practice. However, this 
quality framework emphasizes the need for a holistic approach to quality, rather than 
restricting the focus to individual dimensions. The items are not meant to be prescriptive, and 
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we do not define a minimum set of criteria that an investigation should meet. Although all 
criteria are important and, independent of the setting, any stakeholder group should address 
every dimension, different weights may be applied for different clinical research designs.  
Similarly, certain criteria or “quality promoters” may be difficult to attain in resource-restrained 
settings. Our collaboration with researchers from the Swiss Public and Tropical Health 
Institute aims to adapt the framework for lower income settings. 
 
Next steps in implementation 
The rapid uptake of the framework in Switzerland has been driven by the broad consensus 
across Swiss representatives of all major clinical research stakeholder groups including 
not only academia, but also ethics committees, regulatory and governmental bodies, 
funding agencies, patients, and the pharmaceutical industry. After the initial get -together 
at the national symposium in June, we plan a one-day strategy workshop engaging a 
diverse group of Swiss stakeholder representatives and policy makers at the end of this year. 
Together with the Swiss Clinical Trial Organization, which currently incorporates the 
framework content in its operational and strategic quality policies, we will discuss main 
objectives including how to set a quality research agenda for academic clinical research in 
Switzerland, how to implement measures to improve quality nationally, how to monitor 
progress and how to generate empirical evidence on the impact of these measures in the 
long run. Some of the participants will be the leaders of the Swiss initiative “We Scientists 
Shape Science” (https://naturwissenschaften.ch/wescientists) that held a first congress in 
January with over 200 scientists debating on how to improve science in Switzerland and 
globally.  
 
At local level, multiple initiatives are currently ongoing to test the framework’s real-world 
potential in Switzerland (Box 2). All initiatives aim at evaluating the framework’s content 
validity through a continuous process of evaluation, refinement, and development of future 
versions that we will report on. 
 
Due to its broad acceptance across international stakeholders in round one and two and its 
theoretical underpinning, the framework may also be utilized for setting the agenda for other 
stakeholder groups or geographies. Box 1 and 2 in Appendix E describe a variety of 
scenarios at different organizational and institutional levels in which the framework may be 
applied. 
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Box 2. Increasing value of research at local level – four examples from a 
Swiss academic hospital 
 
(1) Setting the research agenda 
The Department of Clinical Research at the University Hospital Basel uses the 
framework for setting its research agenda. It systematically applies the main 
questions to identify “excellence potential” across research projects that apply for 
scarce Departmental grant funding for special methodological support.  
 
(2) Improving methods support 
The methodological support units have started to use the framework as quality 
guidance in their clinical/epidemiological consulting activities. Depending on the 
research stage of a particular study, the framework is used to guide researchers 
in the conceptualization, planning, conduct, analysis or dissemination of their 
study.  
 
(3) Researching research 
The practical challenges faced by investigators identified during consulting 
services serve as the basis for the methodological research units to initiate 
studies to investigate innovative solutions. These studies aim to generate 
empirical evidence on single aspects of the framework and whether they improve 
value or not.  
 
(4) Monitoring impact  
The Clinical Trial Unit pilots the use of the framework criteria to longitudinally 
asses its impact on research quality for the Swiss Clinical Trial Organisation.  On 
site, a cardiology department has applied the framework as a tool to assess the 
quality of two ongoing large studies, one retrospective cohort and one RCT.  The 
framework has also proven useful as teaching material for early career 
investigators in the group.  
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Conclusion 
The proposed framework is based on the acceptance of a diversity of international and Swiss 
clinical research stakeholder groups with the aim to establish a common, well-differentiated 
academic answer to the discussion initiated by the Lancet series. The framework will, as a 
structure for operationalizing the assessment of quality of clinical research at academic 
institutions, facilitate implementation of waste reduction and value increasing initiatives. To 
take the field forward, we encourage the research community and interested stakeholder 
groups to apply the framework, generate evidence on content validity, and to transparently 
and openly share their approaches. 
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Appendix  
 
A - Methods 
Defining the framework structure 
In a previous systematic survey[25], we had identified a range of quality definitions, criteria, 
and themes across different stakeholder groups, as well as a range of quality assessment 
tools and checklists. These definitions, criteria and themes as well as the derived tools and 
checklist were consolidated into a comprehensive framework matrix applying the framework 
method according to Gale [36].  This included the following two- step procedure: 
First, we derived the following three structural building blocks for an initial framework (Table 
1): 
a) quality dimensions, with a dimension being defined as an overarching concept of 
quality containing multiple individual quality questions, 
b) successive study stages to which the dimensions apply, with a stage being defined 
as a well-defined period within the continuum of a study, and 
c) quality promoters,  with a promotor being defined as set of factors that may enhance 
all listed quality dimensions at a research institution. 
 
Table 1. Initial framework matrix 
 Research stage 1 Research stage 2 Research stage … 
Quality dimension 1 - Item 1 
- Item 2 
- Item 3 
…  
Quality dimension 2 … …  
Quality dimension …    
 
Second, quality definitions, criteria, or themes acquired through our systematic search were 
first coded into quality items (i.e. single aspects of quality) and then thematically grouped into 
overarching quality dimensions. We identified a total of six quality dimensions and five 
successive temporal research stages, resulting in a 5x6 matrix. Two groups of items, those 
belonging to infrastructural aspects and the sustainability aspect of educating junior 
researchers, did not fit within one dimension or temporal stage and were included as quality 
promoters. We subjected this initial framework to iterative consultation about 
comprehensiveness and subsequent editing by the authors and affiliated interested 
academics until we reached internal consensus. 
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Delphi process 
We subjected the framework to a modified online Delphi process consisting of three 
successive stages: 
i) Identification and invitation of stakeholder representatives  
ii) Delphi-rounds 1 and 2: Identification of any additional quality item that we had not 
yet considered, and establishing broad consensus across stakeholders on the 
overall framework structure 
iii) Delphi rounds 3 and 4: Seeking agreement on a more refined framework including 
main quality questions and descriptive examples, with a focus on 
operationalization in the Swiss academic setting 
 
i) Identification of stakeholder representatives 
To allow for broad inclusion of perspectives, we considered the same seven stakeholder 
groups to be relevant as in the systematic survey [25]: (1) patient organizations and 
representatives, (2) academic national research institutions/initiatives, clinical investigators, 
academic clinical trial units, methodological researchers (3) national and supranational 
governmental bodies, (4) regulatory agencies, (5) ethics committees, (6) the pharmaceutical 
industry and contract research organizations, and (7) funding agencies. 
Our team, with help from affiliated collaborators, and by word of mouth among the related 
networks (e.g. European Patient Academy on Therapeutic Innovation (EUPATI) for patient 
representatives) identified potential stakeholder representatives from 16 countries. We 
recruited participants on the basis of awareness of quality issues related to clinical research 
and ability to provide feedback within a specified time window.  
 
ii) Delphi-rounds 1 and 2 
In round one and two, 109 survey participants from 16 countries were invited through the 
survey software SurveyMonkey© (www.surveymonkey.net) to provide their comments on the 
overall suitability and the comprehensiveness of the proposed framework structure, and the 
individual items to be included. These two Delphi-rounds aimed at (i) identifying any 
additional quality item that we had not yet considered, and (ii) establishing broad consensus 
across stakeholders on the overall framework structure. Consensus was pre-defined as an 
agreement of 80% or higher. Only stakeholders who responded in round one were invited to 
participate in the following round. After each round, we shared with respondents a summary 
of the adaptations made based on their suggestions in the previous round and asked for their 
agreement or further improvements and suggestions on structure and content. Of the 109 
invited, 58 (53%) participants provided suggestions or comments in the first round; and 
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45/109 completed both rounds (Table 1). In each round, we sent two reminders via 
SurveyMonkey©. 
 
Table 1. Response rates by stakeholder group for Delphi rounds one and two 
 
 
 
Round 1 Round 2 
 
Number of 
participants 
invited 
(thereof 
(Swiss) 
No of 
respondents 
(thereof 
Swiss) 
Total 
response 
rate,% 
1
 
No of 
respondents  
(thereof 
Swiss) 
Total 
response 
rate,% 
1
 
Stakeholders 
Patient group / 
representative 
20 (19) 10 (10) 50.0 7 (7) 70 
Academia 39 (11) 28 (8) 71.8 23 (8) 82.1 
Pharmaceutical 
Industry / CROs 
12 (5) 10 (5) 83.3 6 (4) 60 
Ethics committee 
/ IRB 
8(5) 4 (3) 50.0 3 (2) 75 
Governmental 
bodies & 
Regulatory 
bodies 
24(2) 3 (1) 12.5 3 (1) 100 
Funding Agency 6 (2) 3 (2) 50.0 3 (2) 100 
No of countries
2
 16 13  11  
Total 109 58 53 45 78 
1 Response rates were calculated based on the number of respondents in each round compared to the 
respondents in the previous round; only respondents were invited to participate in further rounds of the 
survey 
2 International organizations or companies: Location of headquarters 
 
iii) Delphi-rounds 3 and 4 
Seeking consensus on how to operationalize the framework structure in the Swiss academic 
setting, for Delphi rounds three and four, we invited additional 33 stakeholder representatives 
from Switzerland, particularly academics (Table 2). In particular, we invited representatives 
(board members and executive directors) of all six Swiss Clinical Trial Units at University 
hospitals and members of the executive committee and the Quality Working Group at the 
Swiss Clinical Trial Organization. For this round, the previous “quality items” were rephrased 
as “main quality question” accompanied by descriptive examples in order to allow 
operationalization of the framework (Table 3). We asked for the agreement (yes/no) on the 
adapted framework structure, content, and wording of main quality questions and 
corresponding examples and allowed for free text comments on the suitability, the 
comprehensiveness, and the completeness of dimensions and items for each research 
stage. In round four, we additionally provided respondents with all anonymized comments, a 
response by the authors to each comment, and the overall agreement score on framework 
structure and main quality questions Participants were again asked for their agreement on 
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structure and content of the framework and were allowed to suggest specific adaptations to 
the framework using a shareable, but anonymized, googledocs.com 
(https://docs.google.com) format. Final adaptations to the framework were made by the 
authors through iterative discussion and shared with the Delphi participants. After round four, 
an agreement of over 80% was reached for the structure as well as the main quality 
questions in each research stage (Table 2). In each round, we sent minimum two email 
reminders. 
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Table 2. Response rates by stakeholder group for Delphi rounds three and four 
 Round 3 Round 4 
 No of 
participants 
invited 
from round 
2 (thereof 
Swiss)
1
 
No of 
respondents 
(thereof  
Swiss) 
No addit. 
invited 
participants
2
 
(No of 
respondents) 
Total  No of 
respondents 
(thereof Swiss) 
Total response 
rate, % (thereof  
Swiss)
3
 
No of 
respondents
4 
(thereof Swiss) 
Response rate, 
% ( thereof 
Swiss) 
Stakeholders 
Patient group / 
representative 
7 (7) 3 (3) 0 (0) 3 (3) 42.8 (100) 3 (3) 100 (100) 
Academic 
representatives: 
23 (8) 14 (5) 28 (19) 33 (24) 64.7 (66.7) 31 (24) 93.9 (100) 
National research 
institutions 
6 (4) 5 (4) 9 (4) 9 (7) 60.0 (53.8) 9 (7) 100 (100) 
Clinical investigators 4 (2) 2 (1) 5 (4) 7 (6) 77.8 (85.7) 7 (6) 100 (100) 
Academic Clinical Trial 
Units 
0 (0) 0 (0) 11 (9) 9 (9) 81.8 (81.8) 9 (9) 100 (100) 
Methodological research 13 (2) 7 (2) 3 (2) 9 (2) 56.3 (40) 7 (2) 77.8 (100) 
Pharmaceutical Industry / 
CROs 
6 (4) 4 (2) 1 (1) 5 (3) 71.4 (60) 5 (3) 100 (100) 
Ethics committee / IRB 3 (2) 3 (2) 1 (1) 4 (3) 100 (100) 4 (3) 100 (100) 
Governmental bodies & 
Regulatory bodies 
3 (2) 3 (2) 2 (2) 5 (4) 100 (100) 5 (4) 100 (100) 
Funding Agency 3 (2) 3 (2) 1 (1) 4 (3) 100 (100) 4 (3) 100 (100) 
No of countries 11 9 1 9  7  
Total 45 (24) 30 (16) 33 (24) 54 (40) 69.2 (70.2) 52 (40) 96.3 (100) 
1 All respondents from round two were invited to participate in round three 
2 Predominantly representatives of Swiss academia, n=3 were non-Swiss  
3 Response rates were calculated based on the number of participants invited from round two and the additional Swiss participants invited for round 
three and four only  
4 Participants who responded to round three were invited to participate in round four  
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B - All versions of the framework including Delphi survey 
comments. 
Available on request. 
 
 
C - Results  
Table 1. Agreement scores of Delphi participants on framework structure and 
content. Only includes those participants who gave an answer to the respective question. 
 Delphi round 3, n (%) Delphi round 4, n (%) 
Overall framework structure
1 
 
Total : 47/54 (87.0) 
Swiss only: 36/40 (90.0) 
Total: 52/52 (100) 
Swiss only: 40/40 (100) 
Stage I: Conceptualization, main 
questions 
Total: 40/52 (76.9) 
Swiss only: 30/40 (75.0) 
Total: 52/52 (100) 
Swiss only: 40/40 (100) 
Stage II: Planning and feasibility, 
main questions 
Total: 39/51 (76.5) 
Swiss only: 30/39 (76.9) 
Total: 51/52 (98.1) 
Swiss only:39/40 (97.5) 
Stage III: Conduct, main questions 
Total: 43/51 (84.3) 
Swiss only: 32/37 (86.5) 
Total: 52/52 (100) 
Swiss only: 40/40 (100) 
Stage IV: Analysis and 
Interpretation, main questions 
Total: 43/51 (84.3) 
Swiss only:  32/37 (86.5) 
Total: 52/52 (100) 
Swiss only: 40/40 (100) 
Stage V: Reporting and 
dissemination, main questions 
Total: 41/ 51 (80.4) 
Swiss only: 31/37 (83.8) 
Total: 52/52 (100) 
Swiss only: 40/40 (100) 
Quality promoter: Infrastructure 
Total: 45/51 (88.2) 
Swiss only: 34/37 (91.9) 
Total: 52/52 (100) 
Swiss only: 40/40 (100) 
Quality promoter: Education and 
sustainability 
Total: 44/51 (86.3) 
Swiss only: 35/37 (94.6) 
Total: 50/52 (96.2) 
Swiss only: 38/40 (95.0) 
1Agreement score on overall framework structure in round 1: 26/49 (53.1%); in round 2: 33/34 
(97.1%). 
 
Detailed description of quality dimensions 
Protection of patients’ safety and rights 
The first quality dimension, protection of patients’ safety and rights, represents the 
cornerstone of research and is therefore a conditio-sine-qua-non dimension in our 
framework. It assures that participants’ safety, rights, and well-being are respected and 
protected at all times.  
 
Participants should be informed about the research and provide their voluntary consent, but 
also have the opportunity to withdraw.[1-3] Within the context of standard clinical practice 
and the research protocol, potential benefits to individuals and the society must outweigh the 
risks[4],[5] and there should be clinical equipoise- the absence of a consensus regarding the 
comparative merits of the interventions to be tested.[1, 6] During and after the conduct of the 
study, participants’ rights, safety, and privacy must be protected at all times. Further, study 
participants should be selected in a fair and equitable manner.[1] Moreover, the research 
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protocol must be practically feasible. For example, research that could not possibly enroll 
sufficient participants cannot generate valid scientific knowledge and is thus unethical.[1, 4] 
Feasibility assessments prior to study start are crucial in order to avoid waste in financial and 
human resources – and to justify exposing participants to burdens or risks - leading to the 
many clinical trials that are terminated prematurely.[7-15]  
 
Relevance, patient centeredness and involvement  
The second quality dimension, research relevance and patient centeredness and 
involvement reflects the extent to which the research question is scientifically and societally 
beneficial (i.e. leads to improved decision-making in health care) and involves patient values 
and preferences at all stages. 
 
Relevant research should build on what is already known, preceded by systematic 
reviews.[16, 17] Further, it should address a question leading to clinically relevant information 
gain [18, 19] avoiding subjective approaches that may be unduly influenced by special 
interest groups.[20] Institutions should reward rigorous replication of previous work in order 
to battle the low rate of confirmation.[21] Ideally, this is incorporated upfront in designing the 
research agenda in a given field in order to avoid multiple necessary replications or 
redundant meta-analyses combining them.[19, 22] Further, relevant research is patient 
centered and should be aligned with patient priorities, the utilities patients assign to different 
problems and outcomes, and how acceptable they find interventions over the period for 
which they are indicated.[7, 23, 24] As suggested by initiatives such as the Patient-Centered 
Outcomes Research Institute (PCORI) [25], the James Lind Alliance (www.lindalliance.org), 
or the INVOLVE Initiative in the UK (www.invo.org.uk), patient values and preferences 
should be fostered through patient (representative) engagement during all stages of a clinical 
study.  For example, through close collaboration with patient organizations at all stages, 
adaptations of inclusion and exclusion criteria where necessary, or appropriate dissemination 
of lay language summaries of study outcomes.   
 
Minimization of bias – Internal validity 
The third quality dimension, minimization of bias – or internal validity, reflects the extent to 
which systematic error (bias) is minimized, i.e. through selecting an appropriate study design 
and pre-specifying analyses.  
 
Minimizing bias and thereby maximizing internal validity is dependent on the chosen study 
design and has been described to be difficult to avoid.[26] Established tools such as the 
Cochrane Risk of Bias tool for RCTs [27], ROBINS-I for observational research [28] or 
77
Manuscript II 
 
QUADAS-2 for diagnostic accuracy studies [29] provide guidance on how to plan and 
conduct studies with minimal bias.  An effective solution to mitigate self-deception, for 
example, is blinding, which is applicable to some research contexts. Chosen outcomes 
should be pre-specified, valid, reliable, measured at appropriate times, and comparable 
across similar trials.[30-32] Data collection should then be conducted in accordance with the 
procedures pre-specified in the protocol. In general, the adoption of appropriate statistical 
methods [33], standardized definitions and analyses and stringent thresholds for claiming 
discoveries success [34] may decrease false-positive rates. Finally, conflicts of interests 
should be avoided, or at least transparently reported, in order to avoid spinning of more 
favorable conclusions due to the involvement of conflicted parties.[35, 36]   
 
Precision  
The fourth quality dimension, precision - or statistical validity, reflects the extent to which 
random error is minimized (i.e. sufficiently narrow confidence intervals are achieved to 
confirm or reject clinical hypothesis), and to what level precision is reported and described in 
order for readers to be able to judge it.  
 
The development and approval of valid study methods and improvements in study design 
have been described to improve the precision, and therefore reliability of results.[37] Then, 
efforts need to be made to minimize variability of study procedures and measurement error 
throughout study conduct to guarantee interpretable data and an ethical study conduct.[1] 
It is further important that expected treatment effects and event rates in intervention and 
control groups are realistic, and that estimates are based on empirical evidence.  Validated, 
non-surrogate outcomes should provide clinical insights to claim power.[7, 38-40] Sample 
sizes should be justified to measure the expected impact, and recruitment should 
continuously be monitored to ensure successful reach of target sample size. 
 
Transparency and access to data 
The fifth quality dimension, transparency and access to data, reflects the extent to which 
study planning, conduct, data collection and presentation of results are transparent to and 
accessible for the scientific community and the public. It includes the registration of the study 
in a publicly accessible database, publication of the full study protocol,  publication of the 
study results - independent of their effect size or direction-, and explicitly, encouraging 
access to the full patient-level data set (data sharing).  
 
Reporting, review, publication, dissemination, and post-publication review of research 
shape its reliability.[35] There are currently over 300 reporting guidelines to improve and 
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standardize reporting (e.g. as catalogued by the EQUATOR Network, 
http://www.equator-network.org/) and multiple ideas about how to change dissemination 
of information.[41]  Yet, studies that obtain positive and novel results are more likely to 
be published than studies that obtain negative results or report replications of prior 
results.[26, 41-43] Research should be pre-registered, as promoted by websites such as 
Open Science Framework (http://osf.io/) in order to enhance transparency.[44-47] 
Registration has been proposed for many types of research, including observat ional 
studies. Reporting of outcomes should be completely consistent with the pre-registered 
commitments, and avoid adding new ones (see www.COMPare-trials.org). 
 
Further, sharing of data, protocols, materials, and softwares should be promoted as 
happening in several –omics fields and may similarly improve the credibility and 
reproducibility of clinical research studies.[26, 48] The TOP guidelines67 promote open 
practices while an increasing number of journals and funders require open practices (for 
example, open data), with some offering their researchers free and open access 
publication.  
 
Generalizability – external validity 
The sixth quality dimension, generalizability – or external validity-, reflects the extent to which 
study results are applicable and generalizable to the wider patient population in real life 
circumstances. 
 
Thus, the characteristics of planned study participants should be representative of patients 
who would use the intervention after study end. Further, the flow of participants through each 
stage including the reasons for which patients left the study before its end should be 
documented and reported, together with the results of pre-specified subgroup analyses of 
key patient characteristics (e.g. disease severity, age or gender). Treatment effects may be 
similar in nonparticipants and capturing real-life circumstances is possible by utilizing 
pragmatic study designs [49] allowing for greater applicability and consideration of external 
validity.[50-52] In 2009, a first tool called the Pragmatic Explanatory Continuum Index 
Summary (PRECIS) was published to help researchers think more carefully about the impact 
their design decisions would have on applicability.[53] In 2015, an improved, validated 
version of PRECIS was published providing guidance on how to match design decision to 
how the trial results are intended to be used.[51]  
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Description of quality promoters 
Sustainability and Education 
Examples of good scientific conduct should be used in practice to train early-career 
researchers, making quality sustainable. In addition, proper training and continuing education 
of scientists in research methods and statistical literacy are important to train physicians in 
critical thinking skills instead and evidence-based research instead of simply producing more 
papers.[54] Common statistical misperceptions and interpretations could be addressed 
through improved training.[24, 26] Moreover, methodological best practices are under 
constant revision and improvement so that senior as well as junior researchers need 
continuing education, not least because much training of early-career researchers is informal 
and flows from their supervisors or mentors.[26] Educational resources should be accessible, 
easy-to-digest and immediately and effectively applicable to research in order to maximize 
their use.[26] 
 
Infrastructure 
In addition to infrastructural support such as space, equipment, or materials, the need for 
independent methodological support is well established, particularly for clinical trials. Many of 
them have multidisciplinary steering committees to provide advice and oversee the design 
and conduct of the trial.  Including independent experts in the design, monitoring, analysis or 
interpretation of research outcomes may not only improve the study, but also mitigate 
influences such as financial or non-financial conflicts of interests of the investigators.[55, 56] 
Collaboration across many study sites can- instead of relying on the limited resources of 
single investigators- facilitate high-powered designs, standardization, and greater potential 
for testing generalizability across the settings and populations sampled.[26] 
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D - Full framework, including main quality questions and examples 
Study Stage I: Concept 
Milestone: Research question including study type defined and viable 
 
Dimension Main question Examples 
Protection of 
patient safety & 
rights 
Can the research question be answered in 
the given setting? 
Based on a rough resource assessment, and 
potentially available study participants, is it feasible to   
answer the research question?  
Based on a rough budget estimate, is it feasible to 
answer the research question with a specified study 
type? 
Does study consider equity appropriately? 
Are participants selected so that : 
vulnerable individuals are neither targeted for risky 
research nor withheld from research relevant to these 
populations? 
socially powerful individuals are not favored for 
potentially beneficial research? 
Is the research design adequate for the 
stage of an investigated technology to 
ensure patient safety? 
Are sufficient data on toxicity/teratogenicity of an 
intervention available from animal studies or phase I 
studies?  
Do the (assumed) short and long term 
benefits of the study outweigh potential 
risks associated with the study (consistent 
with clinical equipoise)?  
 
Relevance /  
Patient 
centeredness & 
involvement 
Is significant add-on value to already 
existing evidence given, taking into 
consideration burden of disease and 
anticipated benefit of treatment? 
  
Are uncertainties in existing evidence identified and 
discussed in a systematic review? 
Does research: 
Expand or challenge current knowledge? 
Open additional areas for new research activity? 
Justify replication of existing evidence, if applicable? 
Are patient representatives/ advocates and 
their needs and values  adequately 
involved in the development of the 
research question? 
 
 
Are outcome measures patient-relevant? 
  
Are outcomes patient-relevant, including quality of life, 
if applicable, and with judicious use of surrogate 
endpoints? 
Minimization of 
bias  
(internal validity) 
Is the selected study type/design 
appropriate to minimize bias?  
Is the study randomized or, if not, appropriately 
controlled for confounding? 
Are potential sources of bias anticipated, 
evaluating the magnitude and the likely 
direction? 
 
Are outcome measures well-defined, pre-
specified, valid, reliable and measured at 
appropriate times? 
 
Are outcomes: 
well-defined (upfront)? 
valid (measure what they intend to measure)? 
reliable(stable and consistent when repeatedly 
measured)? 
sensitive to important change? 
measured at appropriate times? 
standardized across studies (core outcome sets, if 
applicable) 
Precision 
 
Has estimate of the required sample size 
been made (for feasibility purposes, see 
“Protection of patient safety & rights”)? 
 
Transparency / 
Access to data 
Is the research question clearly specified 
(e.g. in a synopsis)? 
Is each component of P(I/E)(C)O1 as applicable to 
study design clearly defined, i.e. : 
- Patient population to be 
recruited/investigated in the study 
- Intervention to be assessed, 
- Exposure to be assessed, 
- Diagnostic Test to be assessed, 
- Control intervention as comparator,  
- Outcomes to be measured? 
Generalizability  
(external validity) 
Are planned study participants 
representative of patients who would use 
the drug/intervention/diagnostic test in a 
real-life setting?  
Are unnecessary restrictions through 
inclusion/exclusion criteria avoided (to facilitate rapid 
accrual, broader generalization, pragmatic study 
conduct)? 
Is the control group adequate given current evidence 
and clinical practice (e.g. “standard of care” rather than 
“no treatment”)? 
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 Study Stage II: Planning & Feasibility 
 Milestone: Protocol developed and approved by regulatory bodies 
 
Dimension Main question Examples 
Protection of patient 
safety & rights  
Do the potential short and long term 
benefits of the study outweigh study 
burden (due to study visits, intervention, 
procedures etc.)?  
 
 
Are patients’ safety and rights protected 
through the study’s adherence to 
applicable national and international 
regulations and laws?  
  
Are study documents (e.g. protocol, participant 
information etc.) written in accordance with applicable 
national (and international, if applicable) 
regulations/laws? 
Are informed consent documents written in lay 
language and easily understandable for study 
participants? 
Has approval been obtained from ethics committee? 
Has approval been obtained from regulatory agency (if 
applicable)?  
Has feasibility been checked thoughtfully 
based on existing evidence? 
  
Is valid and robust preclinical data present (if 
applicable)? 
Have crucial feasibility aspects (e.g. recruitment) been 
piloted?   
Are recruitment assumptions realistic in a specified 
timeframe (e.g. empirical data from electronic health 
records or from pilot study present)? 
 
Have national/ international study registries been 
checked for studies that could interfere with the 
planned study?  
 
Do anticipated study costs (preparation, conduct, 
analysis, dissemination) match with available budget? 
Is study cost data related to planning, conduct, 
analysis, and dissemination planned to be collected (if 
applicable)? 
Is collection, documentation, and reporting 
of Adverse Events / Serious Adverse 
Events / Suspected Unexpected Serious 
Adverse Reaction  according to the 
applicable regulations planned and 
specified in the protocol? 
 
Are mechanisms established which allow 
early study termination when required and 
prevent early study termination for 
inadequate reasons? 
Is one or few interim analyses for safety considered? 
Is early stopping for benefit with insufficient collection 
of safety data avoided 9? 
Relevance /  
Patient 
centeredness & 
involvement 
 Is knowledge transfer/use (e.g. plans for 
inclusion of results in clinical guidelines) 
planned? 
Are relevant guideline groups identified and contact 
established? 
 
Are patient representatives involved in protocol 
development? 
Minimization of bias 
(internal validity) 
Is statistical analysis pre-specified (using 
outcomes as defined in concept stage)? 
 Are outcomes, datasets, subgroups, handling of 
missing data, etc., pre-specified? 
Is study monitoring (adapted to risk of 
study, if applicable) planned and 
documented in a monitoring plan?? 
 
Is data management planned and 
documented in a data management plan?  
Is minimization of bias planned 
for according to the research question and 
study design? 
  
  
  
  
  
  
  
  
Exemplary items according to study type (non-
exhaustive): 
 
Randomized Controlled Trials: 
Please also refer to Cochrane Risk of Bias tool for 
RCTs 
1
 for full list of items. 
Is randomization adequate and concealed? 
Are (known) prognostic factors distributed equally (i.e. 
are groups prognostically balanced at the start of the 
trial)? 
Is blinding of participants and/or care-givers 
adequate? 
Are concomitant interventions documented? 
Is blinding of outcome assessors adequate? 
Are plans to minimize losses to follow up present? 
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Are plans to analyze study participants in groups as 
randomized present? 
 
  
  
  
  
  
  
  
  
  
  
  
  
 
Observational studies (incl. cohort studies): 
Please also refer to ROBINS-I tool 
2
 for full list of 
items. 
Is collection of data carefully planned, i.e. are all 
relevant confounders considered and measured? 
Are all study participants selected or recruited from the 
same or similar populations (incl. the same time 
period)?  
Do the study participants represent the cases 
originated in the community? (e.g. due to issues with 
healthcare access) 
Are inclusion and exclusion criteria pre-specified and 
applied uniformly to all study participants? 
Are plans to minimize losses to follow-up present? 
Is timeframe sufficient so that one can reasonably 
expect to see an association between exposure and 
outcome if it existed? 
For exposures that can vary in amount or level, does 
the study examine different levels of the exposure as 
related to the outcome (e.g. categories, or exposure 
measured as continuous variable)? 
Is exposure measured more than once over time? 
 
Diagnostic accuracy studies: 
Please also refer to QUADAS-2 Risk of Bias tool 
3
 for 
full list of items. 
Is there an independent, blind comparison between 
index test and an appropriate gold standard of 
diagnosis? 
Is the diagnostic test evaluated in a representative, 
and ideally full spectrum of study participants (like 
those in whom it would be used in practice, spectrum 
ranging from mild to severe, and early to late cases of 
target disorder)? 
Is a reference standard applied regardless of the index 
test results (ideally both index test and reference 
standard should be carried out on all study 
participants)? 
If no, is it planned to follow up study participants for an 
appropriate period of time (dependent on disease in 
question) to see if they are truly negative? 
Precision  
 
Are expected treatment effects and event 
rates in intervention and control groups 
realistic and estimated based on empirical 
evidence? 
  
  
 
Is sample size realistically estimated and clearly 
described (incl. assumed treatment effects, references 
for estimates, power, alpha error, and expected losses 
to follow-up)? 
Is consent rate precisely estimated? 
Are treatment effects and/or event rates estimated in 
both intervention and control groups? 
If yes, are they based on evidence such as systematic 
literature reviews, meta-analysis? 
Is rationale for non-inferiority / equivalence design 
provided (if applicable)? 
Is rationale for maximum clinically acceptable 
difference (equivalence margins) provided (if 
applicable)? 
Is rationale for sample size given if not derived 
statistically? 
Are recruitment procedures and 
recruitment monitoring planned to ensure 
sufficient sample size?  
Transparency / 
Access to data 
Is the protocol in accordance with 
established standards (e.g. SPIRIT 4 or 
other applicable guidelines depending on 
study design)?  
  
  
  
 
Is protocol peer-reviewed? 
Is publication and accessibility of full study protocol 
planned? 
Is study registered in publicly accessible database / 
registry? 
Does protocol state a plan on how to deal with study 
publication in case target sample size could not be 
achieved/study had to be discontinued prematurely? 
Is there a dissemination plan to share 
study information including the protocol, 
summary results, and participant level 
data? 
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Generalizability  
(external validity) 
Are study procedures/observations in line 
with routine practice in the given setting? 
  
Is standard of care/current practice clearly defined? 
Are interventions /observations close to foreseen 
everyday practice? 
Is participant follow up close to everyday practice? 
 
 
Study Stage III: Conduct 
Milestone: Last patient last visit 
 
Dimension Main question Examples 
Protection of patient 
safety & rights 
  
Is respect for and consideration of patient 
rights, well-being and dignity guaranteed 
throughout conduct of study? 
 
Are study participants respected at all times, i.e.: 
Is withdrawal from study at any time explicitly 
permitted? 
Are study participants informed about purpose of 
research, its procedures (including study medication, 
concomitant medication, emergency management, 
etc.) and potential risks, benefits and alternatives, so 
that they can make a voluntary decision? 
In case of routinely collected data (including biological 
material), are study participants informed about the 
further use of their data for research purposes?  
Is study participants’ privacy and confidentiality 
ensured during (and after) study, e.g. through 
appropriate coding? 
Is patient safety guaranteed throughout 
conduct of study? 
 
Are study participants informed of newly discovered 
risks? 
Are side effects / Adverse Events/ Serious Adverse 
Events/ Suspected Unexpected Serious Adverse 
Reactions etc. monitored and reported to the ethics 
committee within required timeframes? 
Is study conducted according to protocol?  
Is compliance of participants and study 
staff with protocol monitored?  
Are patients’ safety and rights protected 
through the study’s adherence to 
applicable national and international 
regulations and laws? 
 
Relevance /  
Patient 
centeredness & 
involvement 
Are there any measures in place to assure 
study participants’ involvement, 
cooperation, and feedback throughout 
conduct of study (e.g. incentives, phone 
calls, etc.)? 
 
 
Minimization of bias 
(internal validity) 
Are data systematically collected as pre-
specified in protocol? 
 
 
Are losses to follow-up minimized?  
Are protocol deviations documented, and reported to 
the respective institutions? 
Are changes in study procedures amended in the 
protocol?  
 
Are missing data documented by individual outcomes? 
Apart from the allocated treatment, are study groups 
treated equally (e.g. no additional treatments or tests)? 
If applicable, are study participants and clinicians kept 
"blind" to which treatment was being received?  
Is monitoring conducted according to the 
pre-specified monitoring plan? 
  
  
Precision  
 
Is enrollment of study participants 
monitored?  
Are formal techniques in place to monitor recruitment 
centrally and at participating sites?  
Are measures in place to allow timely reaction in case 
recruitment deviates from expectations? 
Is variability of study procedures and 
measurement error minimized, e.g. by 
utilizing centralized monitoring strategies? 
 
Transparency / 
Access to data 
Is study conduct transparent to all involved 
parties?  
Are protocol amendments or any necessary deviations 
from the original protocol clearly documented and 
disseminated to appropriate parties within reporting 
timelines? 
Are internal or external audits planned, conducted and 
reported? 
Is an external and independent Data Monitoring 
Committee present or reason provided, why it is not 
needed? 
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Generalizability 
(external validity) 
Are numbers of participants through 
different stages of a study documented 
(patient flow) including reasons for leaving 
the studybefore its end (if voluntarily 
provided by patient)? 
  
Is proportion of study participants who declined 
randomization documented? 
Are the reasons for participants leaving the study 
before its scheduled end documented (if voluntarily 
provided by patient)? 
 
 
Study Stage IV: Analysis & Interpretation 
Milestone: Study data analyzed and interpreted 
 
Dimension Main question Examples 
Protection of patient 
safety  & rights 
Does data sharing adhere to appropriate 
data protection policies? 
Is patient-level data anonymized?  
Have other risks for re-identifying participants been 
minimized? 
Relevance /  
Patient 
centeredness 
Are data analyzed so that the use of 
results by different stakeholders is 
maximized?  
Are confidence intervals calculated on an absolute 
scale to gauge the benefit of an intervention for 
decision makers (e.g. clinicians, patients, policy 
makers)? 
  
Minimization of bias  
(internal validity) 
Is the data analyzed as pre-specified in the 
protocol/statistical analysis plan? 
  
Are post-hoc analyses clearly labelled as such or as 
exploratory analyses? 
Is data analysis performed using standard, generally 
accepted software? 
Are data assumptions checked (e.g. normal 
distribution) as appropriate for planned statistical 
tests/modelling? 
Are key confounding variables adjusted for 
in the analysis (e.g. multivariable analysis), 
if applicable? 
 
Does the analysis follow an adequate 
strategy to deal with participants in whom 
treatment or follow-up was not in 
accordance with study protocol? 
Is the intention-to-treat principle followed (i.e. all study 
participants with data analyzed in groups as 
randomized) in case of a superiority hypothesis? 
Are both a per-protocol and an analysis following the 
intention-to-treat principle conducted in case of a non-
inferiority hypothesis? 
Are results interpreted with least possible 
“spin”? (e.g. without intentionally implying 
greater or lesser effects than actually 
shown by the data)? 
 
Precision  
 
Is the uncertainty of results considered in 
the analysis? 
Are confidence intervals or other measures of 
uncertainty calculated? 
Are reasonable sensitivity analyses for missing data 
conducted? 
Does interpretation adequately reflect uncertainty? 
Transparency / 
Access to data 
Is the analysis code clearly documented 
and the analysis process reproducible?  
Are deviations from the statistical analysis 
plan or protocol adequately documented 
and reported? 
 
Generalizability  
(external validity) 
Does the interpretation put the results 
adequately into context of clinical 
practice/public health? 
 
 
 
Study Stage V: Reporting & Dissemination 
Milestone: Study archived and published 
 
Dimension Main question Examples 
Protection of patient 
safety & rights 
Is study completion/termination 
communicated to appropriate parties and 
documented in registries? 
Is study completion/termination reported to ethics 
committee/regulatory bodies? 
Is study completion/termination appropriately 
documented in national/international registry? 
Are study participants informed about 
outcome/main findings of the study in plain 
language (including treatment allocation of 
participant, if applicable)? 
 
Do study participants get access to 
products/interventions after study, if 
applicable? 
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Relevance /  
Patient 
centeredness & 
involvement 
Do authors critically reflect on research 
findings (results as well as challenges or 
mistakes during study conduct) and the 
implications for future research? 
 
Is the study easily available to 
decision/policy/guideline makers? 
Is the study cited in a clinical guideline? 
 
Are study patients/patient representatives 
involved in the reporting of the study? 
Are patient representatives involved in reporting of the 
study, e.g. in writing of lay term summaries? 
Minimization of bias  
(internal validity) 
Are all outcomes and important study 
characteristics reported as pre-specified in 
the protocol (outcome reporting bias 
prevented)? 
Are all patient-relevant outcomes reported as pre-
specified in the protocol? 
Are important modifications to the protocol (e.g. 
premature discontinuation) reported (if applicable)? 
Precision  
 
Are absolute and relative treatment effects 
reported accompanied by confidence 
intervals?  
Is the analysis set of participants clearly 
specified?  
Are the actual numbers of recruited, randomized (if 
applicable), followed-up, and analyzed participants 
reported for each outcome and for each treatment 
group (if applicable)? 
 
 
 
 
Transparency / 
Access to data 
Is dissemination of data and study results 
maximized? 
  
  
  
  
Is dissemination maximized through open access? 
Is anonymized individual participant-level data made 
available (data sharing)? 
Are study results posted in study registries? 
Does publication in journals include full protocol and 
statistical analysis plan? 
Is dissemination maximized through use of alternative 
media other than medical journals? 
Are resulting doctoral/master theses made publicly 
available (if applicable)? 
Are reporting guidelines followed to 
facilitate critical appraisal and 
reproducibility? 
  
Is reference made to reporting guidelines such as 
CONSORT (Randomised trials) 
5
, STROBE 
(Observational studies) 
6
, STARD (Diagnostic studies) 
7
, or PRISMA (Systematic reviews) 
8
 depending on the 
respective study design. 
Are detailed methods disclosed in publications (to 
enable reproducibility)? 
Are selective reporting, “spin”, plagiarism 
and self-plagiarism avoided and conflicts 
of interest declared? 
Is selective reporting of study results avoided?  
Is plagiarism and self-plagiarism avoided? 
Are study results independently peer reviewed? 
Is “spin” (i.e. reporting to convince readers that the 
beneficial effect of the experimental treatment is 
greater than shown by the results) minimized in 
reporting of results?  
Were conflicts of interest declared? 
Is knowledge transfer & exchange 
fostered? 
Is knowledge transfer & exchange fostered through 
e.g.:  
Community and provider education and outreach 
Facilitation of two-way communication (lay language) 
with diverse populations and community groups 
Knowledge transfer & exchange among clinical 
research groups 
Are study records and data sets kept and 
archived for the legally required period of 
time?   
Generalizability  
(external validity) 
Is potential impact on clinical practice / 
public health outlined in publicly accessible 
research reports (e.g. journal publication)?  
Are characteristics of included participants 
clearly reported? 
  
Are inclusion and exclusion criteria clearly reported?  
Are characteristics of included participants clearly 
reported?  
Are results of pre-specified subgroup 
analyses, if applicable, reported in order to 
assess the importance of key participant 
characteristics (e.g. disease severity, age 
or gender)? 
 
 
Quality promoter: Sustainability / Education 
 
Main question Examples 
Are doctoral students, junior researchers, 
clinicians, or patient advocates actively involved 
in all stages of a clinical study, reliably 
supervised/mentored by senior researchers, 
and are their specific contributions 
Are doctoral students, junior researchers, clinicians, or patient advocates 
actively involved in study design, planning, conduct, analysis, interpretation 
and dissemination of results (e.g. publications, conference presentations, 
reports, or lay summaries)? 
Are doctoral students, junior researchers, or clinicians actively supervised 
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acknowledged appropriately? 
  
by senior researchers at all stages of a clinical study? 
Are doctoral students, junior researchers, or clinicians mentored as to 
career options in clinical research (early career development)? 
Are training options and courses in health research methodology available 
for principal investigators, staff, and patient advocates? 
Are doctoral students, junior researchers, or clinicians mentored to improve 
awareness about value of clinical research to patients and society as a 
whole? 
Are processes continuously adapted and improved to changes, 
developments, issues, and conditions during research continuum (quality 
by design)? 
 
Quality promoter: Infrastructure 
 
Main question Examples 
Is a Quality Management System incl. 
Standard Operating Procedures (SOPs) in 
place? 
Is all staff continuously trained in applicable SOPs? 
 
Are there measures in place to control whether the existing Quality 
Management System is followed? (i.e. internal audits) 
Are well-trained, experienced, and dedicated 
principal investigators and study staff 
present?   
  
  
Has the principal investigator and/or staff been involved in clinical studies 
before? 
Is all staff continuously trained in GCP and protocol-related activities, and 
particularly the informed consent process? 
Is training (e.g. GCP) of each participating investigator and staff member 
clearly documented? 
Are roles and responsibilities of each participating investigator and staff 
member clearly documented? 
Are all involved stakeholders well and adequately informed about study 
procedures and changes? 
Are expert epidemiologists/methodologists, 
statisticians, professional data managers, 
and/or a logistical support unit involved early-
on? 
  
Are epidemiologists/methodological specialists involved in development of 
protocol? 
Are statisticians involved in development of protocol? 
Are data managers involved in the development of the data management 
plan and the setup of the data management system? 
Is a logistical support unit involved in study planning and/or conduct, e.g. 
through regulatory affairs experts, study nurses, or project managers? 
Are adequate human, material, and equipment 
resources available for study conduct? 
  
Is dispense, transport, and storage of investigational medicinal product, if 
applicable, planned? 
Is availability of study-specific materials, hardware, and facilities planned 
and secured? 
Is a transparent study budget available and approved by experienced 
personnel, including costs for experts mentioned above? 
Is funding secured through acquisition of competitive money or through 
collaboration with e.g. industry partners? 
Are adequate facilities ensuring data security 
and privacy in place (incl. competent and 
effective IT support to facilitate solutions 
tailored to specific challenges of individual 
studies or agreement templates for doctoral 
students with respect to data privacy and 
confidentiality)? 
Is an electronic database incl. audit trail in place?  
Is participant data coded? 
Is IT support present at site? 
Is inter-/multidisciplinary collaboration and 
involvement in study planning and conduct 
fostered? 
Have all relevant stakeholders been involved in protocol development and 
conduct? (e.g. investigators at other study sites, etc.) 
Is communication between involved staff, sponsor, contractors, and site 
fostered? 
Are all institutions involved in the study covered 
by compulsory liability insurance?  
Is an overview of the existing research 
infrastructure available and accessible to any 
researchers with a study idea? 
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E - Potential applications of the framework at different levels and 
stakeholder groups 
Box 1. Possible levels of framework application 
Level of application Description 
Stakeholder group Stakeholder groups differ in interests and needs and may operationalize framework 
differently, adapted to their setting, whilst still keeping the comprehensiveness of all 
dimensions represented in the framework (see Box 2 for detailed examples) 
Indication area Indication and treatment areas differ in scientific, ethical, organizational, and cultural 
aspects and therefore require different study designs to answer the scientific question. 
The framework should be applied to indication areas by making use of the flexibility of 
weighing the individual domains, and main questions  
Study design Depending on the study design chosen, different weights across dimensions may have 
to be applied in order to obtain a meaningful assessment of quality, e.g. for studies in 
which randomization is unethical and which therefore score lower in internal validity. 
The examples should support users in applying the framework content to their study 
design. 
Reearch stage The framework is meant to cover all research phases, from planning to dissemination. 
However, certain future applications (e.g. templates supporting study planning) may 
focus on one of the three temporal stages described in the framework. 
 
Box 2. Examples for application of Framework for quality of Clinical Research, by stakeholder group 
Stakeholder  Examples for application 
Patient organizations / individual 
patients interested in research 
participation  
 
 
- Development of educational material on “good clinical research”  
- Development of tool/supporting material assisting in the decision of what clinical 
study to participate in (“how do I know it is a good clinical trial?”), similar to shared-
decision aids 
- Development of “quality labels” for clinical studies issued by patient organizations, 
i.e. in large international consortia 
(Inter-)national funding agencies 
 
- Longitudinal assessment of individual studies, research projects, e.g. in the context 
of excellency programs 
- Extension of current criteria for assessment of research proposals, funding decisions 
Academic institutions, medical 
faculties, clinical trial units 
 
- Development of tools for (longitudinal) assessment of research department, 
research unit, research groups 
- Development of tools for (longitudinal)  assessment of individual studies, research 
projects, e.g. for cost-efficient allocation of ressources 
- Provision of report templates 
- Tools supporting consultancy of trialists at clinical trial units, over entire study 
lifecycle 
Regulatory agencies, health 
technology assessment bodies, 
payers (i.e. health insurances) 
- Refinement of own quality assessment criteria 
- Development of longitudinal assessment of individual studies, research projects, e.g. 
for registration purposes 
Ethics committees - Refinement of own quality assessment criteria 
- Development of tools for longitudinal  assessment of individual studies and their 
outcomes 
Governmental bodies  - Longitudinal assessment of national research program 
- Guidance on selection process for excellency programs 
Drug 
development/Pharmaceutical 
industry 
- Holistic approach to quality assessment, of both internal decision-making as well as 
operational aspects at sites 
All stakeholders - Overarching concept for the development/adaptation of context-specific checklists, 
or scores for the quality of clinical research 
- Development of “quality labels” based on theoretical foundation increasing trust in 
clinical research quality 
- Creation of publicly accessible “quality registries”  
- Adaptation and application of framework to study designs other than the traditional 
study types, e.g. Real-World Evidence   
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Abstract 
Objectives: Randomised clinical trials (RCTs) are costly. We aimed to provide a systematic 
overview of the available evidence on resource use and costs for RCTs to identify lever-
points which may make RCTs more cost-effective. 
 
Study Design and Setting: We systematically searched MEDLINE, EMBASE and 
HealthSTAR from inception until November 30, 2016 without language restrictions. We 
included any publication reporting empirical data on resource use and costs of RCTs and 
categorised them depending on whether they reported (i) resource and costs of all aspects of 
an RCT (including planning, conduct, and reporting); (ii) on several aspects, (iii) on a single 
aspect (e.g. recruitment); and (iv) on overall costs for RCTs. Median costs of different 
recruitment strategies were calculated. Other results (i.e. overall costs) were listed 
descriptively. All cost data were translated into USD 2017. 
 
Results: A total of 56 articles that reported on cost or resource use of RCTs were included. 
None of the articles provided empirical resource use and cost data for all aspects of an entire 
RCT. Eight articles presented resource and cost data on multiple aspects (e.g. aggregated 
cost data of different drug development phases, site specific costs, selected cost 
components). Thirty-five articles assessed costs of one specific aspect of an RCT (i.e. 30 on 
recruitment; 5 others). The median costs per recruited patient were USD 409 (range: USD 
41-6,990). Overall costs of an RCT, as provided in 16 articles, ranged from USD 43-103,254 
per patient, and USD 209,202-494 Mio per RCT. For 12 out of 16 articles (75%) the 
methodology of gathering these overall estimates remained unclear.  
 
Conclusion: Empirical evidence on resource use and costs of RCTs is sparse. Accessible 
resource use and cost data are urgently needed to make RCTs and the current research 
environment more transparent and help improve sustainability. 
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What is new? 
Key Findings 
 Despite frequent claims that clinical research costs are on constant rise, empirical 
evidence on resource use and associated costs for randomised clinical trials (RCTs) 
is sparse 
 Current estimates of overall RCT costs cover a wide range, but the underlying 
methodology of gathering these estimates often remains unclear 
 Most articles focus on the comparison of different recruitment strategies, but none 
provide a detailed overview of all aspects of resource use and associated costs of an 
RCT  
 
What this adds to what was known? 
 To our knowledge this is the first systematic overview of published estimates on trial 
costs. There is a lack of published empirical data on RCT costs and the evidence 
base to support the frequently made claim of increasing costs is elusive 
 
What is the implication and what should change now? 
 Empirical evidence on cost items for RCTs, specifically in the academic setting, is 
urgently needed so that lever-points can be identified to make RCTs more cost-
effective and feasible  
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Introduction 
Cost estimates for research and development (R&D) for new drugs in 2009 were reported to 
range from USD 92 million to USD 884 million per compound [1, 2]. The currently highest 
estimates, published in 2016 by DiMasi et al., are as high as USD 1.4 billion [3]. Several 
institutions criticized these estimates to be intransparent and raised scepticism whether the 
high R&D costs reflect reality or if they are overestimated to justify high drug prices [4-6]. 
 
Of total R&D costs for new drugs, the clinical phase accounts for the highest expenses [3, 7]. 
In contrast to the debate about R&D cost estimates there is wide agreement that randomised 
clinical trials (RCTs) produce the most reliable evidence about the benefits and harms of 
clinical interventions, ultimately leading to better care for patients [8, 9]. However, they come 
at high costs [10]. During the last decades a number of initiatives and regulations were 
implemented to improve research quality and to increase participant protection [11]. 
However, the complexity and the administrative burden of RCTs increased too and may raise 
their overall costs and compromise the motivation of investigators to initiate new trials [8, 12, 
13]. Stagnating numbers of RCTs [14] and a substantial proportion of initiated RCTs that are 
prematurely discontinued due to organisational and recruitment problems [15] risk that more 
uncertainties about medical treatments will remain unaddressed. Thus, efforts to make 
clinical trials more cost-efficient and feasible are urgently needed. A pre-requisite for such an 
optimisation process are empirical cost data and evidence on cost-drivers. Therefore, the 
aim of this study was to systematically review the currently available evidence on resource 
use and associated cost data for RCTs. 
 
 
Methods 
Literature search and eligibility criteria 
An experienced medical librarian (NB) systematically searched Medline, EMBASE and 
HealthSTAR via Ovid from their inception until November 30 2016 without any language 
restriction. We used MeSH terms like “Clinical Trials as Topic” and “Cost Analysis” and text 
words such as “costs” in combination with “clinical trials” (see Online Appendix for the 
detailed search strategy). Any publication that reported empirical data on resource use and 
costs of RCTs were included. We excluded articles that assessed the costs or the cost-
effectiveness of the intervention only and studies that analysed the cost of R&D in general 
without giving any specific cost or resource data for RCTs.  
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Selection of articles and data extraction 
In teams of two, we examined all identified titles and abstracts independently and in duplicate 
(BS, BvN, NS, LH, TF, RA, AA, CPM, MS, MB). For titles and abstracts that were considered 
potentially relevant by at least one reviewer, we obtained corresponding full texts that were 
independently reviewed by two authors (BS, BvN). In case of disagreement, a third reviewer 
(MB) was consulted and the respective article discussed until agreement was reached. Each 
eligible articles was assigned to one of the following four categories: (i) articles presenting 
resource and cost data for all aspects of an entire RCT (including planning, conduct and 
reporting); (ii) articles presenting resource use or cost data for multiple aspects of an RCT 
(e.g. including costs or resource use of different trial specific steps); (iii) articles presenting 
resource use or cost data for only one aspect of an RCT (e.g. recruitment); and (iv) articles 
that reported overall cost numbers (i.e. cost per patient or cost per RCT). The first three 
categories were mutually exclusive, but not the fourth (overall costs).  
 
From all included articles the following information was extracted by one reviewer and cross-
checked by a second reviewer (BS, BvN): Year of publication and time of conduct, 
population, experimental intervention, control, primary outcome, cost data (including costs for 
single trial aspects such as recruitment and overall costs).  
 
Analysis 
Articles presenting resource or cost data on multiple aspects were descriptively summarised. 
For articles covering one aspect of costs, the costs of specific recruitment strategies as well 
as overall costs of recruitment were merged (median; range). Overall costs of RCTs and 
costs per patient for a complete RCT were descriptively listed per article. In case an article 
described the costs of several RCTs, we present the range of those costs. All cost data were 
converted into USD 2017. For the overall costs of RCTs we present the published cost data 
as well as costs converted into USD 2017. We converted currencies into USD [16] using the 
start date of the RCT, or, if unknown, the date of the publication. All costs were converted 
into USD 2017 using the annual inflation listed by the Organisation for Economic Co-
operation and Development [17]. If reported, we used the following date in this order of 
priority to adjust for inflation: (i) date of currency listed in the publication (e.g. USD 2011); (ii) 
date when the RCT was started; (iii) date of publication.  
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Results 
Search results 
Our systematic search yielded 6650 articles after removing duplicates. We excluded 6326 
articles based on titles and abstracts (Figure 1), and 268 based on the full text. We included 
56 articles (Table 1): (i) there were no articles that presented detailed empirical resource and 
cost data for all aspects of one or more RCTs; (ii) eight articles presented resource or cost 
data on multiple aspects of an RCT (three out of these 8 articles also presented overall RCT 
costs); (iii) 35 articles presented only one specific resource or cost aspect of RCTs (i.e. 30 
recruitment costs, 2 costs of protocol development, 1 adverse event costs, 1 pharmacy 
costs, 1 costs of Good Clinical practice [GCP] compliance); and (iv) 16 articles presented 
overall costs. 
 
 
Figure 1: Selection of articles 
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Table 1: Characteristics of the 56 included articles. 
*3 articles presenting overall costs also had data in more detail. 
Articles presenting resource and cost data for all aspects of RCTs 
We did not find any article that empirically assessed the resource use and associated costs 
for all aspects of an entire RCT (including planning, conduct and reporting). 
 
Articles presenting resource or cost data for multiple aspects of RCTs 
Eight articles presented resource or cost data on multiple aspects for RCTs (Table 2) [18-25]. 
In short, two studies assessed the overall costs of several industry-sponsored clinical trials 
stratified by different clinical trial phases [18, 25]. While Sertkaya and colleagues presented 
 All articles 
(n=56) 
Articles 
assessing 
multiple 
aspects  
(n=8*) 
Articles 
assessing 
only one 
aspect 
(n=35) 
Overall 
costs 
(n=16*) 
Year of Publication     
   Median  
   Interquartile range 
   Range 
2009 
2002-2014 
1985-2016 
2008 
1995-2015 
1992-2016 
2009  
2002-2013 
1993-2016 
2013 
1997-2014 
1985-2016 
   Before 2000 10 (17.9%) 2 (25.0%) 5 (14.3%) 4 (25.0%) 
   2000-2009 19 (33.9%) 2 (25.0%) 14 (40.0%) 3 (18.8%) 
   2010-2016 27 (48.2%) 4 (50.0%) 16 (45.7%) 9 (56.2%) 
Number of trials     
   One specific trial 35 (62.5%) 3 (37.5%) 26 (74.3%) 8 (50.0%) 
   More than one trial 21 (27.5%) 5 (62.5%) 9 (25.7%) 8 (50.0%) 
Origin of trials     
   North America 33 (58.9%) 4 (50.0%) 25 (71.4%) 6 (37.5%) 
   Europe 7 (12.5%) 1 (12.5%) 5 (14.3%) 1 (6.3%) 
   Other 3 (5.4%) 0 3 (8.6%) 0  
   Unknown 2 (3.6%) 0 0 2 (12.5%) 
   Multiple 11 (19.6%) 3 (37.5%) 2 (5.7%) 7 (43.8%) 
Type of Article     
   Original article 51 (91.1%) 7 (87.5%) 34 (97.1%) 13 (81.3%) 
   Short communication,   
   Editorial/Comment 
4 (7.1%) 0 1 (2.9%) 3 (18.8%) 
   HTA Report 1 (1.8%) 1 (12.5%) 0 0 
Medical field     
   Medical 18 (32.1%) 2 (25.0%) 10 (28.6%) 7 (43.8%) 
   Surgery 1 (1.8%) 0 0 1 (6.3%) 
   Other (e.g. behavioral, physical  
   therapy,  psychological therapy, 
   dental treatment) 
26 (46.4%) 2 (25.0%) 18 (51.4%) 5 (31.3%) 
   Multiple trials/unclear 11 (19.6%) 4 (50.0%) 7 (20.0%) 3 (18.8%) 
Population     
   Adults 32 (57.1%) 4 (50.0%) 20 (57.1%) 10 (62.5%) 
   Adults and children 3 (5.4%) 0 3 (8.6%) 0 
   Children 5 (10.7%) 0 3 (8.6%) 2 (12.5%) 
   Elderly 3 (5.4%) 0 3 (8.6%) 0 
   Multiple trials 13 (23.2%) 4 (50.0%) 6 (17.1%) 3 (18.8%) 
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“costs per patient”, “per site cost” and “pre study costs” with additional stratification per 
medical field, Getz et al. presented costs stratified into “core” and “noncore” procedures. One 
article from Raftery and colleagues retrospectively assessed the mean costs per patient and 
other cost components (e.g. costs of statistical input) from studies supported by the British 
National Health Service (NHS) between 1995 and 2005 [19]. One article authored by Zhu 
and colleagues [20] listed the overall costs of a large oncology screening RCT and stratified 
the costs for further screening centres, coordinating centre and for collecting biological 
samples. Another article assessed time efforts for 41 cancer-trial tasks from 83 Clinical 
Reseach Associates in 1996 [21]. Thornquist and colleagues estimated the resource use and 
costs of a large academic prevention trial that was conducted between 1988 and 1991 [23]. 
While cost components for specific items are listed (e.g. follow up of an active participant for 
1 year), resource data (i.e. time efforts) are missing. Two studies published in the 1990s 
assessed site-specific resources and costs [22, 24].  
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Table 2: Summary of the 8 articles presenting resource use or cost data on multiple aspects for randomised clinical trials. 
Author and 
year 
Publication content in terms of empirical trial costs and resource use Primary results regarding resource and 
cost data (based on abstract; in USD 
2017) 
Sertkaya et al., 
2016 [25] 
Aggregate cost data of different phases (I-III) from three proprietary data bases (Medidata 
solutions). Cost per RCT across therapeutic areas with aggregated cost details (per patient 
and per site) from the pharmaceutical industry (2004-2012). No resource data available. 
Phase 2: USD 9.1 Mio (cardiovascular) – 
25.4 Mio (hematology). 
Phase 3: USD 14.9 Mio (dermatology) – 
68.5 Mio (pain and anesthesia)  
Getz et al., 
2015 [18] 
Tufts Center for the Study of Drug Development study among working group of 15 
pharmaceutical companies, looked between 2011 and 2012 at study reports and analysis 
plans, identified and assessed costs of “core” and "noncore" procedures per phase II/III 
protocol. No resource data available. 
Phase 2: USD 300,000 (13.1%) is spent in 
direct costs of noncore procedures 
Phase 3: USD 1.8 Mio (18.5%) is spent in 
direct costs of noncore procedures 
Raftery et al., 
2015 NHS HTA 
Report [19] 
Questionnaire used to assess planned and actual costs of RCTs funded by the NHS HTA 
programme (1995-2005). Provides mean cost per patient per year and other cost components 
(e.g. costs of “statistician input). “Research cost, as funded by the HTA programme, 
accounted for some 70% of the total cost…” No resource data available. 
No abstract. Mean annual cost per patient: 
USD 3,062 – 9561  
Zhu et al., 2013 
[20] 
A large trial (n=154,901) assessing different screening strategies for prostate, lung, colorectal 
and ovarian cancer. The trial was funded by the National Cancer Institute Division of Cancer 
Prevention. Besides overall costs, costs are separately listed for screening centers, 
coordinating center and collection of biological samples. No resource data are listed. 
The overall costs over 20 years were USD 
494 Mio with approximately USD 40.3 Mio 
for the collection, processing and storage 
of biospecimens. 
Roche et al., 
2002 [21] 
In 1996 Clinical Research Associates (n=83) collected timing observations of 41 cancer-trial 
tasks (156 subtasks) over 30 consecutive days. Time efforts for all trial stages were obtained. 
No cost data available. 
“Industry-sponsored studies had 
significantly higher overall mean times than 
did local and cooperative group studies. 
Early-phase studies required more time 
than did phase III trials.” 
Evans et al., 
2000 [22] 
Retrospective estimate of resource use and cost of two phase II trials in lung cancer. Only site 
specific costs available in 1993 Canadian dollars. Resource and cost data for the project 
development phase (e.g. development of study protocol) and the phase “after last patient out“ 
not available. 
Taxotere trial: USD 1,755 per patient 
Gemcitabine trial: USD 2,973 per patient 
Thornquist et 
al., 1993 [23] 
Costs and resource use of a large academic prevention trial (i.e. of β-carotene and vitamin A 
in decreasing the incidence of lung cancer in two populations at high risk) conducted between 
1988 and 1991. Resource use (i.e. time effort) not presented in results. 
The total direct costs over 13 years was 
approximately USD 80 Mio 
Eri et al., 1992 
[24] 
Cost and extra time needed for patient recruitment and on site trial tasks in one academic 
hospital conducted between 1989 and 1991. 
The costs for the hospital to carry out a trial 
with 65 evaluable is approximately USD 
127,000 
Abbreviations: RCT= Randomised clinical trial; NHS= National Health Service; HTA= Health Technology Assessment 
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Articles presenting resource or cost data for one specific aspect of RCTs 
A total of 30 articles [26-55] described the costs of recruitment for an RCT (Table 3). Print 
advertisement (described in 14 articles), mail-based invitation (11 articles), and radio 
advertisement (6 articles) were the most commonly assessed recruitment methods. Phone 
screening was the cheapest recruitment method (USD 116, range USD 98-1,146 per 
recruited patient) and combining different media the most expensive (USD 2,058; range USD 
91-16,399 per recruited patient). Fifteen articles reported the overall costs for recruitment 
independent of any recruitment strategy. The median costs for recruiting a patient were USD 
409 (range: USD 41-6,990). 
 
Table 3: Summary of the 30 articles presenting costs to recruit one patient into a 
randomised controlled trial according to different recruitment strategies. 
Recruitment strategy Number 
of studies 
(total 
n=30) 
Median number 
of recruited 
patients (range) 
Median costs per 
recruited patient 
in USD 2017 
(range) 
References  
Print advertisement 14 19 (4-141) 580 (43-2,254) [27, 29, 30, 35, 
37-41, 43-46, 
50]* 
Mail invitation 11 82 (4-337) 228 (15-1,116) [28, 32, 36, 38, 
40, 41, 43-45, 
53, 55]* 
Radio advertisement  6 5 (3-38) 627 (204-5,243) [27, 29, 35, 38, 
43, 50]* 
General practitioner 
referral 
5 18 (4-107) 541 (9-2716) [32, 37, 40, 50, 
55] 
Billboard/posters 5 15 (2-36) 1134 (64-12,538) [27, 37, 45, 50, 
55] 
Community workers 
(Church, social 
service) 
5 5 (1-152) 642 (22-1938) [35, 37, 40, 41, 
44] 
Internet advertisement 4 11 (2-37) 198 (155-2,621) [27, 29, 40, 43]* 
Phone screening 4 192 (87-347) 116 (98-1146) [36, 51-53] 
Public transport 
advertisement 
3 2 (2-26) 1,295 (1,252-
7,750) 
[27, 29, 32] 
Combination of 
different media (i.e. 
radio, newspaper, 
posters) 
3 27 (1-75) 2058 (91-16,399) [31, 32, 55] 
TV advertisement  2 24 (5-174) 440 (69-3,548) [43, 56]* 
Manual chart 
screening and 
algorithm search 
1** 16 (11-20) 297 (227-366) [34] 
Overall costs of 
recruitment 
15 164 (15-4249) 409 (41-6,990) [26, 30, 33, 38, 
40, 42-50, 54]* 
* One article [43] reports on two separate datasets from two RCTs. 
**One article with the two mentioned recruitment strategies (i.e. manual chart screening and algorithm 
search) 
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Five articles assessed other specific cost aspects of RCTs. Two articles evaluated the costs 
of protocol procedures including protocol amendments [57, 58], one article estimated the 
costs of adverse event procedures in an HIV trial [59], one calculated the average costs of a 
hospital pharmacy among all trials where the pharmacy has been involved [60], and one 
article assessed the costs of “GCP-related activities” in an RCT [61]. A comprehensive 
overview of these studies is listed in Appendix Table S1. 
 
Articles presenting overall costs 
Sixteen articles presented overall costs for one or several RCTs [20, 23, 25, 62-74] (Table 4). 
The methods to estimate these cost data were not reported at all in 7 articles (38%), or little 
detailed and intangible in 5 articles (31%; e.g. personal communication; estimated based on 
final study reports). Three out of these 16 articles were published editorials or comments. 
The costs of the cheapest RCT was listed by Detsky [73] and was a trial published in 1983 
assessing the efficacy of propranolol in 24 patients with esophagael varices (overall costs 
USD 209,202) [75]. The most expensive trial was a cancer screening trial enrolling 154,901 
patients over a period of eight years and conducted a follow-up of 13 years (overall costs 
USD 494 Mio) [20]. The data from this trial were used and presented in a total of 335 
publications. The lowest costs per patient (USD 43) were reported in 2014 for a trial using 
routinely collected data as registry embedded trial (TASTE trial) that assessed thrombus 
aspiration during myocardial infarction in 7244 patients [66]. Endpoints were completely 
assessed trough national registries. The highest costs per patient (USD 103,254) were 
reported for a lipid research trial conducted in 1983 [73]. The trial randomised 3,806 men 
with primary hypercholesterolemia to bile acid sequestrant cholestyramine resin or placebo. 
Median follow-up was 7.4 years and participants visited the clinics every two months. 
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Table 4: Summary of the 16 articles presenting overall costs for randomised controlled trials 
Reference  Description/medical field Year RCTs 
conducted 
Sample 
size 
Overall costs in 
USD 2017 
(published costs) 
Costs per patient in 
USD 2017 
(published costs 
per patient in USD if 
not indicated 
differently) 
Methods of cost assessment 
Larson et al., 
2016 [63] 
Three multicentered, 
multinational HIV trials primarily 
funded by the National Institute of 
Allergy and Infectious Diseases 
2002-2016 4,150 - 
5,472 
101.7 Mio-151.6 
Mio  
(71.9 Mio – 111.9 
Mio  
24,512-27,702 
(17,313-20,441) 
NR 
Sertkaya et al., 
2016 [25] 
Aggregated data from proprietary 
databases (Medidata Solutions) 
for pharmaceutical clinical trial 
costs were analysed and mean 
costs for RCT costs of different 
medical fields calculated. 
2004-2012 NR Phase II: 9.0 Mio – 
25.4 Mio (7.0 Mio- 
19.6 Mio) 
Phase III: 14.9 Mio 
– 68.5 Mio (11.5 
Mio – 52.9 Mio) 
NA Aggregate cost data from three 
proprietary data bases 
(Medidata solutions) for 
pharmaceutical industry trials 
were analysed. 
Anguera et al., 
2015 [62] 
Fully mobile automated RCT 
randomising depressive patients 
to two different mobile phone 
applications 
2014-2015 1,098 323,624 (314,264) 295 (286) Cost estimated using a “total 
study cost approach” factoring 
in β testing, staff time and 
efforts beyond those payments 
made for recruitment and 
participant remuneration. 
Roth et al., 
2014 [65] 
NIH funded women's health 
initiative estrogen plus progestin 
clinical trial conducted in 40 
centres in the United States 
1997-2002; 
(costs in 
USD 2012)  
16,608 276.1 Mio 
(260 Mio) 
16,624 
(15,655) 
NR 
Chit et al., 
2013 [67] 
Data from 24 influenza vaccine 
developers and a total of 39 
vaccines. An average trial was 
modelled. 
2000-2012 Phase II: 
517 
Phase 
III: 4,461  
Phase II: 2.3 Mio 
(CAD 2.3 Mio) 
Phase III: 15.1 Mio 
(CAD 15.4 Mio) 
Phase II: 4,354 (CAD 
4,505) 
Phase III: 3,379 (CAD 
3,457) 
Cost estimates from influenza 
research group at the 
Canadian Center for 
Vaccinology. 
Zhu et al., 
2013 [20] 
RCT assessing different 
screening strategies for prostate, 
lung, colorectal and ovarian 
cancer. 
1993-2001 
(costs in 
USD 2011) 
154,901 494 Mio (454 Mio) 3,189 (2,931) NR 
Light et al., 
2009 [69] 
Estimates of drug development 
costs including trials for different 
1987-2003; 
(costs in 
Phase II: 
184-
Phase II: 1.5 Mio-
3.3 Mio (1.3 Mio – 
Phase II: NA 
Phase III: 2,651-
Cost estimates based on 
searches in U.S. Patent and 
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phases of two rotavirus vaccines 
(from Merck and GSK, 
respectively). 
USD 2008) 2,464 
Phase 
III: 
63,225 – 
68,083 
2.9 Mio) 
Phase III: 167.6 
Mio-280.9 Mio 
(148.0 Mio – 248.1 
Mio) 
4,129 (2,340 – 3,646) Trademark Office, the U.S. 
SEC EDGAR database, 
Medline, periodicals, and 
corporate websites and 
interviews with senior 
researchers. 
Baker-Smith et 
al., 2008 [70] 
Evaluations of Trials from nine 
oral pediatric antihypertensive 
drugs submitted to the FDA 
NR 
(submitted 
to FDA: 
1997 – 
2004) 
110 - 
441 
1.8 Mio-17.5* Mio 
(1.3 Mio – 12.9* 
Mio) 
10,475-49,412 
(7,605 – 37,291) 
Cost estimates generated by 
using commercially available 
trial cost estimator software to 
generate approximations of the 
cost of performing a clinical 
trial. 
Li et al., 2007 
[71] 
Sixteen trials from the Pediatric 
Exclusivity program from different 
medical fields. 
NR (costs 
in USD 
2005) 
25 - 404 2.1 Mio-16.2 Mio 
(1.7 Mio – 12.9* 
Mio) 
17,532-94,482 
(14,044 – 75,686) 
Costs estimates based on final 
study reports. 
Thornquist et 
al., 1993 [23] 
Prevention trial assessing if β-
carotene and vitamin A 
decreasing the incidence of lung 
cancer in two populations at high 
risk 
1988-1991 
(costs in 
USD 1989) 
 
17,000 80.7 Mio (40.9 Mio) 4,747 (2,406) Cost estimates were based on 
surveying staff about average 
time per task and materials 
required. A developed 
spreadsheet was used to 
account for all tasks and 
possible costs. 
Drummond et 
al., 1992 [72] 
Diabetic retinopathy RCT  1972-1975 1732 61.2 Mio (10.5 Mio) 35,359 (6,062) NR 
Detsky 1989 
[73] 
Cost effectiveness from 7 RCT (5 
cardiovascular trials; 2 
nutritional/metabolic trials). 
1981-1983 
(Published: 
1982-
1986) 
24 – 
6,400 
209,202-367.2Mio 
(78,000 – 150 Mio) 
4,359-103,254 
(1,625 – 42,182)) 
Cost estimates based on 
publication (2 trials), funding 
source (2 trials), expert opinion 
(1 trial), and the author’s 
assessment (2 trials). 
Detsky 1985 
[74] 
Two secondary infarction 
prevention trials. 1. RCT: 
Anturane Re-infarction trial, 
conducted in Canada and the 
United States; 2. RCT: Aspirin 
Myocardial Infarction Study, 30 
centers in the United States. 
1975-1979 1,629 - 
4,524 
22.7 Mio- 77.0 Mio 
(5 Mio – 17 Mio) 
13,909-17,029 
(3,069 - 3,758) 
Cost estimates based on 
“personal communication” 
Editorials/Comments:      
Muennig, 2015 RCT about “patient activation” to NR (costs NR 283,207 - NR 
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(Commentary) 
[64] 
confront their providers when 
they ordered screening for 
mammography or prostate-
cancer. 
in USD 
2014) 
(275,000) 
Lauer et al., 
2014 
(Editorial) [66] 
“Event-driven” trial assessing 
thrombus aspiration during ST-
elevation myocardial infarction 
(TASTE) conducted in 31 centres 
in Sweden, Finland and 
Denmark. 
NR 7,244 313,964 
(300,000) 
43 
(41) 
NR 
Callaway, 2012 
(NATURE-
News) [68] 
NIH funded trial to assess 
whether chelation therapy 
(TACT) reduces cardiovascular 
events. Conducted at 134 US 
and Canadian sites. 
2003-2011 1,708 41.9 Mio 
(31.6 Mio) 
24,514 
(18,501) 
NR 
* Trial costs of one RCT are presented both in the publication by Baker-Smith and colleagues [70] and the publication by Li et al [71]. 
Abbreviations:  RCT= randomised clinical trial; NIH=National Institutes of Health; FDA=US Food and Drug Administration; NR=not reported; NA=not assessable 
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Discussion 
Our systematic literature search of over 6000 titles and abstracts identified 56 articles that 
presented some cost or resource use data of RCTs in any form but we found no article 
assessing resource use and associated cost data for all aspects of an RCT (including 
detailed empirical resource use during the planning, conduct, and reporting of an RCT, and 
the associated costs).  
 
A large proportion of the included articles assessed the costs to recruit one participant into 
an RCT. Presumably this reflects the fact that recruitment of a sufficiently large number of 
patients is considered one of the biggest challenges by many investigators [15, 76], but also 
the fact that evaluating the costs of patient recruitment is probably a relatively simple study-
within-a-trial (SWAT; 29 out of 30 articles). Our pooled results from 15 articles indicate a 
large range of recruitment-costs (USD 41 – 6,990) which reflects the large diversity of RCTs 
recruiting various patient populations (e.g. patients with chronic depression; diabetic patients; 
rainwater drinkers) and allocating them to a large variety of interventions. This diversity can 
also be seen in the RCTs that presented overall costs. Due to this high diversity of medical 
fields, interventions, necessary measurements and follow-up times it is difficult to generalise 
trial costs. One observation in our study was that some of the oldest RCTs were very costly 
(i.e. USD 61 Mio [72], USD 77 Mio [74], and USD 367 Mio [73]; Table 4), which is in contrast 
to the current opinion that RCT cost are on constant rise.  
 
To the best of our knowledge this is the first systematic review addressing the existing 
evidence on RCT resource use and associated costs. Although we consider our search 
approach comprehensive (3 electronic databases: MEDLINE, EMBASE, and HealthSTAR) 
we might have overlooked articles in journals not indexed in these electronic search 
databases or sporadic cost information in main texts, with no related hint in the title, abstract, 
or keywords. We expect the most impactful journals and articles to be covered by the 
databases searched. Further, we acknowledge that our survey mostly portrays costs of 
RCTs in high income nations that may not necessarily overlap with those of low- or middle-
income countries. We tried to make the available data comparable by translating all cost data 
into USD 2017. We had originally planned to use purchasing power parities to translate costs 
of studies that were conducted outside of the United States, into USD. However, due to the 
fact that many studies were conducted in several countries and some of the RCTs did not 
state where they were conducted, this would have introduced a relevant amount of 
inconsistency, and was therefore omitted. 
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To date, no similar systematic review exists to which we could compare our results. A short 
report published in 2017 by Martin et al. [77] identified similar gaps in the evidence base of 
RCTs. The authors undertook an analysis of cost data from 726 pharmaceutical 
interventional trials, resulting in a median cost of USD 8.6 million for phase II trials and USD 
21.4 million for phase III trials. However, again, the report lacks a transparent methodology 
and presents overall cost numbers only.  
 
Based on our systematic review, cost data for industry funded RCTs are sparse and little 
detailed. For RCTs funded by academic sponsors there seems to be no comprehensive 
analysis of the costs available to date. Therefore, we composed a detailed list of costing 
items applicable to RCTs, collected empirical data on resource use and associated costs for 
two RCTs conducted within our network of collaborators, and summarised the results in a 
case report (Speich et al., submitted together with this manuscript to the JCE). With this we 
meant to set an example for a transparent and comprehensive reporting of actual resource 
use and costs of RCTs. Transparently published resource use and costs may support 
researchers and funders alike to prospectively plan and monitor the costs associated with the 
conduct of RCTs in the future. 
 
 
Conclusion 
While the present systematic review revealed several studies on costs or resource use for 
specific aspects of RCTs or articles providing estimates for total costs of individual RCTs, we 
could not identify any article reporting detailed empirical data on resource use and costs for 
all aspects of a RCT. Accessible empirical resource use and cost data are urgently needed 
to optimise the cost-effectiveness of RCTs and ultimately make the current research 
environment more sustainable. 
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Appendix 
Search strategy 
Medline 
Database: OVID Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid 
MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to November 30 2016. 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Clinical Trials as Topic/ec  
2     exp Clinical Trials as Topic/  
3     ((clinical or random*) adj2 trial*).mp.  
4     2 or 3  
5     "costs and effectiveness".ti,ab,kf.  
6     ((cost or costs) adj3 research).mp.  
7     financial management.mp. or Financial Management/  
8     (clinical trial* cost* or controlled trial* cost* or trial cost*).mp.  
9     opportunity cost*.mp.  
10     (cost driver* or cost factor*).mp.  
11     (research adj2 cost*).mp.  
12     (cost* adj2 conduct*).mp.  
13     or/5-12  
14     13 and 4  
15     1 or 14  
16     exp "Costs and Cost Analysis"/  
17     exp *"Costs and Cost Analysis"/ and 2  
18     exp *Clinical Trials as Topic/ and 16  
19     17 or 18  
20     19 not 15  
21     15 or 19  
*************************** 
 
EMBASE 
Database: Embase <1974 to November 30 2016> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Clinical Trials as Topic/ec 
2     exp Clinical Trials as Topic/  
3     ((clinical or random*) adj2 trial*).mp.  
4     2 or 3  
5     "costs and effectiveness".ti,ab,kf.  
6     ((cost or costs) adj3 research).mp.  
7     financial management.mp. or Financial Management/  
8     (clinical trial* cost* or controlled trial* cost* or trial cost*).mp.  
9     opportunity cost*.mp.  
10     (cost driver* or cost factor*).mp.  
11     (research adj2 cost*).mp.  
12     (cost* adj2 conduct*).mp.  
13     or/5-12  
14     13 and 4  
15     1 or 14  
16     exp "Costs and Cost Analysis"/  
17     exp *"Costs and Cost Analysis"/ and 2  
18     exp *Clinical Trials as Topic/ and 16  
19     17 or 18  
20     19 not 15  
21     15 or 19  
*************************** 
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HealthSTAR 
Database: Ovid Healthstar <1966 to November 30 2016> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Clinical Trials as Topic/ec  
2     exp Clinical Trials as Topic/  
3     ((clinical or random*) adj2 trial*).mp.  
4     2 or 3  
5     "costs and effectiveness".ti,ab,kf.  
6     ((cost or costs) adj3 research).mp.  
7     financial management.mp. or Financial Management/  
8     (clinical trial* cost* or controlled trial* cost* or trial cost*).mp.  
9     opportunity cost*.mp.  
10     (cost driver* or cost factor*).mp.  
11     (research adj2 cost*).mp.  
12     (cost* adj2 conduct*).mp.  
13     or/5-12  
14     13 and 4  
15     1 or 14  
16     exp "Costs and Cost Analysis"/  
17     exp *"Costs and Cost Analysis"/ and 2  
18     exp *Clinical Trials as Topic/ and 16  
19     17 or 18  
20     19 not 15  
21     15 or 19  
 
*********************** 
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Table S1: Summary of the five articles assessing other specific resource use or cost aspects than recruitment to a randomized clinical trial 
Reference Year RCT 
conducted 
Costing unit Study description Main results (cost data as published [not 
converted into USD 2017]) 
Idoate et 
al., 1995 
1993-1994 Pharmacy 
services 
Analysis of cost evaluation model to estimate cost of 
hospital pharmacy services, including fixed (common to all 
trials) and variable (peculiar to each trial) costs were 
determined for each step. Economic assessment of each 
item was based on cost of the materials and means used, 
cost of staff time, and cost of drug storage. The model 
was applied to 24 clinical trials at University Clinic of 
Navarra. 
83% of all pharmacy costs were variable. Drug 
dispensing, stock management and return drugs 
account for 94% of the time expended. 
Approximate cost of pharmacy providing 
investigational services was USD 174 per patient. 
Funning et 
al., 2009 
Industry data 
from 2005 
GCP-related 
activities 
 
Electronic survey of ICH GCP-activities and their related 
costs in 47 of 60 member companies of the Swedish 
Association of the Pharmaceutical Industry. 
In 97% (n=250) of phase III trials performed in 
Sweden in 2005, approximately 50% of the total 
budget was reported to be GCP-related, estimated 
at an average of USD 180 million. 50% of GCP-
related cost was related to Source Data 
Verification, estimated at USD 90 million. 
Chou et al., 
2007 
2005-2006 Adverse 
events 
procedures 
 
Analysis of costs assosicated with adverse events 
procedures in a large HIV perinatal trial in Uganda by 
determining actual resource consumption using activity-
based costing. Resources were organized into cost 
categories (e.g. personnel, patient care expenses, 
laboratory testing, equipment). Cost drivers were 
quantified and unit cost per adverse event was calculated. 
In 18 months, there were 9028 adverse events with 
970 reported as serious adverse events. Unit cost 
per adverse event was USD 101.97). Overall, 
adverse event-related costs represent 32% (USD 
920,581 of USD 2,834,692) of all RCT expenses. 
Costs for personnel (USD 79.3) and patient care 
(USD 11.96) contributed the greatest proportion.  
Getz 2014 Industry Data 
from 2002-
2012 
Study 
protocol 
procedures 
(core, 
required, 
standard) 
 
Review of the results of two major Tuft Center for the 
Study of Drug Development studies quantifying the direct 
cost of conducting less essential and unnecessary 
protocol procedures in industry phase II-III studies and of 
implementing amendments to protocol designs. Data from 
15-17 mid-sized and large pharmaceutical and 
biotechnology companies. 
47.9% of total RCT budget on average spent on 
"core" procedures in phase II and III protocols, 
22.7% of costs for "required" (regulatory 
compliance) and 12.0% for "standard" procedures. 
Completed protocols across all phases (I-IV) had 
an average of 2.3 amendments, requiring an 
average of 6.9 changes to the protocol. Total 
investigative site work burden to administer 
procedures supporting phase II, III, and IV 
protocols increased 73%, 56%, and 57% 
respectively during the ten year period of 2002 to 
2012. 
Getz et al., 
2016 
Industry data 
from 2010-
Protocol 
amendments 
Analysis of data from 836 phase I-IV industry protocols to 
understand amendment prevalence , their impact, and 
57% of protocols had at least one substantial 
amendment, and nearly half (45%) of these 
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Abbreviations: RCT=randomized clinical trial; ICH= International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 
GCP= Good clinical practice; HIV= human immunodeficiency virus 
2013, follow 
up in 2015 of 
2010 RCT 
 associated direct costs 
 
amendments were deemed avoidable. Phase II 
and III protocols had a mean number of 2.2 and 2.3 
global amendments, respectively. A total of 52 
protocols were analysed to derive cost estimates of 
the direct costs to implement amendments. The 
median direct cost to implement a substantial 
amendment was USD 141,000) for a phase II 
protocol and USD 535,000 for a phase III protocol 
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Abstract 
Objectives: Randomised clinical trials (RCTs) are costly and published information on 
resource requirements for their conduct is limited. To identify suitable lever-points to make 
RCTs more cost-efficient and feasible, empirical data on resource use and associated costs 
are needed. We aimed to retrospectively assess resource use and detailed costs of two 
academic, investigator-initiated RCTs using a comprehensive list of cost items.  
 
Study Design and Setting: The resource use of two investigator-initiated RCTs 
(Prednisone-Trial [NCT00973154] and Oxantel-Trial [ISRCTN54577342]) was empirically 
assessed in a standardized manner through semi-structured interviews and a systematically 
developed cost item list. Using information about yearly salaries, resource use was 
translated into costs. Additionally, we collected all “other costs” including fixed priced items. 
Overall costs as well as cost of different study phases were calculated.  
 
Results: The personnel time used in the Prednisone-Trial trial was approximately 2,897 
working days and the overall costs were calculated to be USD 2.3 million, which was USD 
700,000 more than planned. In the Oxantel-Trial 798 working days were spent and the 
overall costs were as originally planned USD 100,000. Cost drivers were similar with 
recruitment delays explaining the additional costs in the Prednisone-Trial. 
 
Conclusion: This case study provides an example of how to transparently assess resources 
and costs of RCTs, and presents detailed empirical data on type and magnitude of 
expenses. In the future, this model approach may serve others to plan, assess, or monitor 
resource use and costs of RCTs. 
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What is new? 
Key Findings 
 The two assessed randomised clinical trials (RCT) had a personnel time of 2,897 and 
798 working days and total costs were USD 2.3 million and USD 100,000, 
respectively. 
 Even though resource use and costs were substantially different, we identified the 
same cost drivers (salary costs, patient enrolment, treatment, and follow-up phase) 
 
What this adds to what was known? 
 To the best of our knowledge this is the first study using a comprehensive list of RCT 
cost items to provide detailed data on resource use and associated costs of 
academic, investigator-initiated RCTs  
 This study exemplifies how resource use and cost data can be systematically 
collected and transparently presented to support others in the planning and 
monitoring of resources for RCTs. 
 
What is the implication and what should change now? 
 More studies of this type are needed to establish cost drivers of RCTs and identify 
lever-points for cost savings.  
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Introduction 
The planning and conduct of randomised clinical trials (RCTs) are often complex and 
consume substantial resources [1-5]. Particularly in resource-limited settings such as 
academic clinical research the conduct of investigator-initiated RCTs is challenging [6]. To 
improve the feasibility and cost-effectiveness of RCTs, it is necessary to identify suitable 
lever-points for interventions based on empirical data on resource use and costs of relevant 
tasks in RCTs.  
 
A systematic literature search about the resources and costs of RCTs identified 56 articles 
that presented some cost or resource use data of RCTs in any form (Speich et al., submitted 
together with this manuscript to the JCE). However, none of these articles reported on the 
detailed resource use and associated costs for all aspects of an entire RCT. Furthermore, 
while 16 articles contained numbers of overall costs of particular RCTs, the methodology of 
how these estimates were obtained remained unclear in 12 studies. There is consensus that 
more transparency in the methodology applied and the reporting of data on resource use 
(e.g. number of clinical procedures performed, hours administrative staff time used, and 
number of variables requiring source data verification) would be powerful to identify main 
drivers of the ever-rising costs of clinical research and development [7, 8].  
 
Therefore, the aims of this study were to i) compile a comprehensive list of cost items 
applicable to RCTs and ii) retrospectively assess resource use and detailed costs of two 
academic, investigator-initiated RCTs [9, 10]. We further exemplify how costs and resource 
use can be systematically assessed for RCTs in general [7].  
 
 
Methods 
Comprehensive cost item list 
We designed and conducted a systematic literature search of costing templates or cost item 
lists on MEDLINE and EMBASE via the Ovid interphase and EconLit on the 3rd November 
2015. Our search was not restricted in terms of language, publication type, or publication 
date (Appendix A for detailed search strategy). In addition, we conducted a systematic 
search of costing templates on the internet (websites and linked information, see Appendix A 
for detailed search strategy). We extracted cost items associated with clinical trials and 
compiled them in an electronic, shareable database (googledocs.com). In addition to the 
systematic searches, we received two clinical trial budget templates from institutions involved 
in clinical research in Switzerland (one industry / one not-for-profit). All articles, websites, and 
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documents were searched for cost items following the principle of saturation, i.e. until no 
additional items emerged. For validation, we circulated the comprehensive item list among 
six experts from the pharmaceutical industry and five experts from academia. We iteratively 
discussed the suggestions and made adaptations to the item list where applicable. In the 
final list, we structured all cost items into direct and indirect costs. Lastly, we introduced 
functionalities (e.g. automatic calculation of staff rates multiplying with hours in costing 
sheets etc.) and developed a short instruction manual as well as a glossary for important 
template terminology. 
 
Cost and resource use evaluation of two randomised clinical trials 
Study selection 
We selected two readily available RCTs for the following reasons: First, both were conducted 
within the close network of the authors, therefore relevant documents and information about 
costs (i.e. budgets, bills) were readily available. Second, both studies were published 
recently, meaning that the responsible persons could be interviewed about undocumented 
costs. Third, based on the different settings and the different pace of enrolment, empirical 
data from these two studies may give a hint about the cost range of investigator-initiated 
RCTs. Fourth, the two RCTs were of high methodological quality and published in high 
impact journals.  
 
An overview of the study characteristics is given in Table 1. The first trial, conducted at seven 
centres in Switzerland from 2009 to 2015, randomised a total of 802 patients with 
community-acquired pneumonia to two different treatment arms ([NCT00973154]) [10]. For 
simplicity, we will refer to this trial as the “Prednisone-Trial” [10, 11]. Patients were randomly 
assigned to receive either adjunct prednisone 50 mg daily for seven days or placebo (all 
patients received antibiotics as standard care) [10]. The time from the beginning of the 
enrolment until the last patient finished the follow-up took 59 months. The initially planned 
time was 48 months.  
 
The second RCT was planned and conducted within a collaboration of researchers from 
Switzerland and Tanzania and took place on Pemba Island, Tanzania, in 2012 
(ISRCTN54577342) [9]. Children from two schools who were infected with intestinal worms 
(i.e. Trichuris trichiura and hookworm) were enrolled and randomly assigned to one of four 
treatment arms over a period of two months [9]. We will refer to this trial as the “Oxantel-
Trial”.  
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Table 1: Characteristics of the two included randomised clinical trials for resource use 
and cost evaluation. 
Study Prednisone-Trial [10] Oxantel-Trial [9] 
Year study conducted 2009-2014 2012 
Year study published 2015 2014 
Setting Seven hospitals across 
Switzerland 
Two schools on Pemba 
Island, Tanzania 
Sample size 802 participants 480 participants 
Population and disease Adults with community-
acquired pneumonia 
Children 6 to 14 years of age, 
infected with soil-transmitted 
helminths (i.e. Trichuris 
trichiura and hookworm) 
Interventions Prednisone 
Placebo 
Oxantel pamoate and 
albendazole 
Oxantel pamoate 
Albendazole 
Mebendazole 
Planned budget USD 1.59 Mio. USD 100,000 
Planned time from start of 
enrolment until last patient 
out (in months) 
48 2 
Actual time from start of 
enrolment until last patient 
out (in months) 
59 2 
Primary outcome Time to clinical stability (in 
days) 
Cure rate and egg reduction 
rate 
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Resource and associated cost estimations 
We conducted semi-structured interviews using our comprehensive cost item list (Appendix 
B) as a guideline to cover all relevant aspects of an RCT. We stratified all items by study 
phases, i.e. “Project development and preparation”, “Patient enrolment, treatment and follow-
up”, “After last patient out”, and “Additional costs”. In all categories, we divided costs into (i) 
costs associated with human resources (“salary costs”) based on the hours worked multiplied 
by the respective staff salary per hour; and (ii) “other costs” including fixed priced items 
(e.g.laboratory materials, approval fees) (Figure 1). As one presented RCT was conducted 
from 2009 until 2014 and the other in 2012 all costs were expressed as values of July 2012 
USD (1 Swiss Franc = USD 1.055). 
 
 
Figure 1: Categories of the cost and resource use evaluation, using the example of 
two randomised clinical trials. 
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Human resources 
We retrospectively estimated human resource use based on available time log sheets and by 
conducting semi-structured interviews with study staff. Some of the authors were involved in 
one of the two RCTs (i.e. CAB, MCC, MB, CB, Prednisone-Trial; BS, JK, Oxantel-Trial) and 
were therefore well aware of the resource use associated with the specific stages of the 
RCTs. 
 
Within the semi-structured interviews, we asked the involved persons what time effort (hours, 
working days) they had spent on each working step (e.g. preparation of specific documents, 
meetings, organising patient insurance, screening patient, enrolling patient, data 
management, statistical analysis, publishing results; see Appendix 1). Moreover, the 
interviewed person explained all their tasks within the study to assess if additional working 
time from other, non-pre-specified tasks had to be considered. To account for non-included 
time (e.g. walking between patients or buildings, discussing study) and for unproductive 
phases, we added 30% of overhead/unproductive time to each item [12, 13]. 
 
Of note, the human resources for patient enrolment, treatment, and follow-up could not be 
assessed in an identical way for the two RCTs. For the Prednisone-Trial it was not possible 
to identify all involved persons at each of the seven recruiting hospitals. We therefore 
extrapolated the data obtained from the main coordinating centre to the co-investigating 
centres in case no time log sheets were available. Within the Oxantel-Trial employees on 
Pemba Island, Tanzania were hired on a daily basis and were working full time only for the 
Oxantel-Trial. Therefore, daily salaries were used rather than costs based on human 
resource estimates. Consequently no 30% of overhead/unproductive time was added. 
 
Human resources translated into salary costs 
Salary tables from 2012 from the University Hospital Basel, from the Swiss Tropical and 
Public Health Institute (Swiss TPH), and the daily salaries for the Public Health Laboratory on 
Pemba Island were used to calculate total salary costs (including social benefits) based on 
estimates of human resource use. In detail, we used (i) daily salaries (Pemba Island, internal 
consulting at the Swiss TPH) or (ii) hourly salary rates, taking into account varying target 
hours per day depending on position of medical staff for all resource use in Switzerland. An 
overhead of 25% for the University Hospital, 20% for the Public Health Laboratory on Pemba 
Island, and 15% for the Swiss Tropical and Public Health Institute was applied. Resources 
and costs were then tabulated as working days and associated costs.  
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Other resources and costs 
To evaluate other costs, we listed all expenditures which were explicitly made for the studied 
RCTs, including fees (e.g. ethical approval, trial registration, publication), expenses, study 
drugs, reimbursement for public transport, infrastructure (e.g. car, freezer), services (e.g. 
diagnosis from hospital laboratory) and materials (e.g. medical material, laboratory material, 
stationery). The vast majority of these costs could easily be assessed from bills or financial 
reports (e.g. to public funding agency). For some items the life expectancy had to be 
estimated (e.g. freezer). It was assessed how many days these materials and infrastructure 
were used and how much the items cost per day. More general, less trial specific 
infrastructure costs such as office space was included in the overhead costs of the salaries. 
 
Analyses 
We descriptively listed and categorised all resources used, their associated costs and 
proportional contribution to the total costs, as mentioned above. Main resource categories 
are listed in Figure 1; a more detailed list is presented in the Appendix (Appendix C-D). 
To determine the robustness of our cost estimates and to assess to what extent the overall 
costs vary if single parameters are modified (different scenarios), a series of one-way 
sensitivity analyses was conducted [14]. The following scenarios were assessed: (i) No 
addition of 30% overhead/unproductive time to evaluate how costs decrease in case the 
added time was overestimated; (ii) salaries increase by 30%; (iii) increase and decrease in 
sample size of 50% (only influence on costs in patient enrolment, treatment, follow-up, study 
drugs, insurance, and data cleaning); (iv) increase and decrease of 50% for project 
development and planning costs; (v) 50% higher and lower costs after last patient out; (vi) 
increase and decrease of 50% for other costs as well as additional costs.  
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Results 
Comprehensive cost item list 
We identified eight relevant templates in our literature search and 17 templates in our 
internet search. All items were listed and we circulated the comprehensive item list amongst 
experts. Four out of six experts from industry and three out of five experts from academia 
provided feedback on the item list. The final item list included a total of 137 different cost 
items which were categorized into direct and indirect costs. 
 
Direct study costs include those required to complete the work outlined in the protocol. These 
can be further subdivided into fixed costs related to the cost of supporting the study and 
variable costs related directly to the sample size of the study [15, 16]. We further stratified 
direct costs by research phase, i.e. i) planning and preparation, ii) conduct, and iii) after last 
patient out. 
 
Results from the case study 
The Prednisone-Trial randomised a total of 802 adults (Table 1). The total personnel time 
used for this trial was approximately 2,897 working days and the total costs were calculated 
to be USD 2.3 million (Table 2; Appendix C). Salary costs and the included overhead 
expenses accounted for 83.8% (USD 1,928,275) of the total costs. The costs stratified by 
categories were USD 231,347 (10.1%) for project development & preparation, USD 
1,938,958 (84.2%) for patient enrolment, treatment, and follow-up, and USD 129,518 (5.6%) 
for the time after last patient out. 
 
In the Oxantel-Trial, 480 children were randomised, treated and followed-up within two 
months in 2012. The total necessary human resources to conduct this RCT were 798 
working days and the overall costs for the RCT were USD 100,374 (Table 3; Appendix D). 
Salary costs accounted for the largest amount of the overall costs (i.e. USD 84,447; 84.1%). 
Costs for the project development & preparation phase were USD 26,437 (26.3%), USD 
45,016 (44.8%) for patient enrolment, treatment, and follow-up, and USD 28,537 (28.4%) for 
the after last patient out phase. 
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Table 2: Resource use and associated costs of the Prednisone-Trial. 
Cost component Persons involved 
Total time 
estimation 
(in days)  
Number 
of 
items 
Costs in 
2012 
USD  
Fraction 
of total 
costs 
(%) 
Project development & 
preparation      
Salary costs:         Study design, developing 
study  protocol  
   and study documents, incl. 
analysis plan  
   and source docs 
PI, 1 methodological expert, 1 
statistician, 13 external experts, 
2 residents, 1 data manager 
85  81,426 3.5 
   Preparation for ethical 
approval at 4 ethics 
   committees, regulatory 
agency, incl.  
   amendments  
PI, 1 resident, 1 study nurse, 10 
local investigators (consultants, 
registrars, and residents), 2 
local study nurses  
64  38,134 1.7 
   Set-up meetings with 7 sites, 
laboratory,  
   and pharmacy 
PI, 2 residents, 5 study nurses, 
5 laboratory personnel, 2 
pharmacy personnel, 10 local 
investigators  
47  37,786 1.6 
Other costs:      
   Approval fees (ethics 
committees, 
   Swissmedic)   
5 5,433 0.2 
   Insurance    1 68,568 3.0 
Subtotal: Project development 
& preparation 
   196   231,347 10.1 
Patient enrolment, Treatment, 
Follow-up      
Salary costs:      
   Study drug and matching 
placebo  
   (production, analytics, 
packaging, labelling, 
   and randomisation, 
concealment, etc.) 
Pharmacy  800 11,922 3.0 
   Screening and enrolment at 7 
sites 
7 residents, 3 registrars, 3 
consultants/co-investigators 716  44,7227 19.4 
   Treatment and follow-up, incl. 
data entry at 
   7 sites 
8 study nurses, 7 residents, 3 
registrars, 3 consultants/co-
investigators 
1,255  720,848 31.3 
   Ongoing data management 1 data manager 17  18,144 0.8 
   Ongoing monitoring 1 monitor 17  14,531 0.6 
   Ongoing biological samples 
management,  
   shipping and administration 
4 residents, 3 study nurses, 7 
laboratory personnel 117  77,687 3.4 
   AE/SAE documentation, 
yearly safety  
   report & Data Safety 
Monitoring Board 
PI, 4 residents, 3 study nurses, 
6 local investigators (for 
approval) 
67  38,603 1.7 
   Ongoing meetings of principal 
investigator  PI 304  292,203 12.7 
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   with staff, collaborations, 
literature  
   research related to project, 
etc. 
   Ongoing training of staff at 
sites 
PI, 1 resident, 1 study nurse, 5 
local investigators, 3 study 
nurses, 3 residents 
40  21,561 0.9 
Other costs:      
   Study drug compound   400 3,070 0.1 
   Biological samples (materials, 
analysis of  
   biological samples)   
16,000 218,624 9.5 
   Other medical material 
(freezer, blood  
   pressure machine,  
pulsoxymeters, etc.) 
  7 23,015 1.0 
   Other material (flyers, 
photocopies, folders  
   etc.)    
10,549 0.5 
   Incentives for sites (e.g. 
breakfasts, dinners,  
   etc.)   
38 14,294 0.6 
   Travel expenses    26,680 1.2 
Subtotal: Patient enrolment, 
Treatment, Follow-up 
   2,534   1,938,958 84.2 
After last patient out      
Salary costs:      
   Data cleaning, statistical 
analysis, and final 
   study report 
PI, 2 residents, 1 registrar, 1 
statistician, 1 methodological 
expert, 1 study nurse 
86  63,483 2.8 
   First publication, incl. writing, 
submission,   
   review process, proofs) 
PI, 4 residents, 1 registrar, 1 
methodological expert, 1 
statistician, 1 secretary 
75  59,780 2.6 
   Conferences PI, resident 7  4,940 0.2 
Other costs:      
   Publication fee   1 1,315 0.1 
Subtotal:  After last patient out    168   129,518 5.6 
Additional costs      
   Computer rental and software      1 2,061 0.1 
Total salary costs       1,928,275 83.8 
Total other and additional 
costs 
      373,609 16.2 
Total   2,897   2,301,884 100.0 
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Table 3: Resource use and associated costs of the Oxantel-Trial 
Cost component Persons involved Total 
time 
estimati
on (in 
days)  
Numbe
r of 
items 
Costs in 
2012 USD 
Fraction 
of total 
costs 
(%) 
Project development & 
preparation 
     
Salary costs:      
  Study design, developing 
study  
  protocol and study 
documents 
1 Principle investigator, 1 PhD 
student, 2 Statisticians, 3 
consulted experts, 2 co-
Principal investigators 
48.6  20,595 20.5 
  Production of oxantel 
pamoate and matching 
placebo, packaging of study 
  drugs 
1 Research Associate 
(Pharmaceutical Technology), 
2 Pharmacists (1 PhD student, 
1 PostDoc) 
7  3,242 3.2 
Other:      
   Ingredients for Oxantel 
tablets 
   251 0.3 
   Trial registration and ethical 
approval from Switzerland  
   and Zanzibar 
   867 0.8 
   Insurance for patients    1,482 1.5 
Subtotal:  Project development 
& preparation 
 55.6  26,437 26.3 
Patient enrolment, Treatment, 
and Follow-up 
     
Salary costs:      
   Screening and enrolment 6 Field staff, 6 Laboratory 
Staff, 2 Data entry staff, 1 
cleaner, 2 co-Principal 
investigators, 1 PhD Student 
382  15,873 15.8 
   Treatment, assessing 
AE/SAE, and follow-up 
2 Local  Physicians, 6 Field 
staff, 6 Laboratory Staff, 1 
cleaner, 2 co-Principal 
investigators, 1 PhD student, 1 
Principle investigator, 2 Data 
entry staff 
263  17,850 17.8 
Other:      
   Material for stool collection 
(inclusive car) and analysis 
   3,280 3.3 
   Transport reimbursement for 
patients/guardians 
  600 720 0.7 
   Study drugs and matching 
placebos 
  1,200 497 0.5 
   Materials and drugs for 
physicians 
   370 0.4 
   Telephone, Fax, Internet, 
stationery 
   432 0.4 
   Costs for investigators from 
Switzerland (flights, bill of  
   expenses, accommodation)  
Principle investigator, PhD 
student 
  5,994 
 
6.0 
Subtotal:  Patient enrolment,  645  45,016 44.8 
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Treatment, Follow-up 
After last patient out      
Salary costs:      
   Treatment of all school-
children 
6 Field staff, 1 PhD student 7  377 0.4 
   Data management, analysis, 
publishing and presenting 
   results 
1 Principle investigator, 1 PhD 
student, 1 Statistician, 2 
consulted experts 
90  26,509 26.4 
Other:      
   Drugs for treatment of all 
school-children 
  2,100 630 0.6 
   Conference fee and 
expenses (British Society for  
   Parasitology) 
1 PhD student   1,020 1.0 
   Publication fees (New 
England Journal of Medicine) 
   0 0.0 
Subtotal:  After last patient out  97  28,537 28.4 
Additional costs      
   Computer rental and 
software (STATA) 
   384 0.4 
Total Salary costs    84,447 84.1 
Total Other and Additional 
costs 
   15,927 15.9 
Total  797.6  100,374 100 
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The use of personnel time split by functions is shown in Figure 2. In short, seven residents 
and five study nurses contributed to 77% of a total of 2,897 working days in the Prednisone-
Trial (2,244 days), followed by the principle investigator (408 days,14%), and the five co-
investigators (112 days, 4%). All other involved personnel accounted for 1% or less of the 
total working time.  
 
 
Figure 2: Personnel resources used (Number of involved personnel; number of 
working days; %) for the Prednisone-Trial and the Oxantel-Trial. 
 
In the Oxantel-Trial, both the six persons working in the field as well as six laboratory 
personnel contributed 192 working days (24%) each, a PhD student 157.5 (20%) working 
days, and the two co-principle investigators 81 (10%) days. Two persons conducting data 
entry worked a total of 70 (9%) days, a cleaner was involved during 32 (4%) days, two 
physicians worked combined 30 (4%) days and the principle investigator invested 28.4 (3%) 
days. All other personnel did not account for more than 1% of the total invested time. 
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The one-way sensitivity analyses demonstrate the influence of alternated cost variables on 
the total costs of the two RCTs (Table 4). Without the additional 30% of 
overhead/unproductive time, the total cost would be reduced by 15.9% (total costs USD 1.9 
million) for the Prednisone-Trial, and by 11.3% (total costs approximately USD 89,000) for 
the Oxantel-Trial. An increase in salaries of 50% would increase the total costs of both trials 
by 25%. Also the impact of the sample size was large for both RCTs: a 50% increase or 
decrease in sample size resulted in an increase or decrease of the total costs of 32.1% for 
the Prednisone-Trial and 25.0% for the Oxantel-Trial. A 50% increase of the project 
development and preparation costs or the costs after last patient out had a relatively small 
impact on the Prednisone-Trial (3.4% and 2.8%, respectively) and on the Oxantel-Trial 
(13.2% and 14.2%, respectively). An increase of 50% for other costs (all costs beside 
salaries) increased the overall costs of both trials by approximately 8%. 
 
Table 4: Results from a series of one-way sensitivity analysis to illustrate the impact of 
alternated cost parameters on the total costs of the two randomised clinical trials. 
 
Parameter tested Costs in 2012 USD (change in %) 
Prednisone-Trial Oxantel-Trial 
Baseline 2,301,885 100,374 
Salary costs   
No addition of 30% 
overhead/unproductive time 
1,935,739 (-15.9%) 
 
88,999 (-11.3%) 
Salaries increase by 30% 2,878,886 (+ 25.1 %) 125,708 (+ 25.2%) 
Sample size   
A) Increase in sample size of 50% 
B) Decrease in sample size of 50% 
3,042,164 (+32.1%) 
1,561,605 (-32.1%) 
125,420 (+25.0%) 
75,327 (-25.0%) 
Project development and 
preparation 
  
A) Increase of 50% in project   
     development and preparation 
costs 
B) Decrease of 50% in project   
     development and preparation 
costs 
2,380,558 (+3.4%) 
 
2,223,212(-3.4%) 
 
113,593 (+13.2%) 
 
87,155 (-13.2%) 
After last patient out   
A) Costs for after last patient out  
     increase by 50% 
B) Costs for after last patient out  
     decrease by 50% 
2,366,645 (+2.8%) 
 
2,237,125(- 2.8%) 
 
114,666 (+14.2%) 
 
86,082 (-14.2%) 
Other costs   
A) Other costs and additional costs  
     increase by 50% 
B) Other costs and additional costs  
     decrease by 50% 
2,491,160 (+8.2%) 
 
2,112,610 (-8.2%) 
 
108,337 (+7.9%) 
 
92,411 (-7.9%) 
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Discussion 
Given the lack of empirical evidence on resource use and associated costs of RCTs, we 
present a comprehensive costing list and detailed data from two RCTs to exemplify how 
costs and resource use can be systematically assessed. We show that two trials in differing 
settings had similar cost drivers but resulted in very different total costs (USD 2.3 million vs. 
USD 100,000). This range of costs is confirmed by our systematic review where we found 
that published estimates of overall costs for RCTs ranged from USD 209,000 to USD 494 
Mio [15, 17] (Speich et al., submitted together with this manuscript to the JCE). In line with 
previous studies [13], personnel costs accounted for the majority of expenditures, mainly 
during the phase of trial conduct (i.e. patient enrolment, treatment, and follow-up). Our 
sensitivity analysis corroborated the high impact of the personnel costs on the overall costs. 
It has to be re-emphasized that the personnel costs also include overhead expenditures and 
hence, infrastructure and some equipment and material (e.g. stationery) is considered 
indirectly through personnel costs. 
 
Reasons for the differing total costs were manifold. The Oxantel-Trial united many pre-
requisites for an inexpensive RCT and stayed within the planned budget. Most of the 
personnel working time was conducted either by a PhD student or in a low-income country 
[11]. The diagnostic test for patient screening was easy and inexpensive [18] so that 
approximately 100 children were screened per day, and due to the high infection rate nearly 
all of them were eligible to participate in the RCT [9]. Treatment was given on consecutive 
days, and adverse events were assessed due to the short half-live time [19] until 24 hours 
after the last treatment. Follow-up was conducted three weeks after treatment.  
 
In contrast, early estimates for the Prednisone trial of USD 1.5 million were exceeded by 
USD 0.8 Mio mainly due to prolonged recruitment duration by 11 months. Reasons were 
multifactorial, including increased complexity due to its conduct at seven different hospitals in 
Switzerland, a high income country with one of the most expensive health care systems 
including highest salaries [11, 20, 21]. Further, the Prednisone-Trial was conducted over five 
years, included a larger sample-size, multiple follow-up assessments per patient were 
necessary, and eligibility and enrolment rates were much lower than expected [10]. It is a 
common scenario with RCTs that the recruitment rate turns out to be lower than anticipated 
[6], leading to longer screening, enrolment, and recruitment times, which in turn is associated 
with higher costs. Underestimation of recruitment rates and lack of feasibility assessment 
frequently even lead to discontinuation of entire RCTs [6]. 
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The assessed cost data indicate that the patient enrolment, treatment, and follow-up phase 
was in each case the most expensive part (i.e. 84.2% Prednisone-Trial; 46.3% Oxantel-
Trial). The percentage difference can be explained by the following reasons: First, the patient 
enrolment, treatment, and follow-up was much shorter in the Oxantel-Trial and, second, this 
particular phase was conducted in a low-income country. The central role of the patient 
enrolment, treatment, and follow-up phase was additionally highlighted by the one-way 
sensitivity analysis which indicated that the sample size had a large influence on the overall 
costs. The sample size, however, affects not only costs during the patient enrolment, 
treatment, and follow-up but also costs during the project development & preparation (e.g. 
insurance fee) and for after last patient out (e.g. data cleaning).  
 
A major strength of the current cost evaluation is that, according to our systematic review 
(Speich et al., submitted together with this manuscript to the JCE), this is the first study 
evaluating empirical costs and resource use of RCTs in the academic setting. While other 
studies on mainly industry-sponsored trials of all phases exist, they do not offer the same 
level of detail and transparency as our analysis [1]. We enable readers for the first time to 
understand how RCT costs actually arose. Moreover, we assessed the working effort for 
each necessary working step of the RCTs. With these data and the personnel expenses the 
overall costs of the two RCTs were calculated. In our opinion, this approach reflects the true 
costs better than taking lump sums which are paid by funders per patient, because these 
incentives for clinicians are often beyond covering only the expenses [22]. In other cases 
different funding sources might be combined and therefore the lump sum from a single 
founder will underestimate the total costs. Furthermore, we used a systematically developed 
item list to cover all relevant resources and costs of an RCT as comprehensively as possible. 
However, we realized that the list was not user-friendly enough to efficiently collect costs. In 
the future, we will therefore continue to adapt and revise the list until it is a tool that may be 
used by researchers to assess cost data or by clinical investigators to plan and monitor study 
costs. 
 
On the other hand, our study has the following limitations: First, the majority of the time 
expenditures in our case study had to be estimated retrospectively within semi-structured 
interviews. Our approach was similar to the one conduct in three trials [23-25] identified in 
our systematic literature review (Speich et al., submitted together with this manuscript to the 
JCE). We tried to break down the overall costs into smaller items to assess more accurate 
data. Furthermore, we added 30% of overhead/unproductive time so that the overall costs of 
RCTs are not underestimated. However, tools to monitor costs of RCTs are needed to 
acquire more data with higher accuracy. Second, as our title implies this study is a case 
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study and cannot be generalised. Both of our included studies were, for example, conducted 
with relatively cheap drugs. In cases where the intervention itself is more expensive (e.g. 
cancer drugs) and given multiple times, this factor alone could already lead to RCTs that are 
several times more expensive than the Prednisone-Trial or the Oxantel-Trial. The highest 
overall cost of a single RCT that we identified in our systematic review (Speich et al., 
submitted together with this manuscript to the JCE) was reported by Zhu and colleagues with 
overall costs of USD 454 Mio [26]. Nevertheless, while the economic evaluation of our case 
study may not be representative for other RCTs, it provides a first indication of cost drivers in 
the academic setting and hopefully encourages the research community to make their cost 
and resource use data publicly available.  
 
Tools to budget and manage costs in the academic setting are urgently needed, and we 
believe that without budgeting and tracking costs efficiently, the clinical research enterprise 
will stay unsustainable [2] and prone to failure [6]. In addition, further research is needed to 
investigate cost-efficient solutions for clinical research, such that it becomes and remains 
affordable for academic investigators. Stakeholders who are able to influence the planning 
and the design of academic RCTs, such as public funding agencies or research ethics 
committees, should diligently put emphasis on well-planned a priori feasibility assessments 
and well thought-through budgets. 
 
 
Conclusion 
Evidence on the main cost drivers of clinical research and development is urgently needed. 
Although our findings may not be transferrable to all academic RCTs, this study proposes a 
structured and transparent methodology and contributes to a better understanding of the type 
and range of expenses associated with RCTs. In the future, this model approach may be 
refined and serve as a toolkit for others. It may allow assessing the costs of RCTs at their 
institutions retrospectively, monitor costs during the conduct of an RCT on an ongoing basis 
[27], and developing more comprehensive and reliable budgets before the start of the trial.  
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Appendix 
 
A – Development of the cost item list  
Systematic literature search 
A systematic literature search of MEDLINE and EMBASE via the Ovid interphase and 
EconLit was designed and conducted on Tuesday 3rd November 2015. Our search was not 
restricted in terms of language, publication type, or publication date. 
 
Ovid search strategy 
1 Randomized Controlled Trial* as Topic.mp. or Randomized Controlled Trials as Topic/ 
2 clinical trial* as topic.mp. or Clinical Trials as Topic/ 
3 1 or 2 
4 (cost* adj2 (component* or item*)).tw. 
5 (budget* adj2 calc*).tw. 
6 ((study or trial) adj2 budget*).tw. 
7 cost* method*.tw. 
8 (unit* adj2 cost*).tw. 
9 4 or 5 or 6 or 7 or 8 
10 3 and 9 
11 remove duplicates from 10 
 
EconLit search strategy 
1st field: TX All Text: 
(randomized control* trial*) or RCT* or (clinical trial*) or (clinical stud*)  
AND 
2nd field: TX All Text: 
 (cost* component*) or (cost* item*) or (budget* calc*) or (study budget*) or (trial 
budget*) or (cost* method*) or (unit* cost*) 
 
Inclusion criteria 
At title/abstract level, we included any articles 
a. Indicating the stratification of costs related to clinical trials into different costing 
groups and/or specific cost items. 
b. Describing the development and implementation of clinical trial budget templates and 
budgeting tools. 
c. Discussing a single clinical trial-related costing group (e.g. study development, study 
implementation), as long as this was the overall topic of the article according to the 
abstract/title and this costing group was considered an integral part of the overall 
study costs. 
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At full text level, we considered all articles providing specific cost items of clinical trials. 
 
Exclusion criteria 
We excluded any articles that focused on i) animal research, ii) hospital / health care costs 
and iii) cost-benefit analyses. 
 
Study selection 
Before starting the systematic literature review, we thoroughly discussed the search strategy, 
tested the results based on a subset of hits and improved the search criteria in order to 
obtain more relevant and less irrelevant hits. Afterwards, we performed the search in all 
databases and screened the articles as outlined above. The number of articles involved in 
each step is displayed in Figure 1. Whenever studies mentioned websites and/or additional 
documents provided via the internet, we flagged the articles and checked the information 
during the systematic internet search process. 
 
 
Figure 1: Overview of the systematic literature review process 
 
All relevant cost items related to clinical research trials based on the systematic literature 
review were gathered and incorporated in an electronic shared database (googledocs.com). 
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Systematic Internet Search 
In addition to the systematic literature review, we systematically searched for direct and 
indirect cost items associated with all phases of an RCT (i.e. planning/preparation, conduct, 
analysis, reporting) by systematically screening websites (and any linked information) of 
various stakeholders involved in clinical research. Stakeholders mostly included 
governmental bodies, academic research organizations, and funding agencies. Websites 
were identified through the Google search engine using the keywords “clinical trial”, 
“randomized controlled trial”, “RCT”, or “clinical research” and “cost”, “costing“, “cost items”, 
“budget”, “budget template”. 
 
Cost items associated with clinical trials were extracted and compiled in an electronic, shared 
database (googledocs.com) together with the findings from the literature review. All websites 
/ documents were searched for cost items until no additional items emerged, following the 
principle of saturation. 
 
In addition to the systematic searches, we received two clinical trial budget templates from 
institutions involved in clinical research in Switzerland (1 industry / 1 not-for-profit). Cost 
items were extracted and added until no new items emerged. 
 
 
B – Cost item list 
The cost item list is available as a separate Excel-file. 
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C – Detailed cost evaluation of the Prednisone trial 
Cost component Persons involved Total time 
estimation (in 
days)  
Number 
of items 
Costs in 
2012 USD  
Fraction of 
total costs 
(%) 
Project development & preparation      
Salary costs:      
   Study design, proposal, documents, analysis plan PI 52  49,949 2.2 
 Methodological expert 4  3,746 0.2 
 Statistician 3  2,497 0.1 
 External expert 1  2,755 0.1 
 External expert 1  2,755 0.1 
 External expert 1  2,755 0.1 
 10 external experts 3  2,497 0.1 
   Source Docs Resident 14  8,142 0.4 
   Consultation of further experts Clinical Trial Unit 6  6,329 0.3 
   After ethics votum: protocol/dossier rewriting Resident 4  2,443 0.1 
   Dossier preparation for different Eks Resident/study nurse 33  18,728 0.8 
 PI 3  3,122 0.1 
   Swissmedic dossier preparation Resident/study nurse 7  4,071 0.2 
   Protocol amendments Resident 17  9,771 0.4 
   Communication with centres for set-up PI 16  14,985 0.7 
   Set-up meeting with pharmacy Resident/study nurse 3  1,628 0.1 
 PI 1  1,249 0.1 
   Meeting with Laboratories Resident/study nurse 11  6,514 0.3 
 PI 10  9,990 0.4 
   Set up of sites Resident/study nurse 6  3,420 0.1 
Other costs:      
   Approval fees (4 ethics committees, Swissmedic)   5 5,433 0.2 
   Insurance    1 68,568 3.0 
Subtotal:  Project development & preparation   196   231,347 10.1 
Patient enrolment, Treatment, Follow-up      
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Salary costs:      
   Study drug and matching placebo (production, analytics, 
packaging, labelling, and 
   randomisation, concealment, etc.) 
Pharmacy Time missing 800 11,922 0.5 
   Coordinating site (2328 patients screened, 400 enrolled)      
·         Screening  Resident/study nurse 99  57,160 2.5 
·         Informing participants  Resident/study nurse 164  94,778 4.1 
·         Enrolment Resident/study nurse 85  48,855 2.1 
   Site 2 (458 screened, 40 enrolled)    0 0.0 
·         Screening  Resident/study nurse 18  10,585 0.5 
·         Informing participants  Resident/study nurse 32  18,646 0.8 
·         Enrolment Resident/study nurse 8  4,885 0.2 
   Site 3 (96 screened, 33 enrolled)      
·         Informing participants  Resident/study nurse 7  3,908 0.2 
·         Enrolment Resident/study nurse 7  4,031 0.2 
   Site 4 (542 screened, 153 enrolled)      
·          Screening  Resident/study nurse 46  26,463 1.1 
·         Informing participants  Resident/study nurse 38  22,066 1.0 
·         Enrolment Resident/study nurse 32  18,687 0.8 
   Site 5 (185 screened, 148 enrolled)      
·         Screening  Co-investigator 64  56,817 2.5 
·         Informing participants  Co-investigator 13  11,551 0.5 
·         Enrolment Co-investigator 31  27,722 1.2 
   Site 6 (11 enrolled)      
·         Informing participants  Co-investigator 1  687 0.0 
·         Enrolment Co-investigator 2  2,060 0.1 
   Site 7 (15 enrolled)      
·         Informing participants  Resident/study nurse 1  611 0.0 
·         Enrolment Resident/study nurse 3  1,832 0.1 
   Additional time for 1/10 patients for which exclusion criteria 
was only noticed 
   after informing the patient 
Resident/study nurse 6  3,257 0.1 
   Additional time for 508 patients with immunosuppression Resident/study nurse 7  4,071 0.2 
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which were assessed for  
   eligibility 
   Additional time for "no ic possible" assessed for eligibility Resident/study nurse 7  3,925 0.2 
   Additional time for patients which did not consent Resident/study nurse 43  24,631 1.1 
   Treatment / Follow up / Data entry at coordinating site Study nurse 392  260,460 11.3 
     Site 2 Study nurse 53  27,684 1.2 
     Site 3  Study nurse 43  22,840 1.0 
     Site 4 Study nurse 201  105,892 4.6 
     Site 5 Study nurse 195  102,432 4.4 
     Site 6 Study nurse 14  7,613 0.3 
     Site 7  20  10,382 0.5 
   Determination of clinical stability Resident 92  52,926 2.3 
   Patient discharge Resident 37  21,496 0.9 
   Ongoing communication/coordination with participating sites Resident/study nurse 204  107,350 4.7 
   Additional insulin therapy necessary in an additional 8 % 
(n=33) of treatment arm  
   patients: 
     
   Informing patients  Study nurse 3  1,344 0.1 
 Resident 1  430 0.0 
   Insulin (covered by insurance)      
   Ongoing data management Data manager 17  18,144 0.8 
   Ongoing monitoring Monitor 17  14,531 0.6 
   Ongoing sample management Resident 59  34,153 1.5 
   Sample sorting (n=16'000) Study nurse/student 38  25,317 1.1 
   Shipping: Admin time and fees Resident/study nurse 20  18,217 0.8 
   AE/SAE documentation Resident 13  7,287 0.3 
   Data Safety & Monitoring Board External expert 1  936 0.0 
 External expert 1  2,755 0.1 
   Yearly safety report Resident, study nurse 53  27,626 1.2 
   Ongoing meetings of principal investigator with staff, 
collaboratios, literature  
   research related to project, etc. 
PI 303  292,203 12.7 
   Ongoing training of staff at sites Resident 14  8,142 0.4 
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Study nurse 26  13,419 0.6 
Other costs:      
   Study drug compound   400 3,070 0.1 
   Biological samples (materials, analysis of biological 
samples) 
  16000 218,624 9.5 
   Other medical material (freezer, blood pressure machine, 
pulsoxymeters, etc.) 
  7 23,015 1.0 
   Other material (flyers, photocopies, folders etc.)    10,549 0.5 
   Incentives for sites (e.g. breakfasts, dinners, etc.)   38 14,294 0.6 
   Travel expenses    26,680 1.2 
Subtotal:  Patient enrolment, Treatment, Follow-up   2,533   1,938,958 84.2 
After last patient out      
Salary costs:      
   Data cleaning Resident 28  12,487 0.5 
 Registrar 26  12,487 0.5 
   Statistical analysis Methodological expert 13  16,285 0.7 
 Statistician 13  18,712 0.8 
   Final study report PI 1  499 0.0 
 Resident 3  1,628 0.1 
 Study nurse 3  1,384 0.1 
   Writing of main publication (Lancet) PI 9  8,741 0.4 
 Resident 14  8,142 0.4 
 Registrar 7  4,678 0.2 
 Methodological expert 3  2,497 0.1 
 Statistician 3  2,497 0.1 
   Submission procedures Resident 1  814 0.0 
 Secretary 2  814 0.0 
   Review process PI 8  8,991 0.4 
 Resident 10  5,863 0.3 
 Methodological expert 3  2,497 0.1 
 Statistician 3  2,497 0.1 
 Registrar 7  6,243 0.3 
 External expert 1  1,377 0.1 
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   Proofs PI 3  2,497 0.1 
 Resident 3  1,628 0.1 
Other costs:      
   Publication fee    1,315 0.1 
   Conference fee and expenses  Resident 7  4,940 0.2 
Subtotal:  After last patient out   168   129,518 5.6 
Additional costs      
   Computer rental and software        2,061 0.1 
Total costs   2,897   2,301,884 100.0 
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D - Detailed cost evaluation of the Oxantel trial 
Cost component Persons involved Total time 
estimation 
(in days) 
Number of 
items 
Costs in 
2012 USD 
Fraction 
of total 
costs in 
% 
Project development & preparation      
Salary costs:      
   Preparation of research protocol (e.g. literature 
review,  
   development of idea, writing-up, meeting time) 
1 Principle Investigator 
1 PhD Student 
2 Statistician 
2 Consulted experts 
1 In house authority 
7.8 
15.6 
1 
1 
0.5 
 5,343 
3,637 
844 
1,055 
527 
5.3 
3.6 
0.8 
1.1 
0.5 
Acquiring funding 1 Principle Investigator 6.5  4,453 4.4 
   Developing/updating investigational brochure, 
standard operating 
   Procedures, case report form and patient 
related forms 
1 Principle investigator 
1 PhD Student 
1 Co-Principle investigator 
1 In house authority 
0.25 
7.2 
1 
0.25 
 171 
1,679 
60 
264 
0.2 
1.7 
0.1 
0.3 
   Applications to ethics committee, authorities, 
insurance (e.g.  
   preparation, submission; but not fees) 
1 Principle investigator 
1 PhD Student 
0.5 
3.4 
 343 
793 
0.3 
0.8 
   Budgeting (study budget calculation and 
controlling) 
1 PhD Student 1.3  303 0.3 
   Reporting to funders, managing clinical trial 
portals 
1 Principle investigator 
1 PhD Student 
1 
1 
 891 
233 
0.9 
0.2 
   Production of Oxantel Pamoate and matching 
placebos 
1 Research Associate 
(Pharmaceutical Technology) 
5  2,637 2.6 
 
   Packaging and labelling of study drugs 1 Pharmacy PostDoc 
1 Pharmacy PhD student 
1 
1 
 356 
249 
0.4 
0.3 
Other costs:      
   Ingredients Oxantel Pamoate   1 251 0.3 
   Ethical approval in Basel, Switzerland   1 317 0.3 
   Ethical approval on Pemba Island, Tanzania   1 240 0.2 
   Trial registration   1 310 0.3 
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   Insurance for participants   1 1,482 1.5 
Subtotal:  Project development & preparation  55.6  26,437 26.3 
Patient enrolment, Treatment, Follow-up      
Salary costs:      
   Screening and enrolment 6 Field staff 
6 Laboratory staff 
1 Cleaner 
2 Co-Principle investigator 
2 Data entry staff 
1 PhD student 
120 
120 
21 
48 
42 
25 
 2,880 
3,024 
252 
2,880 
1,008 
5,829 
2.9 
3.0 
0.3 
2.9 
1.0 
5.8 
   Treatment, assessing AE/SAE, and follow-up 2 Local  Physicians 
6 Field staff 
6 Laboratory Staff 
1 Cleaner 
2 Co-Principle investigator  
2 Data entry staff 
1 PhD student 
1 Principle investigator 
30 
66 
66 
11 
32 
28 
23 
7 
 1,800 
1,584 
1,584 
132 
1,920 
672 
5,363 
4,795 
1.8 
1.6 
1.6 
0.1 
1.9 
0.7 
5.3 
4.8 
Other costs:      
   Material for stool collection (stool containers)   2,400 240 0.2 
   Material for stool analysis (Kato-Katz Kit, wire 
mesh)  
   1,072 1.1 
   Hired car (in days) including fuel and driver   40 1,920 1.9 
   Transport reimbursement for 
patients/guardians 
  600 720 0.7 
   Albendazole   300 90 0.1 
   Mebendazole   150 38 <0.1 
   Albendazole matching placebo   300 158 0.2 
   Mebendazole matching placebo   450 211 0.2 
   Materials for clinical examination and adverse 
event mitigation 
   370 0.4 
   Telephone, Fax, Internet, stationery    432 0.4 
   Costs for 2 investigators from Switzerland 
(flights, bill of  
1 Principle investigator, 1 PhD 
student 
  5,994 6.0 
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   expenses, accommodation)  
Subtotal:  Patient enrolment, Treatment, 
Follow-up 
 645  44,968 44.8 
After last patient out      
Salary costs:      
   Treatment of all school-children 6 Field staff 
1 PhD student 
6 
1 
 145 
232 
0.1 
0.2 
   Data management, data cleaning 1 PhD student 4  933 0.9 
   Statistical analyses 1 PhD student 
1 Statistician 
6.5 
1 
 1,516 
844 
1.5 
0.8 
   Output Tables and Figures plus interpretation 
of results 
1 PhD student 
1 Principle investigator 
13 
0.5 
 3,031 
343 
3.0 
0.3 
   Manuscript preparation and revision 1 PhD student 
1 Principle investigator 
1 Statistician 
2 Consulted experts 
53 
4.5 
3 
1 
 12,358 
3,083 
1,532 
1,055 
12.3 
3.1 
1.5 
1.1 
   Conference (including abstract submission) 1 PhD student 3.5  816 0.8 
Other costs:      
   Albendazole for treatment of all school-children   2100 630 0.6 
   Hired car (in days) for treatment of all school 
children 
  1 48 0.1 
   Conference fee and expenses (British Society 
for Parasitology) 
1 PhD student  1 1,020 1.0 
   Publication fees (New England Journal of 
Medicine) 
1  1 0 0.0 
Subtotal:  After last patient out  97  28,585 28.5 
Additional costs      
   Computer rental and software (STATA) 2   384 0.4 
Total costs  797.6  100,374 100.0 
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Abstract 
Background: In spite of efforts to employ risk-based strategies to increase monitoring 
efficiency in the academic setting, empirical evidence on their effectiveness remains sparse. 
This mixed-methods study aimed to evaluate the risk-based on-site monitoring approach 
currently followed at our academic institution.   
 
Methods: We selected all studies monitored by the Clinical Trial Unit (CTU) according to 
Risk ADApted MONitoring (ADAMON) at the University Hospital Basel, Switzerland, between 
01.01.2012 and 31.12.2014. We extracted study characteristics and monitoring information 
from the CTU Enterprise Resource Management system and from monitoring reports of all 
selected studies. We summarized the data descriptively. Additionally, we conducted semi-
structured interviews with the three current CTU monitors. 
 
Results: During the observation period, a total of 214 monitoring visits were conducted in 43 
studies resulting in 2961 documented monitoring findings. Our risk-based approach 
predominantly identified administrative (46.2%) and patient right findings (49.1%). We 
identified observational study design, high ADAMON risk category, industry sponsorship, the 
presence of an electronic database, experienced site staff, and inclusion of vulnerable study 
population to be factors associated with lower numbers of findings.  The monitors understand 
the positive aspects of a risk-based approach but fear missing systematic errors due to the 
low frequency of visits.   
 
Conclusions: We show that the factors mostly increasing the risk for on-site monitoring 
findings are underrepresented in the current risk analysis scheme. Our risk-based on-site 
approach should further be complemented by centralized data checks, allowing monitors to 
transform their role towards partners for overall trial quality, and success. 
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Background 
Adherence to the International Conference on Harmonization of Good Clinical Practice (ICH 
GCP) guidelines should ensure the safety, rights, and integrity of trial participants as well as 
the confidentiality of personal information and data quality [1]. Trial monitoring through 
trained clinical monitors is requested by ICH GCP, but the guideline provides limited insight 
on the procedures of quality assessment during such monitoring visits [2, 3]. Traditional 
approaches relied on intensive on-site visits and 100% source data verification (SDV) 
irrespective of the risk levels in the study, which have been associated with high cost and 
limited contribution to clinical trial data quality [4-6]. 
 
Recent developments at international bodies and regulatory agencies such as the European 
Medicines Agency (EMA) have supported the need for risk-proportionate approaches to 
clinical trial monitoring [7-9]. In November 2016, the ICH published the final version of the 
integrated addendum to ICH-GCP, advising Sponsors to develop a systematic, prioritized, 
risk-based approach to monitoring clinical trials [3]. Similarly, the forthcoming European 
Union (EU) Clinical Trial Regulation will permit reduced monitoring for low-risk intervention 
trials [10]. Among the first, the Risk ADApted MONitoring (ADAMON) Project proposed an 
instrument for the facilitation of risk analysis allowing on-site monitoring strategy tailored to 
the risk profile of every trial [11]. Risk analysis thereby refers to the risk of jeopardizing 
patient safety and rights or the validity of results and considers patient, site, and study design 
robustness-related indicators. Furthermore, risk analysis takes into account the risks of the 
study intervention compared to the risks a patient would run if treated in routine practice. This 
approach was first proposed in 2009 and later adapted by other stakeholders such as the 
Organization for Economic Co-operation and Development (OECD), the U.S. Food and Drug 
Agency (FDA), and EMA [9, 12, 13]. It encouraged study sponsors to assess, on a case-per-
case basis, the risk associated with an individual trial protocol, implement risk assessments 
that focus on critical data and procedures, and utilize alternative monitoring approaches 
taking advantage of the increasing use of electronic systems.  
 
Sponsors should develop a monitoring plan that describes, based on the risk assessment, 
the monitoring strategy, the monitoring responsibilities of all the parties involved, the various 
monitoring methods to be used, and the rationale for their use [3]. However, in the absence 
of credible data to describe impact of a change of monitoring approach on data quality and 
study cost, the majority of industry-sponsored trials continue to be monitored using a 
traditional monitoring approach with up to 100% SDV. It has been estimated that SDV can 
consume up to 25% of the sponsor’s entire clinical trial budget, even though the association 
between data quality/subject safety and the extent of monitoring and SDV has not been 
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clearly demonstrated [14]. Financial estimates of a single monitoring site visit range from 
US$800 in 1991  to US$1500 in 2009 [15, 16],  with conservative cost estimates for one 
single query of US$150 [17].  The approach taken may therefore be evaluated as 
overcautious at best, and at worst, a complete waste of resources based on current reviews 
[18, 19].  
 
In the academic setting, restricted resources often oblige investigators to apply a risk-based 
approach to trial monitoring which is expected to be less labor intense [20]. At the academic 
Clinical Trial Unit (CTU) at the University Hospital in Basel, Switzerland, we have applied 
risk-based on-site monitoring based on the ADAMON project for all patient-oriented 
research projects since 2012. In order to understand the implications of this approach for 
patient safety and data quality at our institution, we undertook this mixed-method 
investigation. The aim of our study was to i) retrospectively investigate the 
characteristics of findings documented during on-site visits, ii) identify key factors that 
might influence the number and types of monitoring findings, iii) assess the costs 
associated with our approach, and iv) understand the experience of our monitors and the 
challenges they face.  
 
 
Methods 
Setting 
This mixed-method study was performed at the CTU of the University Hospital in Basel. The 
CTU offers monitoring services to investigator- and industry-initiated studies conducted at 
our institution and affiliated sites if desired by sponsors. CTU monitors are qualified by 
training and experience and work according to clearly defined standard operating procedures 
(SOPs) which are reviewed and updated by an autonomous quality-assurance officer on a 
regular basis. The risk evaluation adopted by the CTU (Table 1) includes  a structured trial 
risk classification by the project manager according to the ADAMON project and the Swiss 
Human Research Act as described by the Swiss Clinical Trial Organization [21]. This 
approach allows the categories low, medium, or high risk; and the assessment of additional 
three risk modulators (Table 1). These risk modulators may lower or raise the risk within a 
certain risk category and therefore influence the duration of site visits, but not their 
frequency. After risk classification, the project manager specifies the extent and nature of on-
site monitoring visits in the monitoring plan (Table 2). CTU monitors then conduct on-site 
monitoring visits according to the pre-specified monitoring plan and document monitoring 
findings in monitoring reports which are shared and discussed with both the sponsor and the 
project manager.  
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Table 1. Risk classification procedure at Clinical Trial Unit Basel.  1-3 conducted according to the Swiss Clinical Trial Organization Guidelines 
for Good Operational Practice V2.0. Scheme adapted from Hurley et al. [22].  
 
1 Including indicators on vulnerability of study population, setting of recruitment, critical eligibility criteria, additional risks of therapy, trial procedures that are 
unusually complex, etc. 2 Including essential technical, personnel, storage, transport, or documentation requirements at site. Site-related indicators do not affect 
the risk category of a study, but may modulate the extent and duration of individual monitoring visits. Human Research Act (HRA), ADApted MONitoring 
(ADAMON), Clinical Trials Ordinance (ClinO)
Risk classification procedure 
 
Recommended 
systematic review of 
trial's risk profile 
1. Initial Risk 
classification  
2. Categories of risk 
modulators  
3. Risk classification 4. Modulators of 
monitoring extent 
Potential risk of 
therapeutic 
intervention in 
comparison 
to standard of 
medical care (as 
described in HRA & 
ADAMON): 
 
 Comparable (see 
also ClinO art. 
19,20,61, category 
A) 
 Higher (see also 
ClinO art. 19,61, 
category B) 
 Markedly Higher 
(see also ClinO art. 
19,20, category C) 
Modulators from the 
following ADAMON 
categories may influence 
the initial risk category by 
a max. of +1 or -1 risk 
category (e.g. 
Intermediate to High 
Risk):                                       
 
1. Potential trial 
participant-related 
critical 
indicators1 
2. Robustness related 
indicators 
– “hard primary 
endpoints” and/or 
simple 
clinical trial procedure                          
3. Site-related 
indicators2 
An overall 
risk category is assigned based on the 
results of 1) and 2) as 
follows: 
 
 Low risk: Risk of intervention 
comparable 
& trial has at least one indicator 
of robustness and no participant related 
indicator 
 Intermediate risk: Risk of intervention 
comparable, or higher 
& trial has                                                                                                                          
no indicator of 
robustness, or at least one participant-
related indicator present 
 High risk: Risk of intervention higher or 
markedly higher, 
and trial has no indicator of 
robustness, or at least one participant 
related critical indicator present 
The following modulators 
may influence monitoring 
extent (i.e. number of hours 
per visit) within risk 
category: 
 
1. site experience with 
clinical trials 
2. presence of an 
electronic database at 
site 
3. whether site is 
coordinating lead site 
of the study 
An additional risk 
assessment 
is required if the trial 
undergoes substantial 
amendments 
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Table 2. Recommended on-site monitoring activities based on study risk 
classification. Informed Consent (IC) 
 
Quantitative retrospective analysis 
We included all investigator-initiated trials (IITs) and industry-sponsored studies monitored by 
the CTU between January 1st 2012 and December 31st 2014 with the exception of studies for 
which monitoring had never been fully initiated (i.e. <10% of planned working hours 
completed because of an early study discontinuation or delayed study start). Since the 
introduction of risk-based monitoring at our institution in 2012, a total of six monitors had 
been involved in monitoring activities. For all included studies, we extracted a set of variables 
covering detailed characteristics at the level of the study itself, the level of the study site and 
the individual monitoring visit. 
 
Study-specific variables included 
- study design, 
- study type, 
- study sponsor, 
- type of research, 
- study phase (I-IV), and 
- type of study population (e.g. inclusion of vulnerable populations). 
 
Variables covering study site information included 
- site location, 
- ADAMON risk category, 
- presence of electronic database, 
- principal investigator, and whether he/she changed during conduct, 
- staff experience, and 
- number of planned patients at the site. 
 
At the level of the individual monitoring visit we extracted information on 
- type of visit (i.e. initiation, interim, close-out), 
Risk of 
Study 
Initiation 
visit 
Interim visit Content of interim visits Close out 
visit 
Low  optional after first patients, then 
adaptable (e.g. 1/year) 
Endpoints (extent to be 
defined), IC (usually 100%) 
optional 
Intermediat
e 
mandatory after first patients, then 
adaptable (e.g. 1/year) 
Endpoints (extent to be 
defined), IC (usually 100%), 
safety (usually 100%) 
mandatory 
High mandatory after first patients, then 
in regular intervals  
Endpoints (extent to be 
defined), IC (usually 100%), 
safety (usually 100%) 
mandatory 
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- the number of  
- administrative, 
- patient rights,  
- patient safety, 
- laboratory/biological specimen,  
- data point confirmation, and  
- endpoint related findings.  
 
Extraction and categorization of findings was performed independently and in duplicate (AO, 
MV, CB) from monitoring plans and reports using a validated web-based database 
(secuTrial®). Classification of findings corresponded to the main categories used in our 
monitoring reports and categories were treated as mutually exclusive. Table 6 provides 
examples of findings for each category.  Discrepancies between extractors in classifying the 
variables were resolved through discussion by the extractors. After an initial calibration 
phase, agreement between the extractors was considered “good” if no more than 4 out of 49 
extracted variables differed. Findings that were corrected immediately on-site were often not 
documented and therefore not included in our study. We summarized the number of findings 
descriptively, stratified by key variables and graphically displayed as i) total findings per 
study (or site, depending on the variable), ii) percentage of administrative or patient right 
findings out of total number of findings. Figures were interpreted visually. Furthermore, we 
collected information on human and financial resources employed for monitoring activities 
from the CTU Enterprise Resource Management (ERP) system for each project. We 
calculated total resource use by summing the total hours worked by our monitors during the 
analyzed time period (2012-2014), as retrieved from the ERP, multiplied by the hourly salary 
rate. We then divided the total human resource cost by total number of findings which we 
had documented and extracted from monitoring reports. 
 
Semi-structured interviews 
We interviewed three monitors who were involved in these monitoring visits and who 
continue to work at our institution at present. The main themes covered during these 
interviews were i) monitors’ perspective on risk-based monitoring per se, ii) the practical 
settings in which these visits and findings of events were documented, iii) the challenges 
they faced during these visits, and iv) their perspectives on the future development of  risk-
based monitoring. As interviews did not include health-related data and were therefore not 
within the scope of the applicable Human Research Act (HRA, Art.1), we did not require 
formal ethical approval. Each interview was conducted in German by NR, tape recorded with 
the monitor’s permission, transcribed in full, and anonymized at the level of transcription.  We 
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examined all the transcripts in duplicate (BvN and NR) and BvN coded each interview. We 
then grouped codes into clusters around similar and interrelated themes until we reached 
consensus. In the results section below, we will describe and discuss three key themes that 
emerged from our qualitative interviews (a) factors influencing risk-based monitoring findings; 
(b) the monitoring process and the challenges faced; and (c) the current role of monitors 
and future perspectives. 
 
 
Results 
Study sample characteristics 
We included forty-three studies (39 investigator-initiated, 3 industry-sponsored) monitored 
between January 1st 2012 and December 31st 2014 for analysis. Characteristics of these 
studies are shown in Table 3, study stratification by risk categories and associated risk 
factors in Table 4.  
 
Table 3. Study sample characteristics (number, %). Study sample including 43 studies 
monitored by the CTU Basel between 2012 and 2014. 
  Total 
    n % 
Total studies   43 100 
    
Study design Interventional 34 79.1 
 Observational 9 20.9 
    
Study type  Multicenter  10 23.3 
  Singlecenter 33 76.7 
        
Study sponsor Investigator 
(academic) 
40 93.0 
 Industry 3 7.0 
    
Type of research Drug 29 67.4 
  Medical Device 5 11.6 
  Biological Samples1 4 9.4 
  Other2 5 11.6 
        
Study phase (drug studies, n=29) I 9 31.1 
  II 7 24.1 
  III 8 27.6 
  IV 3 10.3 
  Other3 2 6.9 
1 Biological samples incl. physiological or genetic analysis of human biological samples (e.g. urine, 
blood, tissue, etc.) 
2 Other incl. observational research, health economics assessments, or tissue-based 
intervention/stem-cell transplantation 
3 Other incl. cost-effectiveness trials not specific to a phase 
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Table 4. Study sample by risk categories and associated risk factors. Study sample 
including 43 studies monitored by the CTU Basel between 2012 and 2014, stratified by 
ADAMON risk categories, and factors associated with risk evaluation.  
  Total 
  n % 
Total studies  43 100 
    
ADAMON risk category Low 11 25.6 
  medium 23 53.5 
  High 9 20.9 
  Total  43  100 
    
Electronic database present at first patient in Yes 19 44.2 
  No 24 55.8 
  Total 43 100 
    
 Principal Investigator change during study Yes 3 7.0 
  No 40 93.0 
 Total 43 100 
    
Vulnerable study population
1 
 Yes 7 16.3 
No  36 83.7 
 Total 43 100 
    
Total sites  94 100 
    
Staff experienced
2
, by site Yes 88 93.6 
  No 6 6.4 
 Total 94 100 
    
Staff change, by site Yes 11 11.7 
  No 48 51.1 
  Unknown 35 37.2 
  Total 94 100 
1 Defined as “children, adolescents, adults lacking capacity in the consent procedure, 
pregnant women and in-vitro fertilized embryos and fetuses, prisoners, and subjects in 
emergency situations” (according to HRA, Chapter 3). 
2 Defined as a) GCP trained, b) solely dedicated to research activities (e.g. a study nurse, 
resident, etc.), and c) has been involved in the conduct of one or more clinical research 
studies before. 
 
Characteristics of monitoring findings 
In total, we documented 2961 findings during 214 monitoring visits in 43 studies between 
2012 and 2014 (Table 5, 6). In ten out of 43 studies, we monitored more than one site. 
Overall, administrative findings (46.2%; e.g. missing CVs or incomplete Investigator Site 
Files etc.) were equally predominant as patient rights findings (49.1%; e.g. wrongly signed 
and dated informed consent forms), whilst patient safety issues were found only 
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exceptionally (1.1%). Although the studies varied in their total amount of findings, we 
documented at least one administrative and one patient right finding in almost every study, 
and at least one safety finding in a fifth of all studies (Table 5, 6). The remaining findings 
included issues related to laboratory procedures or biological specimen (2.3 %), and issues 
related to the endpoint which could not be clarified with staff at site and required written 
confirmation (e.g. clarification of a questionable laboratory value which seemed out of range, 
1.2%)  (Table 5).  
 
Table 5.  Characteristics of monitoring findings. 
Sum of findings by CTU monitors in total (number, %). Note: Findings which were resolved on-site 
between monitor and study staff and not documented in monitoring reports are not listed. 
    Total 
    n % 
Total Studies   43 100 
Total Monitoring Visits   214 100 
Findings     
  Administrative 1367 46.2 
  Patient rights 1453 49.1 
  Patient safety 32 1.1 
  Laboratory/biol. specimen 70 2.3 
  Endpoint related data point: confirmation requested 36 1.2 
  Endpoint related data point: Data point changed 3 0.1 
  Total 2961 100 
    Average n findings/visit  13.8  
Studies with     
 at least 1 administrative finding 43 100 
 at least 1 patient right finding 41 95.3 
 at least 1 patient safety finding 9 20.9 
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Table 6.  Examples of monitoring findings. Curriculum Vitae (CV), Case Report Form 
(CRF), Ethics Committee (EC) 
Finding category 
 
Examples of findings 
Administrative  Changes at the investigational site (staff training, staff CVs, address, 
technical equipment, etc.) not documented  
 Functions and responsibilities log not up to date 
 Subject related logs not up to date 
 CRFs not available at site and/or not documented by authorized staff 
Patient rights  Informed Consent Forms not signed and/or not dated correctly 
 No valid and approved version of Informed Consent Form used 
 Amendments/addenda to Informed Consent Form not communicated to 
patients and no re-consent obtained 
 Patient did not fulfill all inclusion criteria  
Patient safety  No description of the process for detecting and reporting serious and 
unexpected adverse events and/or unanticipated problems involving risk 
to participants in place at site 
 Adverse events not correctly documented and/or reported as required 
(e.g. to Sponsor, EC, Competent Authority) 
 New safety information not approved by authorities 
 Staff not trained according to new safety information  
Laboratory 
/Biological 
Specimen 
 Biological specimen not stored correctly according to protocol 
 Process conducted not in accordance with Good Manufacturing Practice 
(GMP)  
Data point 
confirmation 
requested 
 Indicates whether finding challenges the credibility of data point, e.g. by 
stating “Please confirm that blood pressure measure is 100/65mmHg” 
Data point changed  Indicates whether data point was adjusted as direct consequence of 
finding, e.g. “Blood pressure of 100/65mmHg was corrected to 
120/80mmHg” 
 
Influencing factors on number and type of findings 
Generally, the sample size of a study was positively associated with the total number of 
findings (Figure 1).  Due to the low number of other than administrative and patient rights 
findings, the figures display both the percentage of patient rights (X %) and 
administrative findings (100%-X %). Visual inspection of figures showed that factors such 
as observational study design (Figure 2a/b), high ADAMON risk category (Figure 3b), 
industry sponsorship (Figure 3c), the presence of an electronic database (Figure 3d), 
experienced site staff (Figure 3e), and inclusion of vulnerable study population (Figure 3f) 
were associated with lower numbers of monitoring findings. As a trend, studies sponsored by 
industry or with a high risk category tended to result in less patient rights findings compared 
to other studies, for which the proportion pattern (patient rights vs. administrative) varied 
widely (Figures 3b and c).  
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Figure 1. Studies according to the planned sample size and the final total number 
of monitoring findings (log scale). 
  
160
Manuscript V 
 
 
 
 
Figure 2. Total number of findings and proportion of administrative (a) and patient 
rights (b) findings in interventional and observational studies, by study. Diameter 
of circles proportionate to total number of findings per study.  
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Figure 3.  Total number of findings and proportion of patient rights findings in 
studies stratified by (a) study type, (b) ADAMON risk category, (c) study sponsor, 
(d) studies with vs. without electronic database, (e) studies conducted at sites with 
vs. without clinical research experience, (f) studies with vs. without vulnerable study 
population. Diameter of circles proportionate to total number of findings per study (a, c, 
d, f) or per site (b, e). 
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Although observational studies generally resulted in fewer findings, two of the nine analyzed 
studies were outliers (> 400 findings/study) (Figure 2a/b). One was a multicenter study 
including 7 sites but no electronic data capture system, resulting in a total of 413 findings 
(45.8% administrative, 49.6% patient rights) in seven initiation, seven interim 1, and five 
interim 2 visits. The second study was a large single center study (> 2000 planned patients) 
with inexperienced study personnel and principal investigator. No initiation visit was 
performed given the low risk character of the study and an electronic data capture system 
was not available.  In this study, four interim visits resulted in a total of 710 findings of which 
20.1% were administrative and 75% were related to patient rights issues (Figure 2b, largest 
red circle).  In addition, both studies experienced a change in monitor, after which the overall 
number of findings increased. 
 
Out of 43 monitored studies, 39 were monitored more than once (at least one site), and 12 
were monitored at least three times (at least one site) (Appendix Figure 1a). Thereof, 11 
studies had an initiation visit and four studies experienced a change in monitor throughout 
the study. Generally, findings tended to decrease after the second interim visit. One study 
increased in findings after the third visit which was due to a new version of the informed 
consent which was not adequately used in all patients. The proportion of administrative 
findings was high at initiation but showed a decrease during the conduct of the study, 
whereas patient rights findings increased.  (Appendix Figure 1b/c). 
 
In our sample, only three sites conducted three or more different studies within the given two-
year time period (Appendix Figure 2; site 1: studies 3, 4, 8, and 9; site 2: studies 22, 23, 33, 
and 36; site 3: studies 26, 21, and 32). Factors such as study design (interventional vs. 
observational), study type (e.g. phase 1-3), sample size, the risk associated with the studies 
performed (and therefore the associated monitoring risk category), and staff experience does 
usually not differ much within a given site, and visual inspection did not reveal a major 
difference in total number of findings within trials at each of the three sites (Appendix Figure 
2). However, the mentioned characteristics differed significantly across the three sites (one 
high risk pharmacological phase 1 unit, one low risk observational cardiology unit, and one 
medium risk cognitive neuroscience unit) and did therefore not allow for comparison between 
these sites. In the ten multicenter studies included in our sample (1, 7, 12, 14, 16, 19, 21, 26, 
31, and 32 in Appendix Figure 2), no trend in total number of findings across sites could be 
identified. 
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Cost of monitoring 
Data on monitoring costs were only available since May 2012, when an electronic enterprise 
resource management system was implemented at the CTU. Overall, cost data was 
available for 33 out of 43 monitored projects. For these projects, we documented a total of 
4320 working hours for 2401 monitoring findings. With an hourly salary rate of US$92.5 this 
translated into total personnel costs of US$ 399’280 and an average per findings cost of 
US$166. In this estimate, however, the endpoint related findings that were resolved on-site 
are not considered, leading to potential overestimation of costs per finding.  
 
The Monitor’s perspective  
In addition to evaluating the characteristics of findings of our on-site visits, we aimed to 
understand the practical experience of monitors involved, challenges they face during 
monitoring, their perspectives on the risk-based approach, and suggestions for improvement. 
 
Three monitors we interviewed had been working as clinical trial monitors for two to 21 years, 
two of them mainly in the academic setting whereas the third one mainly in the 
pharmaceutical industry environment. With the introduction of risk-based monitoring at the 
CTU in 2012, all three participants started to monitor according to the above described 
standard procedure. Below we describe three main themes from these interviews and 
provide select quotations for each. 
 
Factors influencing risk-based monitoring findings 
All three monitors expressed a generally positive attitude towards the concept of upfront risk 
evaluation, which allows assessment of critical factors in the study design or practical 
challenges that the study team might face while implementing the trial as described by one of 
our monitors.   
 
“The positive effect clearly is that you think more about the study itself. If you take the effort 
to classify the study by risk factors you can actually eliminate many things upfront. Because 
of that evaluation, I know what to set value on when I open a site”. (Monitor III) 
 
The factors that the monitors in general deemed crucial for low numbers of findings in trials 
were professional, trained and motivated study personnel, together with a robust study 
design and rigorous planning of a study. These factors were also attributed to support 
participant recruitment into the trials and eventual success of the trial. Monitor III argued that 
indicators related to the study site were underrepresented in the ADAMON risk evaluation, in 
spite of the fact that they have significant influence on the way trials are conducted. Other 
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factors that the monitors believed to contribute positively to overall trial quality and success 
were the quality of the study protocol, the early involvement of monitor and study nurses in 
protocol development, training and experience of all personnel involved, planning of finances 
and infrastructure before trial begins, available resources, trial coordination and 
management, assignment of clear responsibilities, well planned recruitment, and clear and 
transparent communication among all stakeholders involved as elaborated in the quote 
below. 
 
“But it all depends on the experience of staff on-site, if they have lots of experience with 
studies, they know how to do it. But don’t forget that staff changes so often at the site, you 
never get the same people from the start until the end of a study. The new ones, how will 
they be trained? We as monitors only hear about it half a year later and if you only visit them 
once a year, you hear that they have changed the recruiting physician and that patients have 
been informed wrongly for three quarters of a year.“ (Monitor III) 
 
Monitoring process and challenges faced 
With respect to what the current risk-based approach is able to cover on-site, all monitors 
came up with two distinct topics, namely patient safety and rights, and data quality. Monitor I 
and II felt that minimum aspects of patient safety and rights, incl. informed consent forms and 
inclusion/exclusion criteria, but also “crucial” data points such as the primary endpoint, were 
mostly covered by their on-site visits. Two monitors did not see any issues related to patient 
safety or their rights with the current approach as described below.  
 
“It depends on the monitoring plan; usually we look at 100% of the Informed Consent Forms, 
unless there are too many patients such as in cohort studies. We always look at the inclusion 
and exclusions criteria. Endpoints are to be discussed and defined with the principal 
investigator. Depending on the budget available, we might also look at the Trial Master File, 
and then I am done in no time” (Monitor I) 
 
“I hope that I cover safety aspects with my monitoring. Actually I don’t see any issues with it. 
There is no monitoring plan without the safety aspect, usually it is 100% covered. (…) 
Depending on what you find, you adapt it (the monitoring plan). If you find critical issues, for 
example a Serious Adverse Event that was not documented, you tell the team (on-site) to 
look at the other patients’ data and check whether they were correct.” (Monitor II) 
 
However, Monitor III expressed concerns about rather infrequent on-site visits with long time 
gaps in between during which there was a clear risk of missing patient safety or patient rights 
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aspects in particular. He also feared that these findings would then get resolved only during 
the next visit which might be after six months.   
 
“I question whether this approach is compatible with GCP. According to GCP you put 
patients first, and then the scientific question. There you also include data protection and the 
ICF (informed consent form). You don’t really respect patient rights if, for example, a wrong 
ICF version was signed and I only notice after half a year, just because the study is a low risk 
study according to the evaluation. I don’t think it affects the scientific validity, but more the 
patient safety and rights aspects”. (Monitor III) 
 
With respect to data quality, all monitors mentioned “systematic data errors”, i.e. errors that 
are not produced by chance.  They were concerned to miss systematic errors with the risk-
based approach. Monitor I sometimes preferred to monitor more frequently in order to 
identify systematic data errors as and when they occurred. Monitor I and II would like to 
rather cover 100% source data for fewer patients than single puzzle pieces of several 
patients to be able to pick up systematic errors as described in quote below.  
“One is for sure, if you don’t see that mistake at the beginning, it’s going to repeat with the 
next patients. So that’s a systematic error then, and of course data quality suffers! “ (…) “If I 
knew that every three month there is a monitor at your doorstep who wants to critically look 
at your data, then I am of course required to get my stuff done in time and…a bit more 
accurate as if, you know, I know that there is anyways no one looking at my data. Then you 
get the running around after the data at the end of the year”. (Monitor III) 
 
Monitor II further questioned low importance given to “less important data points” (e.g. lab 
values not specified as outcome variables). These “less important data points” are not 
considered in the risk-based monitoring plan according to ADAMON and therefore not 
checked by the monitors 
 
”Often, we do not look at lab values because they are not seen as risky values, maybe only 
10% is seen as crucial for the primary endpoint. But then you ask yourself whether you 
wouldn’t miss transcription errors if you don’t look at these values at all. (…) There are not 
only systematic errors that you don’t see but also those that appear everywhere and they’re 
even more difficult to detect. And it also depends on the format in which you collect data, if it 
is on paper or not. The CRF (case report form) heavily influences the number of mistakes 
that are made, and you don’t look at all of these with the risk-based approach. (…) If you, for 
example, look at one patient 100% in a study and not the others, you of course detect 
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systematic errors and point to that and make them look at the other patients in their 
documentation as well.” (Monitor II) 
 
All monitors believed that data quality would improve with increased frequency of monitoring. 
Monitor I and III disagreed with the current guidelines that in some low-risk cases, an 
initiation visit is not necessary. They would rather leave out the close-out visit but always 
perform an initiation visit to train the personnel on crucial GCP and study-related aspects.   
 
“I assume that in an inspection, you know, if they were to look at 100% of the data after my 
monitoring, they would find errors even in my monitored data. But I am sure you see exactly 
what documents were monitored and which weren’t. (…) but I believe that data quality would 
for sure be better with more monitoring, there I am 100% sure.” (Monitor I) 
 
“Also the change in personnel has an influence, if you don’t take care of the training of new 
employees, and you don’t involve them. The situation on-site is not reflected adequately in 
ADAMON, it’s more sort of a weak factor, that if you’re there anyways, you monitor longer, 
but it doesn’t influence the frequency of monitoring. Changes and structures on-site should 
have a stronger influence on the frequency of visits, in my opinion. “(Monitor III) 
 
Monitor III further questioned whether in reality the risk-based approach proves cost-effective 
if many errors were missed in between visits due to the low frequency of visits and when 
amendments are needed to correct those. 
 
“It is not clear whether it is cheaper if the monitor visits less frequently and everything on-site 
goes downhill or if it wasn’t better if the monitor had visited once or twice more, you know. To 
make crappy data better again is also not cheap, right? Even if you adapt all ADAMON 
criteria, we should get away from only seeing cost savings in it. “(Monitor III) 
 
When monitors were further asked about why the frequency of monitoring visits could not be 
adapted in cases where needed, all mentioned the difficult financial environment in which 
academic trials are conducted. In their experience, most often, funding limitations were the 
main factor for restrictions in the amount and frequency of monitoring visits that could be 
performed, rather than the actual risk categorization.  
“…just because the budget doesn’t allow, you know, I would like to monitor more frequently 
or follow the risk classification more strictly, but you can’t, because of the financial 
limitations.” (Monitor I) 
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Role of monitors and future perspectives 
We explored further monitors’ views on ways to improve monitoring process and to make it 
cost effective. All monitors discussed few possibilities especially in defining their role as 
monitors and the way they are perceived by the study teams. They would like to be seen as 
trustworthy partners who assist in ensuring trial success and quality instead of being mere 
“controllers”. They hoped that principal investigators would be more familiar with their role 
and study teams will not see them as a “necessary evil” who consume significant part of the 
study budget and with whom they have to deal with, but rather as supporting partners who 
assist in achieving the study goals and ensure study quality. They see themselves as critical 
examiners, a fresh pair of eyes, who provide constructive feedback to the study team, as 
trusted supporters, facilitators of communication across sites, and motivators. 
 
“I would wish for more acceptance of monitoring, they all think it is just a necessary evil. That 
you don’t do it because it’s important and helps data quality, but only because the regulators 
and authorities want it from you. I am sure, often, monitoring reports are not even read. 
There should be more trust that we help data quality and therefore, also help the answer to 
the study question”. (Monitor II) 
 
“I always tried to make them feel like I am their partner, and not some teacher or 
something…I don’t want to point the finger at them, but build a trustworthy relationship so 
that people at the site know they can trust me. So that they know they can call me if there is 
a problem. (…) The aim is to make them understand that we are partners and try to help to 
get to a good result that all of us do a good job, and that patients are safe and their rights are 
protected”. (Monitor III) 
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Discussion 
As far as we are aware, this is the first mixed methods study to retrospectively investigate 
the outcome of on-site risk-based monitoring according to the ADAMON framework with 
regards to patient rights, safety and data quality in a sample of 43 interventional and 
observational studies in the academic setting. We identified a proportionate amount of 
patient rights and administrative findings, while findings concerning patient safety were rare, 
resulting in costs per documented finding of US$166. While administrative findings naturally 
predominantly occurred at the beginning of the studies (e.g. at initiation visit), patient rights 
findings developed proportionately with the proceeding enrolment of patients in the study. 
 
Based on our study sample we found in exploratory investigation factors such as 
observational study design, industry sponsorship, a high risk classification, and the inclusion 
of a vulnerable study population to be associated with fewer findings during on-site visits. 
Surprisingly, a high risk category per se and the inclusion of vulnerable study populations,  
which come with an increased frequency of on-site monitoring visits according to ADAMON, 
do not cause a larger number of total findings. Counterintuitively, high risk studies therefore 
seem to be at lower risk for poor quality, probably due to the more closely monitored 
regulatory and legal environment which supports a well-planned set up of the study.  It is 
therefore questionable whether the current monitoring scheme according to pre-set risk 
factors will be effective, both for quality and cost of trials, unless we learn from these 
findings. An alternative approach could, for example, be “experience-based” in the sense that 
monitoring frequency and extent are continuously adapted after on-site visits depending on 
the findings that have occurred. This would certainly allow for more flexible monitoring 
strategies when and where on-site visits are actually needed in line with current “quality-by-
design” initiatives [23-25]. Practically however, changes in contracts are often difficult after 
monitoring plans have been written and budgets have been allocated.  
 
Further, our results are in line with a systematic review of risk-based monitoring tools which 
states that both ADAMON as well as the SCTO guideline do not assess all 12 fundamental 
risk indicators as described in the recently published risk indicator taxonomy for supervision 
of clinical trials on medicinal products [26, 27].  While ADAMON lacks indicators on 
professionalism, reputation, and level of experience of investigator, clinical trial site, and 
sponsor, the SCTO guideline provides indicators assessing the level of experience at least to 
some extent [27]. We show that the two of the three risk modulators that the CTU has used 
to adjust monitoring extent purely based on experience with previous studies, i.e. the 
absence of an electronic data capture system and the lack of experience of a site, are clearly 
associated with a higher number of findings. This was exemplified by the two observational 
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outlier studies. These factors should therefore be considered not only in the modulation of 
the extent of monitoring, but also influence the frequency of on-sites visits.  
 
Our qualitative enquiry highlighted that the involved monitors understand the positive aspects 
of a risk-based approach in the resource constrained academic setting, but fear to miss 
systematic errors or even patient right violations due to the low frequency of visits or the lack 
of a requirement for initiation visits in low risk studies. They stressed the importance of well 
trained, motivated and experienced trial personnel, i.e. the investigator, study nurses, and 
related site staff, for overall trial quality and success. They further exemplified that these 
human factors should play a larger role in the risk evaluation, and that ADAMON does not 
cover these aspects adequately. The additional factors that were mentioned to be crucial for 
trial quality and success predominantly covered the design of the study, including how well 
the practical aspects of the study are planned, and factors related to the functioning of the 
site, such as training and experience of personnel, planning of finances and infrastructure, 
resources, and recruitment, trial coordination and management, assignment of clear 
responsibilities and transparent communication. While some of these aspects covered by 
ADAMON, none of them has an influence on the final monitoring risk category. We therefore 
encourage to put more emphasis on site-related and personnel-related risk factors in the risk 
evaluation of any studies, both industry- and investigator initiated, in addition to any 
framework used. 
 
The initial concept of risk-based monitoring aimed at optimizing the use of scarce resources 
while assuring patient rights and safety as well as data quality in accordance with the GCP 
guideline. Several years later, cornerstones of the risk-based monitoring concept, such as 
ADAMON and OPTIMON [8, 20], are still under evaluation and evidence on the effectiveness 
and cost savings of this approach in different host organizations, sponsors, settings, or trial 
designs remains relatively sparse [28, 29]. There is, however, emerging consensus that 
100% SDV and dual entry procedures are time and cost inefficient in detecting data 
discrepancies [17, 30, 31], that some types of errors in a clinical trial are more important than 
others [6], and that a site monitoring approach tailored to the risk of the trial can be 
supported in order to detect critical issues [7, 8, 32]. With our approach, we mainly identified 
patient rights and administrative findings, for which we were not able to retrospectively judge 
how critical they were. Our monitors, however, clearly stated the fear of missing systematic 
data errors and even critical issues concerning patient rights during the on-site visits, which 
are restricted in frequency and extent by academic financial constraints, or a low risk 
category. We thus see a need for complementary quality assurance measures for systematic 
data errors that can be performed off-site, such as central data verification. 
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Recently, combinations of central data verification (e.g. patient rights and safety) and  on-
site monitoring strategies have been applied to improve the efficiency of risk-based 
procedures [5, 7, 33]. Compared to other tools, ADAMON does only provide vague guidance 
on the nature and extent of centralized monitoring, while the adapted form by the Swiss 
Clinical Trial Organization recommends that protocol compliance could be monitored 
centrally for low-risk trials, as described in a recent systematic review by Hurley et al [27]. 
According to the FDA’s recommendations on risk-based monitoring for industry and the 
current integrated addendum to ICH-GCP, centralized monitoring processes could provide 
additional capabilities to on-site monitoring in the academic setting, thereby dispelling our 
monitor’s doubts on missing systematic data errors [3, 9]. Statistical monitoring methods are 
an area of active research and have been suggested to  “help improve the effectiveness of 
on-site monitoring by prioritizing site visits and by guiding site visits with central statistical 
data checks” [33]  and were shown to identify the great majority of on-site monitoring findings 
[7]. In line with our results, Tudur Smith et al. have recently described such an approach 
in non-commercial studies, allowing for “triggered”, rather than predominantly “routine” 
on-site visits [5]. However, empirical data on its effectiveness and the costs, advantages 
and disadvantages of alternative methods are still missing. With central monitoring 
strategies allowing for efficient data quality checks, monitors would then also be more 
flexible to transform their roles from “controllers” towards “partners”, as they had 
mentioned in the interviews, and contribute to overall clinical research quality rather than 
mere GCP-conformance. 
 
We are aware of a number of limiting factors in our analysis as follows. First of all, the 
retrospective design of our study did not allow standardization of extracted data across 
studies and monitors. Our sample was heterogeneous in terms of study type, study design, 
intended sample size and the risk categorization. It may further not be entirely representative 
in type and size of all studies conducted at out institution, as we predominantly monitor 
investigator-initiated studies. However, we aimed to minimize selection bias by including all 
trials monitored by the CTU within a given time period. Second, due to the small sample size 
and large heterogeneity of studies, we did not perform multivariable analysis but summarized 
absolute numbers of findings descriptively. Third, these studies were monitored by six 
different monitors with varying degree of experience and over a period of two years. In spite 
of a standardized procedure, each monitor has his or her own personal monitoring style, 
different level of attention to detail and strive for perfection. These factors could have 
influenced their interactions with the study team, generation and documentation of monitoring 
related findings. Fourth, we could only interview three of these six monitors who continue to 
work at our institution. We are fully aware that their experience and perspective cannot be 
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generalized but their perspective is critical in understanding the challenges in effective 
monitoring and ways to improve monitoring process. Furthermore, perspectives of additional 
stakeholders involved in risk-based monitoring (e.g. trial project leaders or principal 
investigators) should be considered in the future. Finally, we want to discuss the subjective 
and flexible nature of risk classification (e.g. risk compared to standard treatment, judging the 
experience of staff at a study site and adjustments to available budgets) and diversity in 
monitoring style of different monitors and their documentation practice. This could have 
contributed to an unknown number of findings that were resolved directly on-site without 
documentation and hence out of scope of current analysis. In addition, we were unable to 
calculate number of findings in relation to number of patients recruited due to inconsistent 
documentation of number of patients monitored during each monitoring visit.   
 
However, by publishing our experiences, we are supporting an ancillary recommendation 
made by the Clinical Trials Transformation Initiative (CTTI) project on effective and efficient 
monitoring to “share knowledge and experiences, so that best practices may be established” 
[34]. The hurdles that we experienced in the generation of urgently needed evidence on 
effectiveness of monitoring strategies have provided food for thought as follows: Our study 
illustrates that while the very concept of the current risk-based approach allows for flexibility 
in tailoring monitoring to the requirements of a specific study, it may also be prone to 
ambiguity. The lack of a "one-fits-all" model may lead stakeholders to be at loss to define a 
relevant trial-specific monitoring strategy. We realized that the combination of flexibility in 
designing the monitoring approach and the subjectivity and individual preferences of 
monitors in documenting findings add to the complexity of analyzing the effectiveness of 
risk-based approaches. For instance, the change of monitor in a project was often 
associated with a specific findings pattern (e.g. an increase in findings), which may be 
explained by preferences regarding the individual documentation style, the level of detail 
monitored, or the monitor’s experience. This haziness including the inter-human and 
inter-institutional variability should receive more recognition in the field when 
investigating the effectiveness of risk-based approaches in the academic setting. 
 
Finally, we perceive that all of the efforts invested so far focus on optimizing the cost-
effectiveness of current strategies, i.e. assuring patient’s rights and safety as well as data 
quality in accordance with the requirements of ICH-GCP. Interestingly, none of the efforts 
has so far questioned the real impact of current monitoring activities in increasing the overall 
quality of academic clinical studies. In line with other authors we believe that the current 
detection of non-critical findings adds only little to overall study quality, while consuming 
significant resources that could be spent in areas known to be critical for successful trial 
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conduct [17]. For instance, empirical data show that academic clinical research in particularly 
suffers from major hurdles in the recruitment of patients, with recruitment failure being the 
main reason for early discontinuation of trials [35-39]. According to a report by the Tufts 
Center for the Study of Drug Development, about 50 % of sites fail to reach the planned 
recruitment targets and more than 95 % of clinical trials do not end on time and on budget as 
planned in the first place. Ninety percent of the studies meet their recruitment goals, but at 
the expense of mostly twice as much time as originally planned [40]. Often, this is due to too 
many avoidable protocol amendments, with a first amendment implemented even before the 
very first patient has been enrolled [41]. Almost half of the protocol amendments are 
considered “somewhat” or “completely” avoidable [40].The European Clinical Research 
Infrastructure Network (ECRIN) hence provides a broad definition of monitoring as activities 
which must be “understood as all onsite and central activities dealing with checks of data and 
procedures as well as with the overall surveillance and stimulation of the trial progress” [42]. 
The interviewed monitors have supported such a holistic approach starting with their 
involvement in protocol development and processes based on trial procedures rather than 
data points per se, supporting overall trial completion with conclusive results. In accordance 
with ICH-GCP E6 R(2), we envision the future monitor to be an on-site partner to the study 
team, supported by centralized data checks adaptable to the risk of a trial, considering the 
experience of and the management at the site itself [3].  
 
 
Conclusion 
In conclusion, we show that the factors which mostly increased the risk for on-site 
monitoring findings are underrepresented in the current ADAMON scheme, but have partly 
been considered by our monitors based on their professional experience. We believe that the 
“human factor” has been underestimated in the evaluation of risk-based approaches so far, 
and should receive more recognition in the future. In line with recent developments, our risk-
based on-site monitoring should be complemented by centralized data checks in the future, 
allowing monitors to transform their role towards partners for overall trial quality, and 
success. However, evidence on the methodology and the (cost-) effectiveness of different 
combinations of the two approaches is still sparse for the academic setting. Future research 
should therefore address urgently needed strategies for efficient and effective monitoring, 
based on the current knowledge on risk factors in the academic setting. 
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Figure 1. Total number (a) and proportion of findings (b/c) over time, per site.  
In (a), only studies (sites) with 3 or more monitoring visits are presented. 
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Figure 2. Total number of findings over time, by individual study and site. Circles 
depict monitoring visit, lines connect visits at one particular site. Circles that are not 
connected by lines depict monitoring visits at different sites. Number 1, 7, 12, 14, 16, 19, 
21, 26, 31, and 32 are multicenter studies. If different sites are not distinguishable, the total 
number of findings at this particular visit was the same (superposed circles). 
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Abstract  
Background: Clinical studies in children are necessary yet conducting multiple visits 
at study centers remains challenging. The success of “care-at-home” initiatives and 
remote clinical trials suggests their potential to facilitate conduct of pediatric studies. 
This pilot aimed to study the feasibility of remotely collecting valid (i.e. complete and 
correct) saliva samples and clinical data utilizing mobile technology.  
 
Methods: Single-center, prospective pilot study in children undergoing elective 
tonsillectomy at the University of Basel Children’s Hospital. Data on pain scores and 
concomitant medication and saliva samples were collected by caregivers on two to 
four inpatient study days and on three consecutive study days at home. A tailored 
mobile application developed for this study supported data collection. The primary 
endpoint was the proportion of complete and correct caregiver-collected data (pain 
scale) and saliva samples in the at-home setting. Secondary endpoints included the 
proportion of complete and correct saliva samples in the inpatient setting, subjective 
feasibility for caregivers, and study cost. 
 
Results: A total number of 23 children were included in the study of which 17 
children, median age 6.0 years (IQR 5.0, 7.4), completed the study. During the at-
home phase, 71.9% [CI= 64.4, 78.6] of all caregiver-collected pain assessments and 
53.9% [CI= 44.2, 63.4] of all saliva samples were complete and correct. Overall, 
64.7% [CI=58.7, 70.4] of all data collected by caregivers at home was complete and 
correct. The predominant reason for incorrectness of data was adherence to the 
timing of predefined patient actions. Participating caregivers reported high levels of 
satisfaction and willingness to participate in similar trials in the future. Study costs for 
a potential sample size of 100 patients were calculated to be 20% lower for the at-
home than for a traditional in-patient study setting.  
 
Conclusions: Mobile device supported studies conducted at home may provide a 
cost-effective approach to facilitate conduct of clinical studies in children. Given 
findings in this pilot study, data collection at home may focus on electronic data 
capture rather than biological sampling. 
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Background  
High quality research relies on the collection of high quality data. Traditionally, this is 
done in the inpatient setting or through ambulatory visits to a study site, which can 
present a barrier to participation (e.g. cost, travel burden, time) and a risk to the 
validity of research (e.g. high loss-to-follow-up, low external validity) [1, 2]. The 
widespread availability of new technologies has the potential of shifting some 
research activities, including enrollment, managing trial activity, reporting results, and 
safety oversight, away from study sites. Such “remote” research may encourage the 
participation of a more diverse group of patients in research with improved 
recruitment rates and at lower costs than those of conventional trials [3-5]. A 
combinatory approach including direct interactions with the study team may allow 
remote data collection to be optimally leveraged [6, 7], e.g. by addressing challenges 
around data quality and retention [8-11].  
 
In pediatric care, empirical evidence on the optimal dosing and action of routinely 
used medicine remains limited [12-14]. The relationship between drug exposure and 
its effects are often different in children compared to adults. For this reason a simple 
extrapolation of pediatric dosing based on adult data can put children at increased 
risk of adverse events and therapeutic failures [15-17].  Therefore, innovative clinical 
study designs in pediatrics are urgently needed. Currently, major challenges of 
designing and conducting clinical trials in children, include (i) small sample sizes of 
pediatric studies, (ii) increased study complexity due to multiple age groups, (iii) 
integration of research in daily activities of the whole family affecting parental time of 
work and supervision of other children, and (iv) child absence of routine activities. 
Together with the burdens of travel and frequent site visits, these limits are 
associated with low recruitment and high dropout rates [18, 19].   
 
Recent „care-at-home“-initiatives indicate that mobile or remote approaches in 
clinical research with children have the potential to increase patient and caregiver 
satisfaction without increasing privately borne costs [20]. In addition, today’s parents 
and their children are technology savvy and frequent users of mobile devices, 
suggesting their high potential as future candidates in remote clinical trials. While the 
methodology is still in its infancy, increasing interest and support from regulators, 
sponsors, and patients will likely propel remote trials forward in the near future [21]. 
Thus, further investigation into the methodology of studies that use a combinatory 
approach is warranted. In this pilot study, we aimed to investigate the feasibility of 
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remotely collecting valid (i.e. complete and correct) clinical data and saliva samples 
in a pediatric population utilizing mobile technologies. In addition, we assessed the 
general acceptance, reasons for non-consent, and the resulting costs of this study. 
 
 
Methods 
Study design  
This was an investigator-initiated, single center, prospective pilot study investigating 
the feasibility of remotely conducting clinical studies with parents/legal 
representatives (“caregivers”) and children. We developed a custom mobile 
application (“app”) allowing patients and their caregivers to participate in the study 
remotely after an initial training session at our institution (details of application 
development may be found in Additional file 1). We elected pain management after 
tonsillectomy as a model due to the frequency of the surgical procedure in children 
younger than 15 years [22] requiring standardized analgesic therapy and the 
potential to remotely assess pain levels by caregivers using a validated scale (The 
Childhood Discomfort and Pain Scale) [23]. In addition, remotely collect saliva 
samples were planned to measure acetaminophen concentrations mimicking the 
design of a pharmacokinetic (PK) study. In addition, the local standard of care 
sequence after tonsillectomy consisting of two to four days inpatient care after 
surgery allowed study staff to train caregivers in the use of study technologies and 
procedures for the at-home phase. 
 
Total study duration for each participant and caregivers was 10 days during which 
data and samples were collected on 2-4 days as an inpatient and on 3 days at home. 
On day 8, the caregivers filled out a feasibility questionnaire. On day 10, study staff 
additionally contacted caregivers for feedback on the study in a follow-up telephone 
interview. 
 
Participant eligibility  
Children presenting for elective tonsillectomy were screened and enrolled at the 
University of Basel Children’s Hospital from May 26 2016 until January 07 2017, 
during the pre-surgery anesthetics consultation. Inclusion criteria were age between 
2-10 years, routine elective tonsillectomy (with or without other additional Ear, Nose, 
and Throat intervention), anticipated inpatient stay of a minimum of 2 days, 
willingness and ability of caregivers to understand and implement study procedures 
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in the hospital and at home, and ability of caregivers to understand, speak, and read 
German. Exclusion criteria were contraindications to acetaminophen administration 
and any reasons precluding the collection of saliva samples. 
 
Study Procedures 
Screening of eligible patients was performed at the pre-anaesthetics clinic 
consultation by a physician and a study nurse. After assessment of inclusion/ 
exclusion criteria and written informed consent, the study nurse informed caregivers 
about the mobile study application, provided them with an instruction manual, and 
supported them in the setup of their login. Caregivers had the possibility to choose 
between their own mobile phone (Bring Your Own Device, “BYOD”), or an iPod-
Touch provided by the study team for the duration of the study. 
 
 
Figure 1. Daily data collection schedule.  
tM: Timepoint directly after awakening of child, t1: 1 hour (+/- 15 min) after 
administration of first routinely scheduled dose of acetaminophen; t2: 4 hours (+2 
hours) after administration of first routinely scheduled dose of acetaminophen.  
* “Medication given” indicates the timepoint at which children had either received 
routine acetaminophen, or not (yes/no). Independent of whether medication was 
given or not, the app used the recorded time stamp to automatically calculate t1 and 
t2.  
 
On the day of tonsillectomy, a study nurse explained the procedures, data collection 
and the Childhood Discomfort and Pain Scale to participating children and 
caregivers. After the surgeon performed tonsillectomy, postoperative pain 
management with acetaminophen was initiated according to the current standard of 
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care of the hospital [24]. The study did not interfere with routine pain management. 
Participating children stayed on the ward for approximately 3 days.  
 
Daily data and sample collection was scheduled to mimic a pharmacokinetics- and 
dynamics (PK/PD) study. The mobile app issued automatic electronic reminders for 
scheduled doses as well as pain assessment/sample collection time points. Data 
entry was automatically time stamped. Pain assessment was repeated 3 times a day 
by the caregivers upon awakening of the participating children in the morning (tM) 
and 1 (+/- 15 min, t1) and 4 (+2 hours, t2) hours after administration of the first 
routinely scheduled dose of acetaminophen. Saliva samples were collected twice 
daily for each participant at t1 and t2. Sample codes were either scanned using the 
mobile application scanning function or typed in by caregivers. All concomitant 
medication allowed according to the guidelines of the hospital was documented 
throughout the study by taking a photograph of the blister or package using the 
mobile application. After initial supervision by a study nurse, caregivers conducted 
these assessments autonomously while still in the inpatient setting.  
 
On day 3(+/- 1 day) post-surgery, participating children were discharged home. The 
study nurse explained how to collect and store saliva samples at home and provided 
labeled containers for all samples. Children staying in hospital longer than 4 days 
were excluded from the study. On the 3 days following discharge, caregivers 
collected data and samples at home following the scheme established during the 
inpatient stay. On study day 8, a bicycle messenger collected all saliva samples. The 
mobile application reminded caregivers to fill in a feasibility questionnaire before 
uploading data to the study server. On day 10, a study nurse conducted a follow-up 
telephone call for general caregiver feedback.  
 
Statistical analyses 
Primary and secondary endpoints  
The primary endpoint of the study was the proportion of simultaneously complete and 
correct data (pain scale or saliva) in the at-home setting. A complete data set 
consisted of five data points (three pain scale assessments and two saliva samples) 
for each day and patient. Complete pain scale data were considered correct if 
collected within the predefined timeframes (1 hour (+/- 15 minutes) and 4 hours (+2 
hours) after first medication). Complete saliva samples were considered correct if i) 
collected within predefined timeframe, ii) saliva volume sufficient for potential 
laboratory analyses, and iii) unique sample ID entered into mobile application. In the 
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initial analysis plan, we aimed to measure acetaminophen levels which were omitted 
due to technical limitations in reliably detecting acetaminophen in saliva. Secondary 
endpoints included the proportion of complete and correct samples in the inpatient 
setting (training setting before hospital release, collected as described for the out-
patient setting), the subjective feasibility for caregivers as measured by an electronic 
questionnaire on day 8, the percentage of consenting patients, the reasons for non-
consent, the legibility of photos of concomitant medication using the mobile 
application, and study cost.  
 
Primary Analysis 
The full analysis set consisted of all patients and caregivers who fulfilled all inclusion 
criteria and consented to take part. We descriptively summarized the proportion of 
complete and correct clinical data (pain scale) and samples (saliva) collected in the 
at home setting. In addition, the number of complete and correct samples per patient 
was modeled in a logistic regression and the 95% confidence interval (CI) was 
estimated based on profiled log-likelihood functions. Based on our experience with 
paper-based patient-reported outcomes (e.g. questionnaires), our hypothesis was 
that the overall completeness and correctness of electronically collected data would 
be above a predefined threshold of 90 %. 
 
Secondary Analyses 
The proportion of simultaneously complete and correct data (pain scale or saliva) in 
the inpatient setting was analyzed as described for the primary endpoint. In addition, 
both analyses were repeated with a secondary analysis set consisting of 15 patients 
who used the newest version of the mobile application. Baseline characteristics, 
study flow statistics, reasons for non-consent, feasibility questionnaires, and legibility 
of images were summarized and presented descriptively.  
 
Missing data and drop-outs 
Missing data were part of the primary endpoint (completeness not reached). Patients 
who were re-hospitalized within three days after discharge were considered drop-
outs, and reasons were documented. All other data were assumed to be missing at 
random and no imputations were performed.  
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Cost analysis 
We describe a total study cost approach factoring in app development and testing, 
on-site, data management, analysis staff time, study-specific materials, laboratory 
sample analysis, and transport costs. Cost calculations were based on salaried staff 
time log sheets and fixed costs for materials. Sensitivity analyses include cost for a 
traditional, fully on-site conducted scenario, and cost for larger samples size studies.  
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Results 
Patient and caregiver characteristics  
Of the 45 patients and their caregivers assessed for eligibility, twenty-three (51.1%) 
were enrolled in the study, and 17 (37.8%) completed the full study (Figure 2). Of the 
15 (33.3%) caregivers who declined to participate, thirteen consented to provide a 
reason for non-consent, which predominantly included the perceived time burden of 
the study (8/13, 61.5%) (Table 1). Of 23 enrolled patients, 6 (26%) dropped out 
during study conduct. Reasons included one non study-related serious adverse event, 
patient refusal to provide saliva samples, technical issues with the mobile application, 
and contraindications to acetaminophen (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. TOMACHI Study Flow Diagram 
  
Patients assessed for eligibility 
(n=45) 
Excluded (n=22, 48.9%) 
   Not meeting inclusion criteria (n=1, 
2.2%) 
   Declined to participate (n=15, 33.3%) 
   Other reasons (n=6, 13.3%) 
 No study iPod available (n=3) 
 Temporary study stop (n=2) 
 Parallel recruitment (n=1) 
Patients included in analysis 
(n=17, 37.8%) 
Patients enrolled (n=23, 
51.1%) 
 
Drop-outs (n=6, 26%) 
    Safety (n=1) 
   Patient refused to provide saliva 
samples (n=2) 
   Technical issues (n=1) 
   Contraindication to paracetamol 
(n=2) 
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Table 1. Reasons for caregiver non-consent 
 n (%) 
Caregivers who declined to participate (n=15) and provided reason for 
non-consent 
13 (86.7) 
  
I do not have the time to conduct the study 8 (61.5) 
I do not believe I can collect data and samples correctly 4 (30.8) 
I do not want to put additional burden on my child 3 (23.1) 
I did not fully understand what the study is about 2 (15.4) 
I generally have doubts about clinical research 0 (0) 
I would be interested to participate in such a study in the future 6 (46.2) 
 
Baseline characteristics of the 17 patients and caregivers who completed the study 
are described in Table 2. Median age of patients and caregivers was 6.0 
(Interquartile Range (IQR) 5.0-7.4) and 35.0 (IQR 32.0-38.0), respectively. A majority 
of patients (11/17, 64.7%) had one sibling, and 14/17 caregivers (82.4%) were native 
German speakers 
 
Table 2. Baseline characteristics of patients and caregivers 
n 17 (100) 
Patient gender (n male (%)) 10 (58.8) 
Age (median years [IQR]) 6.0 [5.0, 7.4] 
Number of siblings (%)   
0 2 (11.8) 
1 11 (64.7) 
2 2 (11.8) 
3 2 (11.8) 
Caregiver age (median years [IQR]) 35.0 [32.0, 38.0] 
Caregiver native German speaker = yes (%) 14 (82.4) 
Caregiver working at the moment = yes (%) 12 (70.6) 
Caregiver occupation (ISCO) (%)   
At home/unemployed 5 (29.4) 
Professional 3 (17.6) 
Service and sales workers 9 (52.9) 
Caregiver volume of work (median weekly % [IQR]) 60.0 [40.0, 70.0] 
IQR, Interquartile Range; ISCO, International Standard Classification of Occupations 
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Completeness and correctness of saliva sampling and pain assessments at 
home  
In total, caregivers collected 303 pain scale assessments and 202 saliva samples. 
During the at-home phase, 71.9% [CI= 64.4, 78.6] of all pain assessments were 
complete and correct (92.2% complete, and thereof 78.0% correct) compared to 
53.9% [CI= 44.2, 63.4] (77.5% complete, and thereof 69.6% correct) of all saliva 
samples (Table 3). Overall, 64.7% [CI=58.7, 70.4] of all data collected by caregivers 
at home was complete and correct. 
 
Completeness and correctness of saliva sampling and pain assessments in the 
inpatient setting  
In the inpatient setting, 62.0% of all pain measurements were complete and correct 
([CI = 54.1, 69.5], 94.0% complete and thereof 66.0% correct, respectively) 
compared to 39.0% ([CI = 29.8, 48.7], 77.0% complete, and thereof 50.6% correct, 
respectively) of saliva samples. Overall, 52.8% [CI=46.6, 58.9] of all data collected by 
caregivers in the inpatient setting was complete and correct. 
 
Table 3. Completeness and correctness of caregiver collected data and 
samples 
   Complete and correct 
   No  Yes 
Location Item Total n n %   n % 
At home Pain scale 153 43 28.1  110 71.9 
 Saliva samples 102 47 46.1  55 53.9 
 All 255 90 35.3  165 64.7 
Inpatient Pain scale 150 57 38.0   93 62.0 
 Saliva samples 100 61 61.0  39 39.0 
 All 250 118 47.2  132 52.8 
All Pain scale 303 100 33.0  203 67.0 
 Saliva samples 202 108 53.5  94 46.5 
  All 505 208 41.2   297 58.8 
 
Reasons for incompleteness and incorrectness and exploratory sensitivity 
analyses 
Incompleteness of data was mostly due to technical issues which two caregivers 
experienced (predominantly affecting saliva samples) or the discontinuation of data 
collection by one caregiver at home. Exploratory analyses of the subgroup of 
participants who did not experience technical issues with an early version of the 
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mobile application (n=15) showed that completeness and correctness of pain 
assessments remained the same (71.9%), but that the percentage of correct and 
complete saliva samples increased from 53.9% to 61.1%. The reason for this was a 
programming issue, which affected the entry of saliva sample IDs in the application. 
 
The major reason for incorrectness of data was incorrect timing (i.e. data was not 
collected within predefined timeframes of 1 hour (+/-15 minutes), and four hours (+2 
hours) after first medication, Table 1 in Additional file 2). Exploratory sensitivity 
analyses assuming that all data had to be collected within one calendar day instead 
of the narrow timeframes of 1 and 4 hours showed that in this case 92.2 % of pain 
scale data and 74.5% of saliva samples would have been complete and correct at 
home, and 94.0% and 73.0% in the inpatient setting, respectively (Table 2 in 
Additional file 2). Further, a positive trend for complete and correct data and sample 
collection was observable from day one in the inpatient setting to day three, i.e. the 
day of hospital release. On the first day at home, the proportion of complete and 
correct data increased once more, before then declined slightly (Additional file Figure 
1). No clear trend in the quality of data collection could be identified regarding the 
individual patient and caregiver (Additional file Figure 2), or when stratifying the 
analysis by number of siblings, caregiver occupation, or caregiver native language. 
 
Legibility of concomitant medication images 
Of the 17 patients who completed the study, 10 (58.8%) took 24 different images of 
medications using the mobile application’s imaging function. All 24 images were 
sharp and legible. Medication names were identifiable on 18 (75%) and dosage 
information (e.g. on drug containers, blisters, etc.) on 13 (54.2%) of all 24 images, 
respectively. 
 
Feasibility and practicability for caregivers 
Out of 17 caregivers, 15 provided answers in the feasibility questionnaire. Nine of 15 
(60.0%) caregivers thought studies at home are a good idea and 53.3% (8/15) would 
probably take part again (Table 3 in the Additional file 2). Over 66% (10/15) of 
caregivers spent less than 15min on study procedures. In 73.3% (11/15), the mother 
was the primary caregiver collecting data and samples for the study at home. 60% 
(9/15) of caregivers said that study goals were explained “very well” to them in the 
beginning, compared to 53% (8/15) who said study procedures were explained “well”. 
Usability of the study app was rated between “ok” (8/15, 53.3%) and “great” (6/15, 
40.0%). 66.7% (10/15) rated the study procedures “easy” in the inpatient setting 
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compared to 40.0% (6/15) in the at home setting. Asking caregivers about potential 
difficulties, 86.6% (13/15) answered that the study flow, i.e. the timing of data and 
sample collection, was sometimes difficult to follow (Table 4 in Additional file 2).  
 
Study cost and cost comparison  
Total study cost included fixed costs ($44’577) such as application development and 
support ($11’955), study-specific materials (two iPods, saliva sampling tubes, 
envelopes, cafeteria vouchers for caregivers, $2’507), laboratory sample analysis 
($2’224), study-material transport costs from caregiver’s home at the end of the study 
($474), database setup, management and statistical analysis ($21’360), study 
monitoring ($6’057) and variable salaried on site staff cost (part time; one physician, 
three study nurses) over the eight months the study was active ($ 19’157), summing 
to a total of $63’734 and $3’749 per patient who completed the study. 
 
Our sensitivity analyses for a traditional, hospital-based approach for the same study 
with the same duration, but six full study days in the inpatient setting and data 
collection by study nurses suggested total fixed costs of $35’593 compared with 
$44’577 for the pilot study, and variable on-site staff costs of $20’202 compared with 
$19’157 for the mobile study summing to a total of $55’795 and $3’281 per patient. 
The difference was driven by the high initial cost for app development and support, 
but lower study nursing, physician, and data entry time compared to a traditional trial. 
Increasing the sample size from 17 to hypothetical 100 evaluable patients would 
have resulted in cost per patient of $1’077 for the mobile trial and $1’307 for the 
hospital-based approach. 
 
 
Discussion 
Results from our pilot study indicate that mobile data and sample collection for 
clinical studies with children and their caregivers are feasible, yet subject to certain 
caveats. We were able to engage and enrol patients and to conduct the study with 
retention rates comparable to those of studies done in traditional settings. 
Furthermore, the participating caregivers reported high levels of satisfaction and 
willingness to participate in similar trials in the future. However, the overall proportion 
of complete and correct data collected in the current framework would not be 
sufficient to obtain valid study results for a stand-alone PK study. However, sparse 
PK data collected in such at-home study may be combined with data from more 
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conventional PK studies to enhance PK/PD analyses including pharmacometric 
modelling. While 92.2% of pain scale data and 77.5% of samples were complete, 
only 78.0% and 69.6% thereof were correct, respectively. We could therefore not 
prove our hypothesis of 90% complete and correct data and sample collection in the 
at home setting. Reasons for this included the narrow timeframe in which data and 
samples had to be collected by caregivers, the handling of saliva samples, and 
technical issues with the application.  
 
Expanding the narrow timeframes to one full calendar day, however, would have 
resulted in over 92% of pain measurements to be complete and correct in the at 
home setting. We therefore believe that other study types such as phase III or IV 
studies or observational research with less time-critical data to be collected may be 
viable options to make use of mobile data collection. Examples may include 
postoperative observations, the assessment of quality of life outcomes, medication 
management in chronic conditions or continuous physiological measures using 
sensor devices.  
 
Exploratory analysis of factors such as number of siblings, caregiver occupation, or 
caregiver native language did not reveal any clear trend in supporting complete and 
correct data collection among caregivers. As expected, this pilot study did not yet 
prove cost-effective due to the development cost of the application. However, future 
studies including larger samples sizes and building on an improved framework of the 
existing application will be a cost-efficient option.  
 
Although our participants seemed broadly similar to those in comparable traditional 
trials, the requirement for ease in mobile phone handling (in our pilot restricted to 
iPhone and iPods), understanding of the German language, and the active choice by 
caregivers to conduct the study at home probably may have resulted in selection 
bias. While this study planned to leverage study participants’ own Internet-enabled 
mobile devices for remote data collection (“Bring Your Own Device”), we also 
provided study mobile devices in order to avoid additional caregiver selection bias. 
External validity is also a common problem for traditional trials, and adequate 
description of the setting and the sample characteristics is needed. In future mobile 
trials, we therefore aim to extend the pilot setting to different mobile technologies (i.e. 
Android) and multiple languages. 
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Furthermore, the mobile application was designed with the highest user flexibility and 
–usability in mind in order to minimize user fatigue or dropout. This flexibility in data 
entry resulted in data points which were often ambiguous (e.g. inconsistencies in 
automatic time stamp versus time point indicated by caregiver, or typing errors for 
sample codes). We decided to strictly analyse the data as transmitted by the 
caregivers although some of these data point ambiguities could have been resolved 
by the investigators by applying logical cross-checks. 
 
While this pilot was efficient with respect to direct caregiver-reported data entry and 
on-site staffing levels, data management and analysis of the app-collected data 
structure was more resource intense than expected. Particular hurdles were (i) the 
translation of structured data recorded by the mobile application (json-format) into a 
tabular format suitable for statistical analysis and (ii) to incorporate the flexibility given 
to the users for data entry. For future studies, translation of structured data can be 
easily optimized by establishing standardized procedures, whereas specific care 
must be taken to reduce flexibility in data entry to avoid a high degree of complexity 
in data analysis. 
 
According to the US Food and Drug Administration, electronic capture of clinical trial 
source data is nowadays preferred over paper-based data collection [21, 25]. 
However, data quality has been reported to be problematic [8, 9], and combinations 
of mobile technologies with appropriate interactive guidance by study staff were 
suggested to be more successful [3, 4]. To our knowledge, this is the first study 
explicitly evaluating the quality of data resulting from mobile data capture in a setting 
imitating pediatric PK/PD modelling. We combined an initial caregiver training 
session in the inpatient setting including the possibility to interact with study staff with 
an independent at-home phase. Caregivers were satisfied with study staff support in 
the inpatient setting, but reported more difficulties following the study procedures at 
home (Table 3 in Additional file 2).  
 
As described by Murray [9] and Coons [25], there are generally two concerns about 
data quality in clinical studies: Validity – to what extent is the information provided by 
participants is “true”- and amount of missing data, in terms of item nonresponse. 
While missing data is generally expected to be minimized with automatic reminders 
issued by electronic applications, patient-reported data validity may be problematic in 
both mobile and traditional on paper studies. In this study, we confirm that missing 
data is less of an issue than data validity. If we had allowed caregivers to collect data 
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and samples within one calendar day rather than within narrow timeframes, 92.2% of 
all pain measurements and 74.5% of saliva samples would have been complete and 
correct in the at home setting (Table 2 in the Additional file 2).  
 
Further, self-reported patient outcomes have generally been criticized before with 
respect to internal validity and data quality, but are often necessary to adequately 
evaluate the treatment benefit provided by new interventions [25]. We used a 
standardised scale for pain assessment [23] by caregivers as a model for mobile 
data collection. Automatic time stamps for data entry aimed to improve data validity 
(e.g. correct timing), and allowed the study team to better judge the validity of patient-
reported measurements compared to paper based data. In future versions of the 
application, all patient-reported assessments will therefore be validated for computer 
use if possible, and methods for case confirmations by study staff will be included to 
be able to judge the validity of data points. 
A recent survey [10] across pharmaceutical companies revealed that just 37% are 
currently using mobile technologies in clinical trials, of which more than two-thirds 
(68%) are mobile apps. The primary benefit that companies see for adopting 
“mHealth” technologies is real-time data acquisition (36%), followed closely by 
increased patient compliance (30%) and improved data quality (25%). The first 
successfully completed fully remote Diabetes management trial, the VERKKO trial, 
sponsored by Sanofi reported initial results on high patient satisfaction rates, reduced 
study coordination activities, faster study completion, and increased patient retention 
rates [26]. Nevertheless, companies still have a number of concerns around the 
technology. Data security is the primary concern for almost a third of respondents 
(32%), whilst difficulty in incorporation (29%) and resistance from patients or 
physicians (23%) are both considerable worries. While we did not experience any of 
these, our study revealed that data quality may only be improved if the mobile 
application is supporting data collection that is a) well-structured and easy to follow 
for patients, b) flexible to some extent (i.e. large timeframes), but still rigid enough to 
assure resulting data quality (i.e. using automatic time stamps rather than patient-
reported time points which are prone to error), and ideally, c) remotely monitored. 
Compared to traditional on paper study settings, users of mobile technologies for 
clinical studies should make use of their potential of real-life data monitoring and 
automatic time stamps that should ultimately improve overall patient-reported data 
validity. 
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Due to the particular scientific and technological issues associated with the use of 
mobile devices that currently inhibit their widespread use, the Clinical Trials 
Transformation Initiative (CTTI) is developing recommendations for managing mobile 
devices in clinical trials, and guiding principles to promote their inclusion [11].  
 
 
Conclusion 
In conclusion, mobile studies conducted at home are a feasible approach when 
certain circumstances are met. Future electronic at-home data collection should 
predominantly include data that is not time critical at pre-defined, yet flexible time 
points. Further, the collection, storage, and shipping of biological samples have 
proven more difficult and should be kept at a minimum. Therefore, we would refrain 
from conducting remote “stand alone PK studies” that require a rigid data and 
samples collection schedule. However, studies with more flexible data acquisition 
schedules, such as clinical phase III or IV trials with sparse PK and biomarker 
sampling, and observational studies could profit from such an approach. Importantly, 
mobile applications need to be designed in a well-balanced manner, allowing for user 
flexibility but also assuring resulting data quality. Current efforts at the CTTI 
specifically target the technical and scientific issues that still remain with mobile 
devices in clinical research. In the future, we expect an enhanced version of our 
current technology to reach wider patient populations and to incorporate lessons 
learned with features such as remote patient monitoring using real life data capture 
and increased site-patient interaction. 
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Additional files 
 
1 - Development of mobile application  
A custom mobile application (“app”) was developed to allow participants to collect 
study information in their daily routine as easily as possible. The planned study 
workflow was extensively discussed with the study team and respective assumptions 
about the ideal app flow and different input methods were explored using multiple 
paper-based interactive prototypes [1]. Subsequently, a high fidelity app design 
mockup [2] was created in agreement with the communication department of the 
involved hospital. User interaction was tested again internally using clickable design 
prototypes [3]. 
 
Due to the required functionality, the application was developed as native mobile app 
primarily focused on iOS devices [4-6]. The mobile app was then beta-tested in 
multiple cycles with various members of the study team and people not directly 
involved in the study. Finally, the application was made available to the study 
participants through download from the Apple App Store using the participants’ own 
iOS device or as a pre-installed app on a dedicated study iPod-Touch. 
 
Data from the mobile application was collected using a custom developed web server 
(Golang Language, RethinkDB). Data transfer was designed to be actively initiated 
by the study participants with all data being encrypted before transfer to the central 
server and transferred using SSL/TLS secured connections. 
 
References 
(1) Interactive Paper-Prototypes: POP [https://marvelapp.com/pop] 
(2) Mobile App Design: Sketch [ https://www.sketchapp.com] 
(3) Interactive Design-Prototypes: Invision [https://www.invisionapp.com] 
(4) Mobile App Development: Swift 3 [https://developer.apple.com/swift] 
(5) Mobile App Development: Xcode 8.2 [https://developer.apple.com/xcode ] 
(6) Mobile App Development: Realm Mobile Database Library for data storage 
[https://realm.io] 
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2 - Tables & Figures 
Table 1. Timing of complete data and samples, by timepoint and location 
  Timing correct 
  No  Yes 
Location Item Total n n %   n % 
At home Pain scale tM 47 0 0.0 
 
47 100.0 
 
Pain scale t1 47 18 38.3 
 
29 61.7 
 
Saliva sample t1 41 16 39.0 
 
25 61.0 
 
Pain scale t2 47 13 27.7 
 
34 72.3 
 
Saliva sample t2 38 6 15.8 
 
32 84.2 
 
All 220 53 24.1 
 
167 75.9 
Inpatient Pain scale tM 47 0 0.0   47 100.0 
 Pain scale t1 47 27 57.4  20 42.6 
 Saliva sample t1 38 20 52.6  18 47.4 
 Pain scale t2 47 21 44.7  26 55.3 
 Saliva sample t2 39 17 43.6  22 56.4 
 All 218 85 39.0  133 61.0 
All Pain scale tM 94 0 0.0  94 100.0 
 Pain scale t1 94 45 47.9  49 52.1 
 Saliva sample t1 79 36 45.6  43 54.4 
 Pain scale t2 94 34 36.2  60 63.8 
 Saliva sample t2 77 23 29.9  54 70.1 
  All 438 138 31.5   300 68.5 
 
 
Table 2. Complete and correct data and samples when timing as a correctness 
factor is neglected (i.e. all data collected within one calendar day are correct) 
 
  Complete and correct 
  No  Yes 
Location Item Total n n %   n % 
At home Pain scale 153 12 7.8  141 92.2 
 Saliva sample 102 26 25.5  76 74.5 
 All 255 38 14.9  217 85.1 
Inpatient Pain scale 150 9 6.0   141 94.0 
 Saliva sample 100 27 27.0  73 73.0 
 All 250 36 14.4  214 85.6 
All pain scale 303 21 6.9  282 93.1 
 Saliva sample 202 53 26.2  149 73.8 
  All 505 74 14.7   431 85.3 
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Table 3. Caregiver feasibility questionnaire 
 
 n % 
What statement(s) apply in your opinion? (n=15)  
I think clinical studies at home are a good idea 9 60.0 
I don’t think clinical studies at home are a good idea 1 6.7 
I am not sure 5 33.3 
How were the aims of the study explained to you? (n=15)   
Very well 9 60.0 
Well 5 33.3 
Sufficiently 1 6.7 
Not well 0 0.0 
Not well at all 0 0.0 
How were your tasks during the conduct of the study study explained to you? 
(n=15) 
  
Very well 4 26.7 
Well 8 53.3 
Sufficiently 3 20.0 
Not well 0 0.0 
Not well at all 0 0.0 
How user-friendly do you rate the mobile application? (n=15)   
Great 6 40.0 
Ok 8 53.3 
Unusable 1 6.7 
Who has mainly collected data and samples in the hospital? (n=16)   
Mother 9 56.2 
Father 1 6.2 
Both parents 3 18.8 
Study Nurse 3 18.8 
Child 0 0.0 
Other 0 0.0 
Who has mainly collected data and samples in at home? (n=15)   
Mother 11 73.3 
Father 1 6.7 
Both parents 3 20.0 
Study Nurse 0 0.0 
Child 0 0.0 
Other 0 0.0 
How feasible were the study procedures for you in the hospital? (ntot=15)   
Very easy 4 26.6 
Easy 10 66.7 
Difficult 1 6.7 
Very difficult 0 0.0 
How feasible were the study procedures for you at home? (n=15) 
 
  
Very easy 2 13.3 
Easy 6 40.0 
Difficult 7 46.7 
Very difficult 0 0.0 
How feasible was taking photos of concomitant medication for you? (n=15) 
 
  
Not used 4 26.7 
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Very easy 4 26.7 
Easy 5 33.2 
Difficult 1 6.7 
Very difficult 1 6.7 
How much time did you spend on study procedures per day? (n=15)   
Less than 15 minutes 10 66.7 
15-30 min 4 26.6 
30-45 min 1 6.7 
45-60 min 0 0.0 
more than 60min 0 0.0 
Would you take part again in such a study? (n=15)   
Yes, for sure 4 26.7 
Probably yes 8 53.3 
Probably not 3 18.8 
Definitely not 0 0.0 
 
 
Table 4. Main difficulties experienced by caregivers during conduct of study 
 
What were the main difficulties you experienced during the conduct of the study? (multiple 
choice) 
 n % 
It was sometimes difficult to follow the study procedures (i.e. timing of data 
collection) 
13 86.7 
There were technical issues with the mobile application 3 20.0 
My child did not want to participate, i.e. provide saliva samples 3 20.0 
I was not able to contact the study personnel 2 13.3 
It took too much time to follow the study procedures 1 6.7 
I did not experience any difficulties 1 6.7 
Other 3 20.0 
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Figure 1. Proportion of complete and correct data and samples by location and 
day 
 
 
 
Figure 2. Proportion of complete and correct data and samples by patient and 
location  
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FURTHER PUBLICATIONS  
 
 
3.1 Published reviews (first author) 
The role of Clinical Trial Units in investigator- and industry-initiated research projects. 
von Niederhäusern B, Fabbro T, Pauli-Magnus C. 
Swiss Med Wkly. 2015 Jul 2;145:w14161 
Six multidisciplinary competence centres (Clinical Trial Units, CTUs) in Basel, Berne, 
Geneva, Lausanne, St. Gallen and Zurich provide professional support to clinical researchers 
in the planning, implementation, conduct and evaluation of clinical studies. Through their 
coordinated network, these units promote high-quality, nationally harmonised and 
internationally standardised clinical research conduct in Switzerland. We will describe why 
this network has been established, how it has been successful in stilling the growing need for 
clinical research support, which training and education opportunities it offers, and how it 
created national awareness for the still-existing hurdles towards clinical research excellence 
in Switzerland. Taking the CTU Basel as an example, we show that a considerable number 
(25%) of the studies submitted for regulatory approval in 2013 were supported by the CTU, 
decreasing the number of findings in ethics reviews by about one-third. We conclude that 
these achievements, together with a Swiss national funding model for clinical research, and 
improved national coordination, will be critical factors to successfully position Swiss clinical 
research at the international forefront. 
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3.2 Published original articles (co-author) 
Premature trial discontinuation often not accurately reflected in registries: comparison 
of registry records with publications. Alturki R, Schandelmaier S, Olu KK, von 
Niederhäusern B, Agarwal A, Frei R, Bhatnagar N, Hooft L, von Elm E, Briel M. 
J Clin Epidemiol. 2017 Jan;81:56-63 
BACKGROUND: One quarter of randomized clinical trials (RCTs) are prematurely 
discontinued and frequently remain unpublished. Trial registries can document whether a trial 
is ongoing, suspended, discontinued, or completed and therefore represent an important 
source for trial status information. The accuracy of this information is unclear. 
 
OBJECTIVE: To examine the accuracy of completion status and reasons for discontinuation 
documented in trial registries as compared to corresponding publications of discontinued 
RCTs and to investigate potential predictors for accurate trial status information in registries. 
 
METHODS: We conducted a cross-sectional study comparing information provided in 
publications (reference standard) to corresponding registry entries. First, we reviewed 
publications of RCTs providing information on both discontinuation and registration. We 
identified eligible publications through systematic searches of MEDLINE and EMBASE 
(2010-2014) and an international cohort of 1,017 RCTs initiated between 2000 and 2003. 
Second, pairs of investigators independently and in duplicate extracted data from 
publications and corresponding registry records. Third, for each discontinued RCT, we 
compared publication information to registry information. We used multivariable regression to 
examine whether accurate labeling of trials as discontinued (vs. other status) in the registry 
was associated with recent initiation of RCT, industry sponsorship, multicenter design, or 
larger sample size. 
 
RESULTS: We identified 173 publications of RCTs that were discontinued due to slow 
recruitment (55%), harm (16%), futility (11%), benefit (5%), other reasons (3%), or multiple 
reasons (9%). Trials were registered with clinicaltrials.gov (77%), isrctn.com (14%), or other 
registries (8%). Of the 173 corresponding registry records, 77 (45%) trials were labeled as 
discontinued and 57 (33%) provided a reason for discontinuation (of which 53, 93%, provided 
the same reason as in the publication). Labeling of discontinued trials as discontinued (vs. 
other label) in corresponding trial registry records improved over time (adjusted odds ratio 
1.16 per year, confidence interval 1.04-1.30) and was possibly associated with industry 
sponsorship (2.01, 0.99-4.07) but unlikely with multicenter status (0.81, 0.32-2.04) or sample 
size (1.07, 0.89-1.29). 
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CONCLUSIONS: Less than half of published discontinued RCTs were accurately labelled as 
discontinued in corresponding registry records. One-third of registry records provided a 
reason for discontinuation. Current trial status information in registries should be viewed with 
caution. 
 
Discontinuation and Non-Publication of Randomized Clinical Trials supported by the 
Main Public Funding Body in Switzerland: a Retrospective Cohort Study. Alain Amstutz, 
Stefan Schandelmaier, Roy Frei, Jakub Surina, Arnav Agarwal, Kelechi Kalu Olu, Reem 
Alturki, Belinda von Niederhäusern, Erik von Elm, and Matthias Briel 
BMJ Open. 2017 Aug 1;7(7):e016216 
BACKGROUND: The Swiss National Science Foundation (SNSF) is the main public funding 
body of randomized clinical trials (RCTs) in Switzerland. The SNSF promotes academic 
excellence through competitive selection of study proposals and rigorous evaluation of 
feasibility. Completion status and publication history of SNSF-supported RCTs have not been 
investigated before.  
 
OBJECTIVES: To assess completion and publication status of all health care RCTs 
supported by the SNSF. 
 
DESIGN: We established a retrospective cohort of all SNSF-supported RCTs for which 
recruitment and funding had ended in 2015 or earlier. For each RCT, two investigators 
independently searched corresponding publications in electronic databases. In addition, we 
approached all principal investigators to ask for additional publications and information about 
trial discontinuation. Teams of two investigators independently extracted details about study 
design, recruitment of participants, outcomes, analysis, and sample size from the original 
proposal and, if available, from trial registries and publications. We used multivariable 
regression analysis to explore potential risk factors associated with discontinuation due to 
slow recruitment and with non-publication, and to compare our results to data from a 
previous cohort of Swiss RCTs not supported by the SNSF.  
 
RESULTS: We included 101 RCTs supported by the SNSF between 1986 and 2015. Eighty-
seven (86%) principal investigators responded to our survey. Overall, 69 (68%) RCTs were 
completed, 26 (26%) RCTs were prematurely discontinued (all due to slow recruitment), and 
the completion status remained unclear for 6 (6%) RCTs. For analyzing publication status, 
we excluded 4 RCTs for which follow-up was still ongoing and 9 for which manuscripts were 
still in preparation. Of the remaining 88 RCTs, 53 (60%) were published as full articles in 
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peer-reviewed journals. Multivariable regression models suggested that discontinued trials 
were at higher risk for non-publication than completed trials (adjusted OR 7.61, 95% CI, 
2.44-27.09). Compared to other Swiss RCTs, the risk of discontinuation for SNSF-supported 
RCTs was higher than in industry-initiated RCTs (adjusted OR 3.84, 95% CI 1.68-8.74) but 
not significantly different from investigator-initiated RCTs not supported by the SNSF 
(adjusted OR 1.05, 95% CI, 0.51-2.11). We found no evidence that the proportion of 
discontinued or unpublished RCTs decreased over the last 20 years. 
 
CONCLUSIONS: One fourth of SNSF-supported RCTs were prematurely discontinued due 
to slow recruitment, 40% of all included RCTs and 70% of all discontinued RCTs were not 
published in peer-reviewed journals. There is a case to reconsider how public funding bodies 
such as the SNSF could improve their feasibility assessment and promote publication of 
RCTs irrespective of completion status. 
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CHAPTER 4 
 
DISCUSSION 
 
 
4.1 Improving value, reducing waste: Who’s listened? 
“Perhaps all of us engaged in the enterprise we call “science” need to pause and reflect on 
the present state of what we do”.  - After three years, I am quite confident to say that this is 
the centerpiece of our work described here. Our initial aim was to generate a simple cost-
consequence approach to improving the quality of research. However, much more needed to 
be done to just even define what this equation contains. We needed to critically reflect on the 
current state of science, and research involving human beings in particular. This included 
diving into a basin of vague concepts and scarce evidence that most others had avoided 
swimming in so far.  When we started our work, the 2009 estimate that 85% of biomedical 
research and more than US$ 100,000,000,000 [1] are wasted had sent ripples through the 
scientific community. Many causes of this waste, including asking the wrong questions, bad 
design, or poor publication and reporting, were called “simple problems” that could easily be 
fixed, for example through appropriate randomization or blinding of a clinical trial [2]. Who’s 
listened?  
 
As a first step, the REduce Waste and ReWARD Diligence (REWARD) campaign invited 
everyone involved in biomedical research to critically examine the way they work to reduce 
waste and maximize efficiency [2]. Institutions and researchers around the globe have signed 
up for the REWARD statement. One of the signees, for example, is the UK’s national funding 
body, the National Institute for Health Research, which is committed to Adding Value in 
Research (AViR) by ensuring that its funded research projects answer the right questions, 
deliver the research efficiently and publish the results in full in an accessible and unbiased 
report [3]. AViR has received one of the first Cochrane-REWARD prizes that were awarded 
for reducing waste in research in 2017 [4].  Similarly, the Evidence Based Medicine 
Manifesto grew from the yearly conference “Evidence Live” at Oxford University, inviting 
everyone to join a movement towards better evidence by “providing a roadmap for how to 
achieve the listed priorities and to share the lessons from achievements already made” [5]. 
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Since the publication of The Lancet’s recommendations in 2014 [6-10], multiple stakeholders 
showed initiative to improve the system, including journals, funding agencies, and regulators 
[11, 12]. Still, academic institutions and the affiliated research force lagged behind.  Some of 
the potential underlying reasons we identified throughout this dissertation was a lack of (i) a 
common understanding of what “quality” or “value” is constituted of, (ii) practical guidance on 
how to improve it in the specific setting of academic clinical research, and (iii) empirical 
evidence on what works, and what doesn’t.  I believe that we provide an answer to (i) and (ii). 
The impact of these findings in practice and an answer to (iii), however, will now depend on 
their rigorous implementation at different levels, and by different stakeholders.  
 
 
4.2 The academic response  
In 2014, “value” has become the preferred term over “quality”. Yet, these terms are 
interdependent. Value is a measure of “monetary worth” and defines quality in terms of costs 
and prices. According to the value-based approach, a quality product is one that provides 
performance at an acceptable price or conformance at acceptable cost [13]. However, “the 
difficulty in employing this (value-based) approach lies in its blending of two related but 
distinct concepts. Quality which is a measure of excellence is being equated with value, 
which is a measure of worth (and therefore cost). The result is a hybrid – “affordable 
excellence” that lacks well-defined limits and is difficult to apply in practice” [13]. 
 
This work represents the first effort to formulate an academic response for clinical research 
to The Lancet series on increasing value, investigating both “quality” as well as “cost”. Based 
on a systematic review of existing quality concepts, we suggest a comprehensive, 
consensus-based quality framework that is applicable to all study types from 
conceptualization of the research question to dissemination of study results. Primarily, it has 
been designed to be operationalized in the academic setting and fully supports the REWARD 
Statement [14]. At Swiss national level, the framework has triggered all stakeholders to 
convene in a first symposium on how to increase value of academic clinical research. In 
addition, we lay the foundation for future study cost assessments in academia by providing (i) 
a comprehensive list of items for the retrospective and prospective assessment of costs, and 
(ii) first evidence on main cost drivers in academic RCTs, i.e. personnel costs during the 
phase of trial conduct. Finally, we describe how to investigate the added value of two aspects 
that affect both study quality and cost, i.e. trial monitoring and data collection. 
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In contrast to cost, quality has always been a perceptual, conditional, and somewhat 
subjective attribute that may be understood differently by different people. An almost 100% 
agreement on a definition for quality, as realized here in our work, can therefore be seen as a 
major achievement. Other disciplines have a long standing and controversial tradition when it 
comes to defining quality, also for more simplistic things such as “products”.  In 1984, David 
A. Garvin understood the problem, i.e. “the host of competing perspectives, each based on a 
different analytical framework and each employing its own terminology”, as one of coverage 
[13]. Scholars from philosophy, economics, marketing, and operations management had 
considered the subject, but each group had viewed it from different vantage points. He 
identified five approaches to the definition of quality: (1) the transcendent approach of 
philosophy, (2) the product-based approach of economics, (3) the user-based approach of 
economics, marketing, and operations management, and (4) the manufacturing based and 
(5) value-based approaches of operations management. Ideally, the approach to quality is 
shifted as products move from design to market (i.e. the study from conceptualization to 
conduct): The characteristics that connote quality must first be identified through market 
research (a user-based approach to quality, identifying the gap in evidence and posing a 
patient-relevant research question); these characteristics must then be translated into 
identifiable product attributes (a product-based approach to quality, design of the study and 
writing of protocol), and the manufacturing process must then be organized to ensure that 
products are made precisely to these specifications (a manufacturing-based approach to 
quality, conduct of the study according to protocol). Garvin however identified a common 
problem that is shared by each of these approaches: Each is vague and imprecise when it 
comes describing its basic elements [13]. 
 
With the development of our framework, we were able to comprehensively cover multiple 
quality dimensions and research stages that apply to all clinical studies involving patients. By 
formulating main quality questions for each dimension and each research stage, we offer 
precise guidance on how to assess quality. Moreover, it is the first framework that 
incorporates the patients’ voice along with other stakeholders such as funders, regulators, or 
industry. Although some may criticize it to be too comprehensive, bureaucratic, generalist, or 
theoretical, it lays the first agreed-on foundation for all stakeholders. We do not prescribe its 
use in practice, but we recommend covering at least all dimensions when assessing the 
quality of a particular study. First experiences from clinical research practice have shown that 
the framework is practicable and supports study staff in the development of high-quality 
study protocols and the internal monitoring of study conduct. 
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4.3 Look into the future: The value equation 
At a time when the scale of investments has raised justifiable concerns, the long-run 
sustainability of research programs will depend on value for money. In addition to quality and 
the costs incurred, the value-based approach is based on the costumer’s willingness to pay. 
While we provide guidance on the quality of research and preliminary evidence on cost 
drivers in this work, “willingness to pay” is a crucial subjective aspect that will need further 
investigation in the future. Academic decision makers in resource constrained settings will 
need to balance between broad improvement of quality in smaller steps and focusing on 
fostering excellence potential of only few projects when applying the framework. In order to 
be able to make these decisions, evidence on “what works, and what doesn’t” is needed. 
 
In contrast to the scarce evidence on cost drivers from industry-sponsored trials [15] 
identified in our systematic review, our case study on the cost of two academic RCTs should 
enable readers to understand how resource use and RCT costs actually correlate and how 
realistic cost estimates should be developed. However, our findings do not allow direct 
assessment of monetary investment versus quality improvement yet. The challenging future 
of our quality framework, therefore, will be to make it a tool to assess value for money. In the 
academic setting, in which resources are specifically scarce, any allocation of available funds 
for an improvement in quality needs to be justified. The evidence for potential quality 
improvement must be compelling, and worth the money. So far, the need to formally assess 
research value for money on funding allocation by national governments, funding agencies, 
and research institutions has received remarkably little recognition [16]. The framework will 
further need to be populated with methodological investigations on the cost-effectiveness of 
specific quality items in order to be able to differentiate between “nice to haves” and actual 
value drivers. For example, how much does patient engagement cost and how much does it 
eventually improve the quality of a clinical study? What is the most cost-effective approach to 
risk-based monitoring of a study and does it improve overall study quality? What is the most 
cost-effective way of collecting high quality, i.e. complete and valid, data? We tried to answer 
the latter two aspects by evaluating our current monitoring approach and by investigating the 
data quality and resulting cost-effectiveness of remote clinical studies. Surprisingly, we found 
that the risk-based approach ensures study data quality with much more flexibility in terms of 
resource use, but also leads to much more ambiguity across monitors. Similarly, while we 
identified a need for the conduct of patient-centered mobile studies, the resulting data quality 
let us question the cost-effectiveness of remote data collection. Much more evidence and 
many more of these studies, for example in the form of Studies-Within-A-Trial (SWATs), are 
therefore needed to answer questions regarding the actual value of our quality items 
satisfactorily.  
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4.4 Future directions 
In the future, the aim of this work is threefold: (1) Implement, validate, and revise the current 
quality framework in various settings; (2) improve usability of costing tools and generate 
evidence on main cost drivers from different medical fields, study types, and phases; and (3) 
conduct research on the cost-effectiveness of individual aspects of the quality framework in 
order to inform decisions on actual value improvement.  
 
In the near future, the currently ongoing initiatives to test the quality framework in real-life 
practice will soon generate evidence on its practicability. These findings will need to be 
incorporated in the adaptation and future versions of the framework. Importantly, the impact 
of the framework’s application on study cost and quality should be rigorously monitored. First 
evaluations of the “Research Excellence Framework” which supports the assessment of 
societal and economic impact of clinical research in the UK have shown that although the 
proposed indicators have some validity, there are challenges in operationalizing and 
measuring them reliably and across different cases in a standard manner [17]. Therefore, 
revised versions of the framework will also need to include feedback on the feasibility and 
scope of reliably assessing its content.  Cross-validation from different settings, e.g. different 
medical areas, CTUs, departments or geographic areas will support this refinement. Three 
pillars will be crucial to propel the framework’s impact forward in the future: (1) National 
support from policy makers, funding bodies, regulators, methodologists, and roof 
organizations, (2) local buy-in from stakeholders including medical faculties, university 
hospitals, CTUs, and clinical investigators, and (3) broad involvement of and dissemination 
across patients and the public. 
 
At Swiss national level, we plan a one-day strategy workshop to engage Swiss stakeholders, 
both national and local representatives, to discuss the framework’s implication and 
implementation. The Swiss Clinical Trial Organization is currently revising its quality policies 
and will take the lead in implementing the framework content at local CTU level. The Office of 
Public Health has shown interest to consider the framework’s content and definitions for the 
revision of the Swiss Human Research Act.  
 
At local level, the CTUs will have to drive the implementation of the framework’s content by 
supporting the quality of study protocols, conduct, data management, statistical analysis, or 
the reporting of results. This will further fuel their already existing impact on the quality of 
clinical research in Switzerland [18]. In our Delphi process, all CTUs were represented by 
their managers and quality experts who embraced the framework content and agreed on its 
implementation in the future. Ideally, the Departments of Clinical Research at the University 
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Hospitals support the CTUs and disseminate the framework content to the medical faculties 
of the Universities, and the affiliated research force. Researchers are particularly important to 
have on board, as they are at the center of research conduct. Based on the framework 
structure, the Department of Clinical Research in Basel is now offering a journal club that 
invites interested researchers and clinicians to join discussions on how to increase value of 
clinical research in practice. 
 
In order to disseminate the framework content across the public and educate patients, it will 
be crucial to develop applications that are easily accessible, e.g. through digitalization of the 
framework content. The patient community around EUPATI has shown interest in teaching 
materials on how to identify “good research” as a research participant. A concept on how to 
best communicate research content to patients is currently under development at the 
University Hospital Basel and will serve as a driver for the development of plain language 
explanations of the framework.  This will allow engaging patients and the public, i.e. the 
broadest base of citizens who have the greatest stake in research results, in the discussion 
on good research.  
 
In order to generate broader evidence on the costs associated with clinical research and the 
main drivers, our comprehensive item list will need to be revised until it is a user-friendly tool 
that may be used by researchers and clinical investigators to (i) assess the cost of RCTs at 
their institutions retrospectively, (ii) monitor costs during the conduct of an RCT on an 
ongoing basis [19], and (iii) develop more comprehensive and reliable budgets before the 
start of the trial. In a project commissioned by the Swiss Federal Office of Public Health 
(FOPH), we will continue to populate our database of currently 14 retrospective cost 
assessments of RCTs conducted in Switzerland as described here for the case study. This 
will allow generating a broader evidence base on the main cost drivers stratified by medical 
field, study type, and phases of research. Yet, the vast diversity of studies and settings will 
remain a major challenge in generalizing the findings, particularly as most evidence is 
generated in high-income countries. 
 
Once a solid costing methodology has been established, the framework will then need to be 
populated with methodological investigations on the cost-effectiveness of specific quality 
items. This will allow differentiating between crucial quality items, and those that can be 
applied depending on the setting, for example according to the risk of a study. In the long 
run, the use of new information technologies, such as web-based or mobile clinical trials, or 
routinely collected electronic health data may provide solutions to reduce costs of research 
while retaining or improving value [20, 21]. Alternative approaches in clinical trials, including 
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disease modeling, alternative trial designs, and remote assessments have already generated 
their results at lower costs [21-24]. Importantly, a diligent agenda should guide these 
transformations based on the available evidence and educate health professionals on how to 
design efficient and meaningful research programs. In addition to our two studies on risk-
based monitoring and remote data collection, the framework will therefore also serve as 
guiding principle for future research-on-research at the Department of Clinical Research in 
Basel, and potentially other institutions. 
 
Finally, stakeholders who are able to influence the planning, design, and conduct of 
academic studies, such as public funding agencies or research ethics committees, should 
diligently put emphasis on well-planned a priori feasibility assessments, well developed 
budgets, and other main aspects of quality that are covered in our framework. The results of 
the project commissioned by the FOPH on RCT costs and any future projects resulting from 
the work described in here should therefore be disseminated to a broad audience at policy 
level and be used to inform the before-mentioned stakeholders to improve practice.  
 
 
4.5 Closing remarks 
Value and waste have become buzzwords in the academic as well as public debate 
surrounding health research. Yet, evidence and guidance on the underlying concepts have 
been remarkably sparse. In this work, we provide a humble basis for the definition and the 
assessment of quality and cost of academic clinical research. We have certainly created 
awareness on value and waste in the academic context and engaged the major stakeholders 
in a discussion on how to improve the current situation. However, the impact of this work - 
and whether it eventually increases value in the system - now critically depends on its 
implementation, both nationally and on site. In whatever setting value is assessed, be it for 
individual studies or entire research programs, the longitudinal impact of any assessment on 
quality and cost will need to be rigorously monitored. Following the Lancet’s 
recommendations, all major stakeholders have to assume responsibility for their respective 
parts in the value discussion. Or as Goethe would say - “Knowing is not enough; we must 
apply. Willing is not enough; we must do.”  
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